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(3-Lactams are widely used to treat S. pneumoniae and H. influenzae respiratory
infections. However, resistance to (3-lactams is increasing in the UK. To establish if this
results from spread of a small number of resistant strains or from a wider emergence of
resistance, the molecular type and mechanisms of resistance in S. pneumoniae and H.
influenzae isolates, from throughout the UK, were determined.
Resistance of S. pneumoniae to penicillin is due entirely to the development of altered
forms of the high molecular weight penicillin binding proteins (PBPs) and decreased
affinity of PBP 2x, 2b and la together give high-level penicillin resistance. Between 1995
and 1996, 80 isolates of S. pneumoniae were obtained from centres throughout the UK.
Eighteen isolates were penicillin-resistant and these were typed by pulsed-field gel
electrophoresis (PFGE). In addition, changes in penicillin binding proteins (PBPs) 2x, 2b
and la were examined by polymerase chain reaction (PCR) and restriction fragment
length polymorphism (RFLP). Cluster analysis of patterns produced by PFGE of
chromosomal DNA digested with Smal revealed that penicillin resistance was not simply
the result of clonal spread. Screening for changes in PBPs and RFLP of the amplified
pbp2x, 2b and la genes by Hinfl showed that there was a correlation between resistance
and alteration in PBPs. The results indicate that penicillin resistance in S. pneumoniae in
the UK is evolving in a variety of different strains and this raises cause for concern.
P-Lactam resistance in H. influenzae is mainly mediated by the production of P-
lactamases. P-lactamase-mediated resistance is associated with the production of TEM-1,
ROB-1 and VAT-1 P-lactamase enzymes. Impermeability and alteration in PBPs are
further mechanisms that mediate resistance to P-lactams. The epidemiology and
mechanisms of resistance to amoxycillin and amoxycillin/clavulanic acid (co-amoxiclav) in
H. influenzae isolates from the UK were examined. Between 1995 and 1996, 231 isolates
ii
of H. influenzae were obtained from centres throughout the UK. Twenty percent of
isolates were amoxycillin-resistant and, of these, 19% were also resistant to co-
amoxiclav. Amoxycillin-resistant isolates were genotyped by PFGE, and screened for (5-
lactamase production by isoelectric focusing (IEF) followed by PCR employing primers
for the TEM-1 (3-lactamase. 1EF demonstrated that all the (3-lactamase-positive strains
produced an enzyme that co-focused with TEM-1. PCR confirmed the identity of the (3-
lactamase. Cluster analysis of patterns produced by PFGE of chromosomal DNA digested
with Smal revealed that amoxycillin-resistant isolates susceptible to clavulanic acid
showed little genetic relatedness. In contrast, among co-amoxiclav-resistant isolates only
two major groups of strains were identified. One group were TEM-1 producers and
exhibited high MICs of amoxycillin (>8 mg/L) which were reduced by the addition of
clavulanic acid. The second group had the same MIC of amoxycillin as that of co-
amoxiclav and showed no evidence of (3-lactamase production. Impermeability and
alterations in PBPs were examined in these isolates. Amoxycillin resistance in H.
influenzae throughout the UK is mediated by the TEM-1 enzyme which appears to have
spread into a wide variety of different strains. In contrast emerging resistance to
clavulanic acid appears to be restricted to a few strains.
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1.1. Bacterial Respiratory Tract Infections
1.1.1. Causative Organisms
Bacterial respiratory tract infections are a serious health problem worldwide. These
infections are very prevalent and continue to be a leading cause of morbidity and
mortality (Klugman, 1990). These airway infections often involve more than a single
bacterial pathogen and interactions between bacteria can worsen the problems of
bacterial resistance, so choosing the most appropriate antibiotic remains a key clinical
decision.
Although several microorganisms can produce respiratory tract infections, the most
common bacterial pathogens are Streptococcus pneumoniae, Haemophilus
influenzae, and Moraxella catarrhalis, as well as Mycobacterium tuberculosis.
Staphylococcus aureus and gram-negative bacilli, though rare causes of community-
acquired pneumonia are, however, associated with the highest rates ofmortality, 39 &
33%, respectively (Gilbert & Fine, 1994). Mortality associated with S. pneumoniae
and H. influenzae is much lower, at about 11 and 2%, respectively (Gilbert & Fine,
1994). Atypical bacterial pathogens, such as Mycoplasma pneumoniae and Legionella
spp. are not sufficiently common to allow an accurate determination ofmortality.
For the purpose of this thesis, almost all my writing will be to discuss in details the
two most commonly isolated pathogens in airway infections: S. pneumoniae and H.
influenzae.
1
1.1.2. Upper Airway Infections
i. Acute & Chronic Otitis Media
This condition is very common in infants and small children, partly because the
auditory tube is open more widely and immunity is lower at this age. One study
showed that 80-90% of children have at least one episode before they are 2 years old
(Teele et al., 1989).
H. influenzae is the cause of 10-30% of acute otitis media whereas S. pneumoniae
accounts for 20-40% of the cases (Martin et al., 1995). In chronic otitis media, H.
influenzae predominates (15 vs. 7% with S. pneumoniae). More than 90% of H.
influenzae responsible are non-capsulated (Klein, 1990) and only a minor percentage
are H. influenzae type b. S. pneumoniae causes otitis media in children, affecting up
to 7 million American children a year (MMWR, 1996).
ii. Sinusitis
Sinusitis can occur at all ages and it develops as a complication in 1-5% of all upper
airway infections. Although sinusitis is a common infection, it is potentially dangerous
because of the proximity to the central nervous system. This condition develops when
allergy or viral infections obstruct normal drainage and aeration. In the first stages of
the infection the most common pathogens are S. pneumoniae and H. influenzae.
Anaerobic organisms become involved as the infection turns chronic and the levels of
tissue oxygen decline (Carenfelt & Lundberg, 1977).
iii. Epiglottitis
H. influenzae type b is one of the most common cause of epiglottitis (Albritton,
1988). Although the incidence of H. influenzae epiglottitis is high in children, its
occurrence in adults is also well recognised (Frantz & Rasgon, 1993). However, cases
of epiglottitis in children appear to be diminished since the introduction of H.
influenzae type b vaccine (Takala et al., 1994).
2
1.1.3. Lower Airway Infections
Lower airway infections are a very common cause ofmorbidity and mortality.
i. Acute Bronchitis
This is an inflammatory condition of the tracheobronchial tree usually associated with
viral infection. Secondary bacterial infection with S. pneumoniae and H. influenzae
may play a role in pathogenesis.
ii. Acute Exacerbations of Chronic Bronchitis
Bacterial infection does not appear to initiate the disease but is probably significant in
perpetuating it and in producing the characteristic acute exacerbations. Infection
appears to be only one component of the syndrome, the other being cigarette smoking
and inhalation of the dust or fumes from the workplace (Brook, 1994). S. pneumoniae
and non-capsulated strains of H. influenzae are the organisms most frequently
isolated.
iii. Community-Acquired Pneumonia
The classical bacterial cause of community-acquired pneumonia is S. pneumoniae with
H. influenzae the second most common bacterial pathogen. S pneumoniae also seems
to be the most frequent cause of severe community-acquired pneumonia (Moine et
al., 1994). In the UK, S. pneumoniae is responsible for 30-50% of community-
acquired pneumonia (Meyer & Finch, 1992). Though the case fatality rate in
pneumococcal pneumonia decreased significantly with the advent of antibiotics in the
1940s, the incidence has remained almost unchanged (Austrian, 1981). Interestingly,
the frequency of pharyngeal carriage has fallen dramatically, but the incidence of
pneumococcal infection remains unchanged (Foy et al., 1975).
3
1.1.4. Infections in Immunocomprised Patients
Infection is a frequent complication of patients with the acquired immune deficiency
syndrome (AIDS). Approximately 5% of all hospital admissions of AIDS patients are
due to bacterial pneumonia. Pneumococcal pneumonia may be the first manifestation
of human immunodeficiency virus (HIV) infection in a substantial number of patients
(Garcia-Leoni et al., 1992). Also S. pneumoniae is the leading cause of invasive
bacterial respiratory disease in adults and children with HIV infection (Janoff et al.,
1992).
1.1.5. Nosocomial Infections
Nosocomial infections are an important cause of morbidity and mortality. It has been
estimated that approximately 5% of patients in the United States develop a hospital-
acquired infection (Haley et al., 1985). A recent report on pathogens reported from
nosocomial infections in hospitals in the United States found S. pneumoniae to be the
fourth most frequent pathogen causing nosocomial pneumonia (accounting for 6.5%
of the infections) (Jarvis & Martone, 1992).
1.1.6. Invasive Infections
H. influenzae used to be the most common cause of bacteraemic disease and
meningitis in children with the great majority of cases caused by encapsulated strains
of type b (Moxon & Wilson, 1991); however the introduction of a vaccine against
type b strains has altered this (Slack, 1995). S. pneumoniae is one of the leading
causes of acute bacterial meningitis with bacteraemia. In the United States the overall
incidence of pneumococcal meningitis is 1.1 per 100 000 population, but in infant
under 5 months old the incidence is higher at 30 in 100 000 with 10% mortality
(Schelch et al., 1985).
Many underlying conditions are important for susceptibility to pneumococcal
infections. S. pneumoniae is responsible for at least half of the cases of infection with
encapsulated bacteria in asplenic individuals and for most of the fatal ones (Kalin,
4
1998). The reason that the splenectomised individuals are more susceptible to
infection with encapsulated bacteria is probably the spleen's unique role in the
clearance ofnon-opsonised organisms (Bruyn et al., 1992).
1.1.7. Epidemiological Aspects
i. Healthy Carrier
S. pneumoniae is an exclusively human pathogen, which is spread from person to
person by aerosols. It is carried in the nasopharynx of up to one third of the adult
population without any apparent symptoms, and this is presumably how it manages to
persist as a human parasite.
Most people harbor H. influenzae in their pharynx and, to a lesser extent, these
organisms also colonise the mucosa of the conjunctiva as well as the genital tract
(Moxon, 1990). Although respiratory carriage of non-capsulated organisms is
common (30-80%), the carriage rate of the H. influenzae type b is much lower (2-
5%).
ii. Seasonal Occurrence
Although studies by Davies and Maesen (1986) showed no constant seasonal
variation in infections caused by H. influenzae, seasonal variation was observed by
Howard et al., (1991) for invasive infections caused by type b strains of H.
influenzae-, infections arose more commonly in the winter months. In S. pneumoniae
there is seasonal variation in the incidence of pneumococcal infections. In temperate
climates infections are most frequent in winter but in the tropics they occur mostly at




S. pneumoniae has been the subject of intensive investigation at both the clinical and
basic scientific level during the past century. In a number of instances, these studies
have resulted in important progress toward the comprehension of basic biological
principles (Watson et al., 1993).
S. pneumoniae was first visualised in pulmonary tissues by Klebs in 1875, later by
Eberth in 1880, and then by Koch in 1881 (Reviewed by Austrian, 1981). However,
the organism was first isolated in the laboratory, from human saliva, independently by
George Sternberg in the United States and Louis Pasteur in France, and reported by
both in 1881 (Reviewed by Austrian, 1981). At the turn of the century, Neufeld
reported on the solubility of pneumococci in bile (Reviewed by Austrian, 1981). Most
important were demonstrations of the development of antibodies against the
homologous pneumococcus following infection and vaccination and the description of
the specific agglutination and Quellung reactions in homologous antisera by Neufeld
in 1902 (Reviewed by Austrian, 1981). In 1928, Griffith demonstrated that the genetic
material of the virulent S. pneumoniae strain, which remained intact despite being
heated, was released from the heat-killed cells and was able to transform a non-
virulent strain into a virulent one (Griffith, 1928). This experiment led to the principle
of the genetic transformation.
1.2.2. Morphology & Growth Characteristics
S. pneumoniae is a gram-positive coccus, about 1.0 pm in diameter, and may be ovoid
or lanceolate, occurring in pairs with the broader ends opposed. It is a relatively
fastidious organism that grows best on complex media containing additives, such as
blood or serum, and is classified as an aerobe and facultative anaerobe, but most
strains prefer an atmosphere of 5-10% C02 for primary culture. On culture
pneumococci are a-haemolytic but are distinguished from other a-haemolytic
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streptococci by optochin sensitivity and by sensitivity to surface-active agents such as
ox bile or sodium desoxycholate.
1.2.3. Capsular Serotypes
The capsules of S. pneumoniae are made up of polysaccharides varying in their mono-
and disaccharide components (Lund & Henrichsen, 1978). There are 90 different
capsular serotypes together with their antigenic formulae presently known
(Henrichsen, 1995). Two serotyping nomenclatures of pneumococcal serotypes exist,
namely the Danish and the American systems, but the consensus usage has for some
time been the Danish system, with all typing sera provided by the Statens Serum
Institute, Copenhagen (Lund & Henrichsen, 1978). Serotyping is based on the
structural diversity of the capsular polysaccharide. The first stage of serotyping
involves the use of pools of sera, and then individual sera from positive pool, to assign
a number, such as 1,3, and 14. No further subtyping is possible and hence the number
is referred to as a serotype. For others, such as 6, 19, and 23, subtyping sera can
distinguish further subtypes such as 6A and 6B, 19F (First), 19A, 19B and 19C, and
so on; in these cases the number is referred to as the serogroup, and the number plus
letter as the serotype or subtype. This nomenclature reflects the cross reactivity of
subtypes within a serogroup (Lund & Henrichsen, 1978).
The prevalence of these serotypes varies around the world and amongst different age
groups, with certain capsular serotypes being more or less effective immunogens than
others. It is not clear which factors influence the worldwide distribution of serotypes.
However, there could be a selective advantage for pneumococci to switch serotypes
as they move around the population, perhaps to avoid clearance during carriage, or to
further evade the immune system during disease (Dowson et al., 1997).
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1.2.4. Pathogenicity
S. pneumoniae is carried in the upper respiratory tract by many healthy individuals.
The mechanisms by which pneumococci translocate from the nasopharynx to the lung,
thereby causing pneumonia, or migrate directly to the blood, giving rise to
bacteraemia or septicemia, are poorly understood (AlonsoDeVelasco et ai, 1995).
Most infections do not occur after prolonged carriage but follow the acquisition of
recently acquired serotypes (Johnston, 1991). This suggests that the immune status of
the host at the moment of colonisation, as well as the virulence of the particular strain,
determines whether pneumococci will remain confined to the nasopharynx or become
invasive.
Unrestrained multiplication of pneumococci in the lungs, meninges, or middle ear will
result in pneumococcal lysis. There is a release of lysozyme in the mammalian
secretion fluids at the sites of infection may contribute to pneumococcal lysis through
the activation of autolysin (Cottagnoud & Tomasz, 1993). Pneumococcal lysis will, in
turn, trigger the inflammatory process, directly by attracting and activating
phagocytes and indirectly through complement activation and toxin formation. There
is increasing support for the hypothesis that such inflammation may be responsible for
the morbidity and mortality of pneumococcal infection (Musher, 1992).
1.2.5. Virulence Factors
i. Capsule Polysaccharide
It has been known since the beginning of the century that the polysaccharide capsule
is crucial for the virulence of the pneumococcus (Johnston, 1991). Rough strains
without capsules are virtually avirulent, the number of pneumococci that are required
to establish a lethal infection in laboratory animals being increased by a factor of 10\
Though necessary for virulence, the capsular polysaccharides are non-toxic when
injected into laboratory animals as pure substances. The mechanism by which they
promote virulence is by protecting the bacteria against immediate ingestion by animal
phagocytes. However, there is a considerable difference in virulence among the 90
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known capsular types; some of the capsular structures are connected with significant
invasiveness (e.g., 6, 9, 19, 23) while most of them seem to confer only minor
virulence.
ii. Cell Wall & Cell Wall Polysaccharide
Toxic products produced during growth or degradation have been thought to be
responsible for the often dramatic clinical presentation of a pneumococcal infection,
but no single toxin or other cell product has been definitively identified as responsible.
However, cell wall constituents seem to be largely responsible for the inflammatory
reaction (Tuomanen et al., 1985; Boulnois, 1992). The phosphorylcholine residue of
the C-polysaccharide is highly immunogenic, eliciting antibody response, complement
activation and binding of an acute phase reactant p-globulin of human serum, the C
reactive protein. Furthermore, the latter reaction results in opsonisation and activation
of complement.
iii. Pneumococcal Protein Antigens & Toxins
Various proteins have been suggested to be involved in the pathogenicity of S.
pneumoniae. Two enzymes, neuraminidase and pneumolysin, released primarily
during autolysis, may be of importance in the pathogenesis (Bruyn et al., 1992;
Boulnois, 1992). The mechanism of release may be the reason why autolysin-deficient
strains are less virulent than autolysin-producing variant. Also, the surface protein A
may be involved in the pathogenetic events during pneumococcal infection (Bruyn et
al., 1992; Boulnois, 1992). Both pneumolysin- and protein A-deficient strains show
reduced virulence in experimental animals with prolonged survival of the animals after
pneumococcal challenge. The same effect can also be achieved by active or passive
immunisation of the animal against either of these two antigens. Pneumolysin also
seems to be directly injurious to the pulmonary vascular endothelium (Rubins et al.,
1993). However, although several new pathogenic facets have emerged in recent
years, the importance of different mechanisms by which pneumococcal cell wall or
other constituents, alone or in concert with each other and with host factors, damage




In 1892, Pfeiffer claimed that the small gram-negative haemophilic coccobacillus that
he had isolated in large numbers from the sputum of patients suffering from epidemic
influenza was the causative agent of that disease (Slack & Jordens, 1998). The
specific name H. influenzae (Winslow et al., 1917) which was given to the organism
is a permanent reminder of this erroneous association.
1.3.2. Morphology & Growth Characteristics
H. influenzae is a slender, short, poorly staining gram-negative rod or coccobacillus,
0.3-0.5 pm x 0.5-1.0 pm with rounded ends. Specific growth factor requirements are
major criteria by which the genus Haemophilus is defined. The species will not grow
in the absence of certain factors that are present in blood, hence the generic name
Haemophilus or 'blood-loving'. H. influenzae requires 2 accessory growth factors, a
heat-stable growth promoting substance present in blood cells (X factor), and a heat-
labile vitamin-like substance (V factor). X factor is involved in oxidation-reduction
processes in the growing bacterial cell and it can be satisfied by iron-containing
compounds like haems. V factor is essential for the synthesis of iron-containing
respiratory enzymes and it can be satisfied by nicotinamide-adenine dinucleotide
(NAD") or NAD phosphate (NADP+). The optimal medium for growth is chocolate-
blood agar at 35-37° in 5-10% CO2.
1.3.3. Capsular Serotypes
In 1931 Pittman found that H. influenzae strains isolated from the cerebrospinal fluid
or blood of patients with meningitis appeared iridescent when cultured on Levinthal's
agar. This iridescence was shown to be caused by the presence of a polysaccharide
capsule (Pittman, 1931). Subsequently, six serotypes (a-f) based on capsular antigen
were described. Each capsule is composed of a linear polymer of disaccharide units.
The capsules are negatively charged, acidic and hydrophobic. Types a and b differ
from the others in containing the 5-carbon component ribitol, and type b is unique as
10
both sugars are pentoses. However, not all organisms express this surface antigen;
those that do not are referred as non-capsulate H. influenzae (NCHI).
1.3.4. Classification of Biotypes
In 1976 Kilian developed a biochemical scheme for classifying H. influenzae into eight
biotypes, namely biotypes I-VIII, based on 3 biochemical tests (indole, urease and
ornithine decarboxylase) (Kilian, 1976 & 1985). Most clinical isolates of H.
influenzae are distributed between 4 biotypes (I, II, III & IV); H. influenzae type b
isolates from invasive disease are mainly biotype I and the majority of NCHI are
biotype II or III (van Alphen, 1993).
1.3.5. Pathogenicity
i. Capsulate H. influenzae
H. influenzae is the most important species causing human disease. It is strictly a
parasite ofMan and is associated with the normal commensal flora of the respiratory
tract. Infections caused by H. influenzae generally result from invasion of the
bloodstream or contiguous spread from the respiratory tract. It causes serious
invasive disease in children under 5 years of age, such as meningitis. Up to 20% of
survivors of H. influenzae type b meningitis have long term neurological sequelae.
Risk factors for H. influenzae type b disease are mainly socioeconomic and include
overcrowding, attendance at day-care centres, chronic illness and lack of access to
good health care facilities (Jorden & Slack, 1995).
ii. Non-Capsulate H. influenzae (NCHI)
NCHI are often associated with infection of previously damaged tissues, causing
respiratory infections in patients with chronic bronchitis, bronchiectasis or cystic
fibrosis. Recent reports show that NCHI are also an important cause of invasive
disease in both adults and children (Jorden & Slack, 1995). In most cases there are
predisposing factors such as head injury, Otitis media or sinusitis, and the infection is
presumed to result from direct extension (Bol et al., 1987).
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1.3.6. Virulence Factors
i. Capsulate //. influenzae
The possession of the type b capsule has been shown to be a major virulence factor.
The bacterial capsule aids colonisation and is probably the most important virulence
factor for invasive disease as it protect against phagocytosis and complement-
mediated lysis (Tunkel & Scheld, 1993). Other virulence factors which may be
involved in adherence and colonisation of H. influenzae type b include
lipopolysaccharide (LPS) (Moxon & Maskell, 1992), which is expressed differently in
the nasopharynx and the bloodstream, and fimbriae, which have been shown to be
important for nasopharyngeal colonisation but not for invasion (van Alphen & van
Ham, 1994). Outer-membrane protein P2 (OMP P2) has been shown to affect the
virulence of H. influenzae type b (Sanderes et al., 1993) and peptidoglycan was
shown to cause brain oedema and inflammation by increasing blood-brain barrier
permeability (Burroughs et al., 1993). Haemocin, a bacteriocin, is strongly associated
with type b strains (LiPuma et al., 1992). IgA proteases are produced by all H.
influenzae type b but have been shown to be inhibited by human milk (Plaut et al.,
1992).
ii. Non-Capsulate H. influenzae (NCHI)
Recent studies suggest that fimbriae (Sirakova et al., 1994) and OMP P2 may be
important virulence factors for NCHI (Sanders et al., 1993). The secretory products
IgA protease and ciliotoxin may contribute to the pathogenesis of pneumonia (Moxon
& Wilson, 1991). Transferrin-binding proteins have been detected on NCHI (Hardie





Pneumococcal vaccines based on the capsular polysaccharides from the 23 serotypes
most commonly associated with disease have been available for some years (Klein,
1999). These have serious limitations as they fail to protect young children and do not
elicit immunological memory. Invasive II. influenzae disease has been essentially
eliminated among vaccinated children and, since the vaccine reduces the level of
carriage, which decreases transmission within the community (Booy & Kroll, 1994,
Slack, 1995). The success of the H. influenzae serotype b vaccine has depended on
special circumstances that do not apply to the pneumococcus. Firstly, almost all
invasive disease is caused by serotype b isolates of H. influenzae, whereas a
substantial proportion of the >90 serotypes of S. pneumoniae can cause serious
disease. Secondly, there is clear evidence that pneumococci can relatively frequently
change the polysaccharide capsule that they express, which may lead to vaccine
escape (Crook & Spratt, 1998), whereas alterations of serotype are extremely rare in
H. influenzae. These deficiencies in pneumococcal vaccine are being addressed by the
introduction of vaccines in which the capsular polysaccharides from about eight of the
most important serotypes are conjugated to a protein carrier and a number of these
conjugate vaccines are in clinical trials (Kayhty & Eskola, 1996, Klein, 1999).
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1.5. Treatment of Infections
i. Treatment ofStreptococcus pneumoniae Infections
Since it became available for clinical use in the early 1940s, penicillin has been the
antibiotic of choice for treating pneumococcal infections, so causing a marked
reduction in mortality and morbidity. The efficacy of penicillin for the treatment of
pneumococcal infections was unquestioned until reports of strains resistant to
penicillin began to emerge (Klugman, 1990). The earliest reports of such resistance
came from an area in Papua New Guinea where systemic prophylaxis with penicillin
had been tested as an approach to the control of pneumococcal pneumonia (Klugman,
1990). The consequence of this approach to infection control has been the emergence
of strains ofS. pneumoniae with increased resistance to penicillin.
Several pneumococcal infections, such as pneumonia or meningitis, are in many
countries still treated with penicillin G. In the treatment of pneumonia, high doses are
necessary (Brewin et al., 1974), and mortality is still in the order of 5-20%,
particularly in the very young and very old. The mortality rate is independent of
resistance to antibiotics, occurring even with appropriate antibiotic therapy. No
antibiotic has yet been shown to be superior to penicillin in pneumococcal meningitis
but some, such as cefotaxime, may be equally effective.
Of the other (3-lactams, only the extended-spectrum cephalosporins, excluding
ceftazidime, and the carbapenems are usually equally or more active than penicillin
against penicillin-resistant pneumococci. Indeed, it may be the use of ceftazidime that
precipitated the emergence of resistance (Linares et al., 1992). Although all
pneumococcal strains are susceptible to vancomycin, there is little justification for the
use of this agent in pneumococcal pneumonia, especially in light of the recent spread
of vanocomycin-resistant enterococci. The macrolides and azithromycin may also be
used for pneumococcal pneumonia, but resistance is a problem in certain areas. Most
of the older quinolones, like ciprofloxacin, have limited in vitro activity against
pneumococci and clinical failures have been described (Gordon & Kauffman, 1990).
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However, newer quinolones, like levofloxacin and moxifloxacin, exhibit greater
activity against pneumococci.
ii. Treatment ofHaemophilus influenzae Infections
Until the early 1970s the treatment of choice for H. influenzae infections was
ampicillin. However, the increasing prevalence of ampicillin resistance in both
capsulated and non-capsulated strains has affected the antibiotic therapy for invasive
and non-invasive infections (Gunn et al., 1974).
The drug of choice for treatment of invasive infections including meningitis caused by
ampicillin-susceptible H. influenzae is still ampicillin. For ampicillin-resistant H.
influenzae strains, many cephalosporins have proved to be highly effective.
Nevertheless, the limited susceptibility of this species to most first generation
cephalosporins and the poor CSF penetration of these drugs restrict their application
to non-invasive infections. The ability of cefaclor to resist the hydrolytic activity of (3-
lactamases, allow this antibiotic to achieve greater periplasmic concentrations than
ampicillin, and sufficient binding to crucial penicillin-binding proteins in H. influenzae
(Picard & Malouin, 1992). Lower and upper respiratory tract infections caused by H.
influenzae are treated with ampicillin, co-amoxiclav, cefuroxime and cefpodoxime.
Erythromycin has minimal activity against H. influenzae. However, azithromycin and
clarithromycin are considerably more active. Tetracycline is active but has unfavorable
pharmokinetics and side effects. Newer agents to which H. influenzae is highly
susceptible are the fluoroquinolones, aztreonam and the carbapenems, but the
reliability of CSF penetration has often not been fully established.
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1.5.1. The Discovery of (3-Lactam Antibiotics
The discovery of the antibacterial action of penicillin and the subsequent
demonstration of its therapeutic power led to the production of a large family of
antibiotics, whose single common structural feature is the possession of a (3-lactam
ring. This group of antibiotics includes both penicillins and the cephalosporins, in
addition to the newer carbapenems and monobactams. The discovery of 6-
aminopenicillanic acid (6-APA) and 7-aminocephalosporanic acid (7-ACA) as the
nucleus of penicillins and cephalosporins respectively, and their preparation by
enzymatic and chemical methods, followed by chemical modification of the side chains
of these antibiotics, have introduced vast numbers of semi-synthetic penicillins and
cephalosporins into the chemotherapeutic field. This opened a new era by giving novel
compounds effective against various species of bacteria resistant to the early (3-
lactams.
The widespread use of [5-lactam antibiotics stems from their specific inhibitory effect
on the biosynthesis of peptidoglycan, a unique structure of bacterial cell walls, and
from their low toxicity. Compared to other antimicrobial agents, P-lactam antibiotics
can be easily and extensively modified by chemical synthesis. The introduction of
specific side chains has resulted in a variety of changes in biological properties,
expansion of the antibacterial spectrum, an increase in stability against P-lactamases
and improved pharmacokinetic properties.
1.5.1.1. Penicillins
In 1929, Alexander Fleming isolated penicillin from a strain of Penicillium notatum.
By 1941, benzylpenicillin could be produced in sufficient quantity to treat several
infected patients. Clinical trials with the agent, conducted by Flory, Chain and
colleagues (Chain et al., 1940), were successful, and during World War II,
benzylpenicillin was used to treat patients with streptococcal, gonococcal, and
treponemal infections. Shortages of the agent continued until the 1940s when
production of large amounts of drug became possible by a deep-fermentation
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procedure (Fleming, 1946). Since then, many synthetic penicillins have been
developed, but resistance to the agents has increased. Despite the emergence of
resistance to penicillins and the development of other classes of antimicrobial agents,
the penicillins remain one of the most important antimicrobial classes of drugs well
into the nineties. In fact penicillin G is still the drug of choice for many types of
infections, including syphilis and certain types of endocarditis.
The basic chemical structure of all penicillins consists of a P-lactam ring, a thiazolidine
ring, and a side chain (6-APA) (Figure 1.1). The antibacterial activity of the penicillins
lies within the P-lactam ring. Any alteration in this ring structure forms penicilloic
acid, and the antibacterial activity of the compound is lost. The side chain varies with
each penicillin compound and generally determines the spectrum of activity as well as
the pharmacokinetic properties of the compound.
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The penicillin compounds can be divided into categories based upon their spectrum of
activity. Often these early agents are not effective against P-lactamase-producing
organisms unless combined with a (3-lactamase inhibitor (e.g. clavulanic acid).
i. Natural Penicillins
There are several natural penicillins (penicillin dihydro F, X, and K), of which
benzylpenicillin (penicillin G) is the most active and the only natural penicillin used
clinically (Figure 1.1).
Penicillin G is produced directly from the fermentation of Penicillium crysogenum.
Penicillin V is a derivative of penicillin G and, because of similarity in spectrum of
activity, is considered a natural penicillin. The natural penicillins have activity against
non-P-lactamase-producing gram-positive cocci (Chow & Muder, 1992; Betriu et al.,
1994). Activity against gram-negative cocci is limited. However, it is inappropriate to
use natural penicillins as empirical treatment for a suspected staphylococcal infections
or gonorrhea, due to the increased potential of a resistant organism and subsequent
treatment failure.
ii. Penicillinase-Resistant Penicillins
The penicillinase-resistant penicillins are also known as the antistaphylococcal
penicillins. Addition of an isoxazolyl side chain to the penicillin compound protects
the P-lactam ring from acid hydrolysis by penicillinases produced by Staphylococcus
spp.
Methicillin, the first agent synthesised in this group, is rarely used currently because of
a high incidence of occurrence of interstitial nephritis. Nafcillin, dicloxacillin, oxacillin,
flucloxacillin and cloxacillin are the agents commonly used. While less active against
streptococci than the natural penicillins, use of the penicillinase-resistant penicillins is
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acceptable against these organisms. A notable exception to the gram-positive
coverage of this class of penicillins is the enterococci, which are not susceptible to this
class of penicillins and activity against gram-negative is nonexistent.
iii. Aminopenicillins
Adding an amino group to the basic penicillin compound led to development of the
aminopenicillins. Ampicillin and amoxycillin are the important drugs in this class. The
spectrum of activity against gram-positive organisms is similar to that of the natural
penicillins. These agents retain activity against streptococci and have slight greater
activity against enterococcus than the natural penicillins. The added side chain does
not, however, inhibit hydrolysis by staphylococcal penicillinases or gram-negative (3-
lactamases. The enhanced spectrum of these drugs includes activity against gram-
negative bacilli, including H. influenzae, E. coli, Salmonella spp. and Shigella spp.
Presently, however, many strains of these gram-negative organisms are resistant to
ampicillin (Schiffer et al., 1974; Spencer et al., 1990; Gross eta/., 1981).
iv. Carboxypenicillins
A carboxyl group substitution in place of the amino group yields penicillin compounds
that have a greater gram-negative spectrum of action, including activity against
Pseudomonas aeruginosa, most likely because of increased bacterial penetration
through the cell wall. Carbenicillin and ticarcillin are the two drugs in this class.
v. Ureidopenicillins and Piperazine Penicillin
The addition of a ureido group to the penicillin structure produces the compounds
azlocillin and mezlocillin, while the addition of ureido group plus a piperazine side
chain produces piperacillin. This class of penicillins has a greater gram-negative
spectrum of action. The activity against streptococci is slightly less than that of the
natural penicillins and ampicillin.
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1.5.1.2. Cephalosporins
The first cephalosporin antibiotic was isolated in 1945 from a fungus,
Cephalosporium acremonium, near a sewer outlet on the Sardinian coast, by
Guiseppe Brotzu. In 1953 Abraham and Newton discovered Cephalosporin C (Figure
1.2) while they were studying the antibiotics of a strain of C. acremonium (Reviewed
by Abraham, 1987). Removal of a side chain from this molecule yielded a nucleus, 7-
ACA, from which all subsequent cephalosporins have been derived as semisynthetic
compounds (Figure 1.2).
In 1964, cephalothin and cephaloridine were introduced into medicine and were
followed by cefazolin. These antibiotics were active against penicillinase-producing S.
aureus and, unlike methicillin, they also showed significant activity against a number
of gram-negative bacilli. In the early 1970s, another family of (3-lactam antibiotics was
discovered, the cephamycins. Similar to the cephalosporins, these compounds differed
in having a methoxy group in the 7-position of the P-lactam ring and being produced
naturally by actinomyces rather than fungi.
Thousands of structural modifications have been made to virtually every position on
the cephem nucleus. The search for new substitutions at C-3' led to the discovery of
quaternary ammonium cephems (cefpirome, cefepime, cefprozan, etc.)
Classification of Cephalosporins
Numerous classifications of cephalosporins have been published based on chemical,
biologic, microbiologic, pharmacologic, and immunologic criteria (Belfiglio &
Bryskier, 1999; Bryskier & Belfiglio, 1999). No classification has been entirely
suitable; nevertheless, the somewhat arbitrary system that is most widely used
combines the parental and oral cephalosporins into "generations" on the basis of their
antibacterial activity and spectrum ofmicrobiologic activity.
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i. First Generation Cephalosporins
First generation cephalosporins (cefazolin, cephapirin, cephradine, cephalothin,
cefaclor, etc.) are very active against gram-positive cocci and have moderate activity
against E. coli, K. pneumoniae, Salmonella spp., and Shigella spp. The antibacterial
activity against other Enterohacteriaceae is unpredictable and should not be assumed.
First generation cephalosporins have poor activity against H. influenzae, penicillin-
resistant pneumococci, methicillin-resistant staphylococci and enterococci.
ii. Second Generation Cephalosporins
Second Generation Cephalosporins should be considered in two groups: the true
cephalosporins (cefuroxime and cefprozil) and the cephamycins (cefoxitin, cefotetan,
cefmetazole). The true cephalosporins in this group provide greater activity against
staphylococci and nonenterococcal streptococci than the first generation group. In
addition, they have significantly improved activity against H. influenzae and M.
catarrhalis. Cephamycins have inferior activity against staphylococci and
streptococci.
iii. Third Generation Cephalosporins
These agents (cefotaxime, ceftazidime, ceftizoxime, cefepime, etc.) are commonly
viewed as the most potent cephalosporins against facultative gram-negative bacilli. In
addition, however, they have superior antimicrobial activity against S. pneumoniae
(including moderately penicillin-resistant strains), S. pyogenes, H. influenzae and M
catarrhalis. Most have modest activity against S. aureus, with the exception of
ceftazidime. This group of cephalosporins, like all of the compounds based on cephem
nucleus, lack activity against Enterococcus spp., methicillin-resistant staphylococci,
and highly penicillin-resistant S. pneumoniae. The superior broad activity of these
agents against Enterohacteriaceae has recently been challenged by (3-lactamase and
plasmid-mediated resistance, representing a widening threat to the efficacy of third
generation cephalosporins.
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iv. Fourth Generation Cephalosporins
Cefpirome has superior activity against streptococci, S. aureus, H. influenzae and the
Enterobacteriaceae (Wise et al., 1985; Spangler et al., 1994). Cefepime has an
exceptionally broad spectrum of antibacterial activity against S. pneumoniae, S.
pyogenes, S. aureus, H. influenzae, and the Enterobacteriaceae (Thornsberry et al.,
1993; Yee et al., 1993).
1.5.1.3. Carbapenems
The thienamycins are a group of bicyclic P-lactam compounds that share a common
carbapenem nucleus. These naturally occurring antibiotics are produced by the soil
organism Streptomyces cattleya and were first discovered in the mid-1970s (Albert -
Schonberg et al., 1978). There are two main structural differences between
carbapenem and penicillin antibiotics: the substitution of carbon atom for sulphur
atom at position 1 of the 4:5 fused thiazolidine ring structure, and the presence of an
unsaturated bond between C-2 and C-3 (Figure 1.3).
Thienamycin was noted to be stable to p-lactamase hydrolysis and to have a broad
spectrum ofantimicrobial activity; however it was chemically unstable in concentrated
solution. Imipenem (Figure 1.3), a semisynthetic N-formimidoyl derivative of
thienamycin, was developed to overcome the chemical instability of the parent
compound but was subsequently found to be extensively metabolised by human renal
dehydropeptidase I (DHP-I). This enzyme substantially decreased renal excretion of
unchanged imipenem and limited the antimicrobial activity of imipenem in urine
(Norrby et al., 1983). Cilastatin, a competitive inhibitor of DFLP-I with a
pharmacokinetic profile similar to that of imipenem, was then developed and
combined with imipenem in a 1:1 ratio (Kahan et al., 1983). This combination of
imipenem and cilastatin has been available and has proven extremely useful in clinical
practice.
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Figure 1.3. Structure of Carbapenems
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Meropenem (Figure 1.3), also a semisynthetic derivative of thienamycin, is the second
carbapenem agent available. Meropenem was developed after chemical modification
of thienamycin to provide greater resistant to DHP-I metabolism. The DHP-I stability
of meropenem is such that it eliminate the need for coadministration of a
dehydropeptidase inhibitor (Moellering et al., 1989).
The carbapenems as a class exhibit the broadest antimicrobial spectrum of any 3-
lactam antibiotics available to date. They possess excellent activity against both
aerobic and anaerobic gram-positive and gram-negative bacteria. Among gram-
positive aerobes, the carbapenems are active against S. pneumoniae strains with
intermediate- or high-level resistance to penicillin; however, these strains are usually
four- to eightfold less susceptible than fully penicillin-susceptible strains (Linares et
al., 1992). The carbapenems are extremely active against both P-lactamase-positive
and -negative strains of H. influenzae, including ampicillin-resistant P-lactamase-
negative//. influenzae (Yeo & Livermore, 1994).
1.5.1.4. Monobactams
The monobactams (monocyclic bacterially derived P-lactams) are a unique class of p-
lactam antibiotics whose central core is composed solely of a four-member P-lactam
ring and who differ from penicillins, cephalosporins, and carbapenems in that they lack
a five- or six-membered side ring (Figure 1.4). They were originally discovered in
parallel by two groups of scientist working independently; one for Squibb
Pharmaceuticals and the other for Takeda Pharmaceuticals (Sykes et al., 1981; Imada
et al., 1981).
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Figure 1.4. Structure ofMonobactams
Nuclear Structure of Monobactams
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Aztreonam
The first monobactams isolated did not exhibit particularly potent antimicrobial
activity; however, synthetic side-chain modification resulted in active compounds with
increased potency and P-lactamase stability (Sykes & Bonner, 1985). Aztreonam
(originally named azthreonam) was among the first synthetic candidates selected for
clinical development (Figure 1.4). Since aztreonam is the only representative of its
class to be commercially developed, most available information regarding
monobactams relates specifically to aztreonam.
Aztreonam has potent activity against most aerobic gram-negative bacteria, including
P. aeruginosa, but is very limited in its activity against gram-positive bacteria and
anaerobes (Jacobus et al., 1982; Barry et al., 1985). Its activity against gram-negative
organisms is similar to that of third-generation cephalosporins. Aztreonam is active in
vitro against most gram-negative aerobic bacteria because of its resistance to
hydrolysis by transferable as well as chromosomal (3-lactamases (Livermore &
Williams, 1981; Philips et al., 1981). Aztreonam is both a poor inducer and a poor
substrate for P-lactamase (Barry et al., 1985).
1.5.1.5. |3-Lactamase Inhibitors
In 1940, penicillin resistance secondary to enzymatic inactivation of penicillin was
reported, even though penicillin was not yet widely used. The enzyme, first isolated
from E. coli by Abraham and Chain, was called penicillinase (Abraham & Chain,
1940). Soon after this discovery, penicillinase was also described in other organisms
including S. aureus, which by the mid-1940s was widely resistant to penicillin.
Following the introduction of penicillin for general use in the 1950s, most isolates of
S. aureus isolated in hospitals produced penicillinase.
Many unsuccessful attempts to find an inhibitor of this enzyme were made. As early as
the 1950s, it was initially that some semisynthetic penicillins, such as oxacillin, could
function in vitro as P-lactamase inhibitors, however none proved clinically useful.
Olivanic acid and clavulanic acid were discovered as part of a large-scale screening of
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compounds which began in the mid-1960s (Rolinson, 1991). In 1981, clavulanic acid
became the first P-lactamase inhibitor introduced into clinical practice, when a
formulation that combined it with amoxycillin became available. Since that time,
clavulanic acid has been formulated in combination with other broad-spectrum
penicillins (e.g., ticarcillin), and other (3-lactamase inhibitors, including sulbactam and
tazobactam, have been developed (Rolinson, 1991) (Figure 1.5). These antibiotic
combination have significantly enhanced spectrum of activity compared with the P-
lactam component alone (Livermore, 1993). Resistance due to P-lactamase
production occurs in strains of many common organisms such as S. aureus, and H.
influenzae. These agents provide additional therapeutic alternatives for increasingly
resistant pathogens.
Most P-lactamase inhibitors developed to date are mechanism-based inhibitors or
"suicide" inhibitors of P-lactamases. These compounds, initially recognised as normal
substrates by the P-lactamase, eventually form covalent bonds with various amino
acid residues within the active site, thus leading to irreversible inactivation of the
enzymatic activity. P-Lactamase inhibitors are P-lactam compounds that lack
significant antibacterial activity but potentiate the activity of classical p-lactamase-
susceptible antibiotics by protecting them from the hydrolytic activity of p-lactamases.
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Figure 1.5. Structure of (3-Lactamase Inhibitors
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1.5.2. The Mode of Action of p-Lactam Antibiotics
The site of action of penicillins was demonstrated by Cooper who observed that
radio-labelled penicillin bound to the cell membrane and that consequently the cell
died (Cooper, 1956). Tipper and Strominger (1965), later observed that penicillin-
treated cells of S. aureus possessed more non-cross-linked peptidoglycan in the cell
wall than untreated cells. It was therefore concluded that (3-lactams inhibit the
proteins situated in the cell membrane which catalyse the transpeptidation step of
peptidoglycan synthesis so that consequently the cell loses its rigidity and lyses.
It was realised that there are different groups of proteins involved in the final stages of
peptidoglycan synthesis and each preferentially binds to a certain class of (3-lactam
(Spratt, 1975). This led to the description of the penicillin binding proteins (PBPs) in
E. coli (Waxrnan & Strominger, 1983). The usual substrate for PBPs is D-Alanyl-D-
Alanine which is very similar in structure to the (3-lactam ring. Therefore, the P-lactam
can compete with the D-Ala-D-Ala for the active site of the PBP and block the
transpeptidation step in cell wall synthesis (Tipper & Strominger, 1965).
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1.5.3. The Development of Quinolones As Antimicrobial
Agents
Unlike the (U lactam antibiotics, quinolones are completely synthetic and bear no
known resemblance to any compounds found in living organisms. The quinolones
have contributed an increasingly important chapter to the evolution of antimicrobials,
and their value is still expanding. The story of the quinolones begins in 1962 with the
discovery of nalidixic acid, the prototype 4-quinolone antibiotic (Figure 1.6) (Lesher
et al„ 1962). Nalidixic acid had adequate activity against gram-negative aerobes, but
its modest serum and tissue concentrations and its relatively high minimal inhibitory
concentrations (MICs) removed the opportunity to treat systemic infections.
Therefore, the basic quinolone structure (4-oxo-l,4-dihydro quinolone) was modified
to create more potent quinolones, with a broader spectrum and better
pharmacokinetic properties. Oxolinic acid and cinoxacin were developed in the 1970s,
but these compounds had a narrow spectrum also. The breakthrough came when
fluoro-quinolones were developed which have a much greated potency as a result of
addition of the fluorine atom at position C7 and a wider spectrum as a result of
addition of a piperazine ring at position C6 (e.g., norfloxacin, ofloxacin,
ciprofloxacin) (Figure 1.6) (Koga et al., 1980). Ciprofloxacin possessed considerably
more potent antibacterial activity than earlier fluoroquinolones.
With extensive chemical modification of the main structure, the resultant group of
fluoroquinolones have an improved antibacterial spectrum, favorable pharmacokinetic
parameters (including absorption by the oral route and better tissue penetration),
lower toxicity profiles, and a reduced tendency to develop bacterial resistance.
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Recent structural modifications among the fluoroquinolones include additional
fluorine atoms at position 8 and substitutions other than piperazine on position 7.
These new compounds enhanced the gram-positive activity of this class at the expense
ofactivity against Pseudomonas spp. Fluorine or chlorine atoms at position 8 seem to
enhance the phototoxicity of these compounds (Domagala, 1994). A methoxy group
in place of fluorine or chlorine at position 8 appears to remove the risk of
phototoxicity, as was discovered by the manufacturer ofmoxifloxacin (BAY 12-8039)
(Figure 1.6).
1.5.4. The Mode of Action of Quinolones
Over recent years there has been an enormous explosion of interest in the quinolone
drugs in general and the fluoroquinolones in particular (Hooper & Wolfson, 1993 a &
b; Kuhlmann et al., 1998).
Gyrase is essential in bacteria as it is involved in a number of cellular processes,
including DNA replication and transcription. Therefore, gyrase is an ideal target for
antibacterial agents. Evidence that gyrase is the target of the quinolones comes from
various types of experiments (Maxwell & Critchlow, 1998). Prior to the discovery of
DNA gyrase, early studies had shown that nalidixic acid was an inhibitor of bacterial
DNA replication (Pedrini et al., 1972). Following the isolation of gyrase from E. coli
by Gellert et al. (1976), it was shown that its supercoiling activity could be inhibited
by oxolinic acid (Gellert et al., 1977). Since that time a large number of quinolone-
resistance mutations have been mapped to the gyrase genes, principally to gyrA but
also gyrB (Hooper & Wolfson, 1993 a & b). One example of such a mutation is the
Ser83 to Trp mutation of GyrA found in E. coli (Yoshida et al., 1988). Enzymes
bearing this mutation are resistant to a range of quinolones in vivo and in vitro
(Yoshida et al., 1988), and, when complexed with DNA, show a greatly reduced
ability to bind the drugs (Willmott & Maxwell, 1993).
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DNA gyrase is a member of a family of enzymes called DNA topoisomerases which
control the degree of supercoiling in DNA (Wang, 1985). There are two types of
topoisomerase, I and II, which are characterised by reactions involving a single- or
double-stranded break in DNA, respectively; DNA gyrase is a type II enzyme. Gyrase
consists of two subunits, GyrA and GyrB, encoded by the gyrA and gyrB genes
(Wigley, 1995).
Gyrase binds to DNA, and a segment of approximately 130 bp is wrapped around the
protein. This wrapped DNA is cleaved in both strands, with a 4-base stagger between
the break sites, which results in the formation of DNA-protein covalent bonds
between the Gyrase subunits and the 5'-phosphates. Another segment of DNA is
passed through this double-stranded break which may then be released. This catalytic
supercoiling requires the hydrolysis of ATP. The quinolone drugs interrupt this
process at the DNA breakage-reunion step.
Although the evidence that gyrase is the intracellular target of the quinolones is
compelling, the existence of a second target, DNA topoisomerase IV (topo IV), has
recently been established. Like gyrase, topo IV is a bacteria type II DNA
topoisomerase, but unlike gyrase it cannot supercoil DNA (Kato et al., 1990). Topo
IV is composed of two subunits, ParC and ParE, which in E. coli are encoded by the
parC and parE genes. Evidence for a possible interaction between topo IV and the
quinolone drugs has come from various studies (Maxwell & Critchlow, 1998). The
function of Topo IV is to decatenate DNA, when replication has occurred, the
daughters DNA strands are often interlinked and Topo IV separates them by passing
one strand through the other.
In gram-positive bacteria, fluoroquinolones readily pass through the outer areas of the
cell membrane and enter the cytoplasm to reach the enzyme. In these organisms, the
binding affinity to DNA gyrase appears to be critical to their antibacterial activity. In
contrast, gram-negative bacteria have outer cell wall lipopolysaccharide components
and porin channels for entry of molecules. There appear to be three mechanisms for
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the uptake of fluoroquinolones by gram-negative bacteria. The first is simple diffusion
through the outer wall and the cytoplasmic membrane. Fluoroquinolones bind to the
cell surface and rapidly diffuse through both components to produce an intracellular
pool in the periplasmic space and subsequently within the cell. Fluoroqiunolones can
also enter cells via outer membrane protein porins. Finally, it appears that
fluoroquinolones chelate magnesium, causing stripping of lipopolysaccharide due to
the carbonyl groups at C-3 and C-4. Thus, the hydrophobicity of a specific
fluoroquinolone is important in its activity against some gram-negative organisms.
There are indications of an active efflux mechanism that removes quinolones from the
inside of both gram-positive and gram-negative bacterial cells.
1.6. Development of Antimicrobial Resistance
1.6.1. Mechanisms of Resistance to (3-Lactam Antibiotics
Resistance to (3-lactam antibiotics can occur by at least three routes. By far the most
widespread cause of resistance is the production of a ^-lactamase which catalyses the
hydrolysis of the antibiotic to a biologically inert product. In gram negative bacteria
resistance to P-lactam antibiotics can also result from a decrease in the rate of
penetration of the antibiotic through the outer membrane to the PBPs in the
cytoplasmic membrane. The third mechanism of resistance to P-lactam antibiotics
comes from alterations in the properties of the physiological targets of the antibiotics,
the PBPs.
1.6.2. Mechanisms of (3-Lactam Resistance in
S. pneumoniae
1.6.2.1. Penicillin Resistance in S. pneumoniae
Classification of penicillin resistance in pneumococci falls into three categories. Fully
susceptible isolates have MICs for penicillin <0.06 mg/L, MICs for intermediate
susceptible isolates are 2- to 20-fold higher than those for fully susceptible ones (i.e.,
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0.12-1 ing/L), and isolates with MICs of penicillin >1 mg/L are considered to be
resistant (Klugman, 1990).
The absence of P-lactamases in pneumococci and the probable lack of a permeability
barrier to (3-lactams in all gram positive bacteria infers that resistance to penicillin in
pneumococci stems from alterations to their penicillin-binding proteins. Resistance to
penicillin in S. pneumoniae has been shown to be entirely due to the development of
altered forms of the high molecular weight penicillin-binding protein, which have
resulted in a reduction in their affinity for the antibiotic (Hakenbeck et al., 1980;
Zighelboim& Tomasz, 1980; Spratt, 1989).
1.6.2.2. Penicillin-Binding Proteins in S. pneumoniae
Penicillin-binding proteins (PBPs) are cell membrane bound proteins that are present
in almost all bacteria. These proteins are associated with cell wall synthesis and are
important in cell functions such as division and cell differentiation processes. Major
enzymatic activities of PBPs include peptidoglycan transpeptidase and DD-
carboxypeptidase. PBPs are targets for P-lactams. Binding of p-lactam antibiotics to
PBPs leads to cell lysis, death or growth arrest (Tipper, 1985).
Penicillin-susceptible strains ofS. pneumoniae contain six PBPs, divided into five high
molecular weight PBPs and one low molecular PBPs. PBPs la, lb, 2x, 2a and 2b and
the low molecular weight PBP 3, with molecular weights of 92, 89, 82, 81, 74 and 43
kDa respectively (Hakenbeck et al., 1986 a & b; Dowson et al., 1989b & c; Laible et
al., 1989).
All six PBPs can occur as low-affinity variants in P-lactam-resistant laboratory
mutants (Laible & Hakenbeck, 1987), clinical isolates (Hakenbeck et al., 1980;
Zighelboim & Tomasz, 1980; Laible et al., 1991) or transformants obtained with
chromosomal DNA of resistant Streptococcus spp. (Reichmann et al., 1997;
Hakenbeck et al., 1998). The combination of low-affinity PBPs expressed in a
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resistant strain varies, perhaps reflecting different selective conditions and indicating a
flexibility of the resistance development pathway.
Penicillin resistance in pneumococci has been shown to be due to the sequential
alterations of up to three chromosomally encoded high molecular weight PBPs, PBP
2x, 2b and la (Dowson et al., 1993). Alterations to these PBPs, particularly to amino
acids around the active site serine residue, or around other conserved motifs typically
associated with PBPs, substantially reduce their affinity for the antibiotic (Dowson et
al, 1993).
1.6.2.3. Penicillin-Binding Proteins ofPenicillin-Susceptible
& Penicillin-Resistant Pneumococci
The pattern of PBPs on sodium dodecyl sulphate polyacrylamide (SDS-PAGE) gels
and their affinities for penicillin appear to be similar for different truly-susceptible
pneumococci (Hakenbeck et al., 1986 a & b). Isolates with low- or intermediate-level
resistance to penicillin appear to retain a normal set ofPBPs, but one or more of these
have a lower affinity for the antibiotic than the same PBPs from susceptible isolates
(Hakenbeck & Tomasz, 1986; Markiewicz & Tomasz, 1989). The PBPs from highly
resistant pneumococci have been shown to contain much more complex alterations
(Zighelboim & Tomasz, 1980; Markiewicz & Tomasz, 1989). In high level penicillin-
resistant pneumococci there have been reductions in the affinity of at least four of the
five high molecular weight PBPs (Spratt, 1989; Hakenbeck et al., 1991).
1.6.2.4. The Evolution ofMosaic Penicillin-Binding
Protein Genes
The size of the S. pneumoniae genome is between 2,240 and 2,700 kbp (Gasc et al.,
1991). The fact that the pneumococcal genome chromosome is smaller than that ofE.
coli (Smith et al., 1987) may be related to its many requirements for growth, i.e., 12
amino acids and six vitamins (Sicard, 1964). The genome sizes (1,980 kbp) and
growth requirements of H. influenzae (Kauc et al., 1989) support this notion. The
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reduced size of the pneumococcal chromosome may have resulted from the
evolutionary addition of genetic information to a smaller genome or from the
elimination of DNA from a more complex organism. This model has been suggested
to explain the recent acquisition of new sequences of penicillin-binding proteins
(Dowson et al., 1989c).
The exchange of genetic material is restricted by different mechanisms. Haemophilus,
for example, have evolved uptake mechanisms that interact specifically with
sequences that are frequent in the DNA of this species (Danner et al., 1980). S.
pneumoniae, in contrast, can take up any DNA and the formation ofmosaic genes is
restricted by the recombination machinery that requires approximately 80% sequence
identity between two homologous DNA molecules (Humbert et al., 1995).
In the late 1980s DNA sequence analysis revealed that low affinity PBPs from
penicillin-resistant pneumococci had arisen by a novel route, interspecies
recombination, presumably mediated by transformation and homologous
recombination (Dowson et al., 1989a, b). Unlike penicillin-susceptible isolates of S.
pneumoniae which possess very uniform PBP genes (<1% sequence variation),
penicillin-resistant isolates were found to have very variable PBP genes. They are
called "mosaic" genes; since these genes were composed of blocks of nucleotides that
were either similar or identical to those from susceptible isolates and blocks that were
up to 21% diverged from penicillin-susceptible isolates (Dowson et al., 1989a, b).
The genes encoding resistant PBPs la, 2x, and 2b consist of mosaics, while the PBP
lb and 2a genes have not yet been sequenced. It was concluded that these mosaic
PBP genes were the results of localised recombination events between S. pneumoniae
and the homologous genes from at least two closely related species (Dowson et al.,
1989b). It is now clear that one of the species that has donated PBP 2b genes to
pneumococci is Streptococcus mitis, which is a commensal member of the oral flora
(Dowson et al., 1993). One of the donors of PBP 2x genes is thought to be another
member of the oral flora, Streptococcus oralis (Sibold et al., 1994). Interestingly,
transformation ofS. pneumoniae from optochin sensitivity; a characteristic trait of the
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species, to optochin resistance has also been observed under laboratory conditions
using S. oralis chromosomal DNA as donor (Fenoll et al., 1994).
Although some mosaic PBP 2b genes are composed of a single block derived from S.
mitis, others are more complex and are the result of recombination with several
donors, possibly each bringing in alterations that further reduce the affinity for
penicillin or other P-lactams.
1.6.2.5. Penicillin-Binding Proteins 2B, 2X & 1A
PBPs 2b, 2x and la are three of the five high molecular weight PBPs found in S.
pneumoniae with molecular weights of 74, 82, and 92 kDa, respectively. The pbp2b,
2x and la genes encoding PBP 2b, 2x, and la have been cloned and sequenced
(Dowson et al., 1989a; Laible et al., 1989; Martin et al., 1992 ) and 2280, 2250, and
3378 -bp open reading frames were identified as encoding PBP 2b, 2x, and la,
respectively.
PBP 2b is thought to be an important killing target for penicillin (Tuomanen & Sande,
1989) and inactivation of this protein by |3-lactam antibiotics has been associated with
their ability to cause cell lysis (Hakenbeck et al., 1987). The affinity of PBP 2b for (3-
lactam antibiotics has been found to be greatly reduced in penicillin-resistant
pneumococci (Tomasz et al., 1984).
PBP 2x is thought to be a major target for P-lactams since it is the first PBP altered in
P-lactam-resistant laboratory mutants (Laible & Hakenbeck, 1991), as well as
penicillin-resistant clinical isolates (Laible et al., 1991). Additionally, PBP 2x has also
been shown to be involved in the resistance to third-generation cephalosporins in
clinical pneumococcal strains (Munoz et al., 1992). In conjunction with other high
molecular weight PBPs, PBP 2x develops distinct changes in its affinity towards
penicillin in pneumococci that have become penicillin-resistant (Hakenbeck et al.,
1991). The first three-dimensional crystal structure of PBP 2x has been reported
(Pares et al., 1996) and it has been found that the molecule has three domains, the
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central domain being a transpeptidase, which is suitable target for antibiotic
development.
Comparison of the PBPs from penicillin-susceptible and -resistant pneumococci have
shown alterations ofPBP la to be associated with resistance to penicillin (Markiewicz
& Tomasz, 1989; Hakenbeck et al., 1991). This protein presumably plays a role in the
development of resistance to penicillin in pneumococci. The pbpla gene was found to
map close to the pbp2x gene on the chromosome (Gasc et al., 1991). In conjunction
with PBP 2x, altered forms of this protein have been shown to confer resistance to
third-generation cephalosporins in clinical pneumococcal strains (Munoz et al., 1992).
A low-affinity PBP la considerably increases the resistance in a strain with low-
affinity PBP 2x and/or PBP 2b (Munoz et al., 1992; Reichmann et al., 1996).
A low affinity PBP 2b alone confers low levels of resistance to penicillin. However, it
does confer another remarkable phenotype, which is reduced lysis upon P-lactam
treatment (Grebe & Hakenbeck, 1996). This is reminiscent of the fact that third-
generation cephalosporins that do not interact with PBP 2b invoke a tolerant response
(Hakenbeck et al., 1987), and a low affinity PBP 2b mimics that effect in regard to
other P-lactams. This property, which had been noted in most penicillin-resistant
pneumococci, indicates that resistant strains are generally better survivors and can
therefore spread more easily than the highly autolytic wild-type strains, and may
contribute to the fact that clones of resistant pneumococci are sufficiently stable to be
recognisable (Moreillon & Tomasz, 1988; Tuomanen et al., 1988). It also implies that
strains with low affinity PBP 2b have a better chance to take up DNA , including
genes encoding low affinity variants of other PBPs that are required for higher
resistance levels (Hakenbeck, 1998).
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1.6.3. Mechanisms of p-Lactam Resistance in
H. influenzae
I.6.3.1. p-Lactamase-Mediated Resistance
There are nearly 300 (3-lactamases found in clinical bacteria and several attempts have
been made to classify them (Table 1.1). They are most easily categoriesd by their
molecular structure (Ambler class) in which there are four classes; three have serine at
the catalytic side and one has a metal ion, usually zinc.
The mode of action of the serine type (T lactamase, such as that found in H. influenzae
(3-lactamase, is shown in (Figure 1.7). Phases of the reaction are: (I) reversible non-
covalent binding of the P-lactamase and the P-lactam ring; (II) rupture of the P-lactam
ring, which becomes covalently acylated on to the active-site serine; and (III)
hydrolysis of the acyl enzyme to reactivate the p-lactamase and liberate the inactivated
drug molecule (Livermore, 1998).
The major mechanism of resistance to P-lactam drugs in H. influenzae is the
production of P-lactamases, and the prevalence of P-lactamase-producing isolates has
increased over the last 2 decades. The extent of non-P-lactamase-mediated resistance
has always been difficult to assess and it is possible that P-lactamase production may
be missed by routine testing (Shanahan et al., 1996).
Three P-lactamases have been described in H. influenzae, TEM-1, ROB-1, and most
recently, VAT-1. TEM-1 has been found in c. 80% of P-lactamase-positive isolates
(Shanahan et al., 1996). Although less numerous than TEM-1, ROB-1 has been found
in up to 8% of isolates in some studies (Scriver et al., 1994).
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Figure 1.7. Mechanism of Serine-Based (3-Lactamase





The first reports of clinical resistance to ampicillin in cases ofH. influenzae meningitis
appeared in 1974 (Gunn et ah, 1974; Thomas et al., 1974). After that report it was
soon shown that the resistance was associated with the presence of a P-lactamase
(Williams et al., 1974; Sykes et ah, 1975). As judged by its substrate profile and
isoelectric focusing (IEF) point (pi 5.4), the P-lactamase present in the resistant
isolate is similar to the TEM-1 P-lactamase found in E. coli (Sykes et ah, 1975).
Elowever, DNA sequence analysis of TEM-1 genes (blajEM) in H. influenzae suggests
that the blajEM in this species may differ from its E. coli counterpart, and that silent
amino-acid substitutions in TEM-1 have occurred (Vali et ah, 1995; Vali, 1995). The
genetic basis of the TEM-1 P-lactamase-mediated resistance in H. influenzae has been
well characterised and result indicates that it belongs to Bush group 2b, Ambler class
A enzymes (Bush et ah, 1995). The P-lactamase is shown to be plasmid-mediated,
and restriction enzyme analysis suggests that this enzyme is derived from TEM-1 from
Enterobacteria, and that DNA deletion and substitution account for its heterogenicity
(Harkess & Morray, 1978).
Some of the plasmids can conjugatively transfer among H. influenzae strains, and
carry an intact TnA-type transposon as well as other resistance genes. Other plasmids
are smaller, are transfer deficient and have undergone deletions of transposon DNA
(deGraaff et ah, 1976). However, some P-lactamase-producing isolates of EI.
influenzae do not contain plasmid DNA and studies show that the plasmid encoding




In 1981, a second p-lactamase was reported in H. influenzae by Rubin et al., and
referred to as ROB-1. Its substrate profile is quite similar to that of TEM-1, but has a
much higher pi value of 8.1. It is more strongly inhibited by cloxacillin than is TEM-1.
The ROB-1 gene (blazon) is harbored by a 4.4 Kbp plasmid and shows no
hybridisation with an intragenic probe for the 6/«tem (Medeiros et al., 1986). The
ROB-1 p-lactamase is shown to be plasmid-mediated and transferable. A 4.4 Kb
ROB-1 plasmid was also found in Pasteurella haemolytica (Livrelli et al., 1991),
while a 5.4 Kb ROB-1 coding plasmid was isolated from Haemophilus ducreyi
(MacLean et al., 1992) and also from Actinobacillus pleuropneumoniae (Medeiros et
al., 1986). All these plasmids are highly related, as measured by DNA hybridisation
studies (Medeiros et al., 1986; Livrelli et al., 1991).
The 6/tfROB gene encoding ROB-1 has been sequenced, and result indicates that it
belongs to Bush group 2b, Ambler class A enzymes (Juteau & Levesque, 1990; Bush
et al., 1995). The demonstration of similar enzyme in Pasteurella haemolytica and
Actinobacillus pleuropneumoniae suggests that the family Pasteurellaceae may be
the source of this P-lactamase gene.
iii. VAT-1 p-Lactamase
A completely novel P-lactamase, VAT-1, has also been identified recently in H.
influenzae (Vali et al., 1994). The significance of this enzyme is not clear at present,
but it has been detected in isolates from different geographical centres in Scotland
(Shanahan et al., 1996; Vali et al., 1995). The gene encoding VAT-1 has not been
sequenced, but biochemical data suggest that it is a Bush class 1, Ambler class C P-
lactamase (Bush et al., 1995). VAT-1 exhibits cephalosporinase activity and
resistance to the P-lactamase inhibitors clavulanic acid, sulbactam and tazobactam
(Vali et al., 1994).
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1.6.3.2. Changes of Penicillin-Binding Proteins
In the 1980, ampicillin-resistance in the absence of p-lactamase production was
reported in H. influenzae (Bell & Plowman, 1980; Markowitz, 1980). The major
mechanism of intrinsic ampicillin resistance appears to be due to altered PBPs since
reduced affinity ofPBPs for ampicillin and other P-lactam agents are observed in such
isolates (Parr & Bryan, 1984; Mendelman et al., 1984; Reid et al., 1987). In
ampicillin-susceptible H. influenzae, a relatively homogeneous pattern of eight PBPs
are found (Serfass et al., 1986; Mendelman et al., 1990), whereas intrinsically
ampicillin-resistant //. influenzae has heterogenous PBP profiles, with five to ten
PBPs detected (Serfass et al., 1986; Clairoux et al., 1992). The numbering of the
PBPs in H. influenzae has become rather confused. Nevertheless, PBPs 3, 4 and 5
appear to be involved in this resistance phenotype. Furthermore, the role of PBP
alterations in resistance has definitely been proven by the selection of transformants
with similar defects. The genetic basis of this form of resistance is poorly understood
but the altered genes are known to be carried on the chromosome. The genes for the
altered PBPs have been cloned (Malouin et al., 1987) and results showed that the low
penicillin-binding capacity and the P-lactam resistance profiles may be attributed to at
least two distinct chromosomal mutations.
1.6.3.3. Outer Membrane Proteins & Permeability
Although it is likely that the alteration of PBPs is the most frequent cause of non-P-
lactamase-mediated resistance in H. influenzae, decreased outer membrane
permeability has also been reported. Burns and Smith (1987) found that some H.
influenzae resistant to p-lactams lacked a 40 kDa major porin. However, the PBPs of
that particular isolate were not investigated. Reid et al. (1987) implied that outer
membrane profile differences exist between ampicillin-susceptible and -resistant, P-
lactamase-negative H. influenzae isolates of the same biotype. However, no specific
protein change was accounted for this finding.
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1.6.4. Mechanisms of Resistance to Quinolones
There are three mechanisms by which microorganisms develop quinolone resistance:
(1) a mutational change in the microbial DNA topoisomerase, (2) selected changes in
outer membrane proteins, and (3) development of a highly active energy dependent
efflux system.
1.6.4.1. Target Sites Modification
Mutations of the gyrA gene confer a degree of broad spectrum resistance to all
quinolones. Resistance caused by gyrA mutation has been reported in the following
species: H. influenzae, S. aureus and S. pneumoniae (Tankovic el al., 1996; Vila et
al., 1999). These mutations involve the substitution of amino acids at key enzymatic
sites that are involved in the generation of the DNA-gyrase-bacterial complex (Mayer
et al., 1995). The effect of these amino acid changes on the secondary and tertiary
structures of the GyrA are unknown; however, these alterations affect the affinities of
the quinolones for the DNA gyrase-DNA complex. The GyrA protein mutations are
closely clustered in a region of about 40 amino acids in the N-terminal domain of the
A subunit (Maxwell, 1992). It has been proposed that quinolone binding is
cooperative, with at least four molecules binding per site and being associated with
each other by hydrophobic interactions between the gyrase via the group at the C7
position of the quinolone (Maxwell, 1992). This quinolone-gyrase-DNA complex
forms a barrier to the passage of polymerase.
Mutations can occur in both topoisomerase IV and DNA gyrase in S. aureus, and
mutations in gyrA and gyrB can occur in the same strain of S. aureus, having an
additive effect in raising the resistance level to ciprofloxacin (Gootz & Brighty, 1996).
gyrB mutations are associated only with low-level resistance (Bryskier, 1993). In
addition, quinolone resistance in pneumococci has been found to be caused by
mutations in parC (Tankovic et al., 1996). Neither plasmid-mediated nor transposon-
mediated resistance to the quinolones has been described to date in clinical isolates.
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1.6.4.2. Decreased Uptake
The second mechanism involves mutations that affect the permeability of the cells to
the quinolone, therapy resulting in reduced uptake into the microbial cell. This may be
the result of diminished production of the outer membrane proteins, particularly
OmpF, of gram-negative microorganisms (Piddock et al., 1991) and is of particular
concern because the decreased permeability leads to cross-resistance with structurally
unrelated antimicrobial agents. In contrast, decreased uptake has not been
demonstrated to be a mechanism of resistance in gram-positive bacteria.
Hydrophobic quinolones (e.g., nalidixic acid) pass directly through the lipid bilayer of
the cell membrane whereas hydrophilic quinolones (e.g., ciprofloxacin) pass through
water-filled protein pores called porins. In E. coli, the inactivation of the ompF gene
and mutations in the regulatory genes controlling expression of the major porin ompF
gene can cause resistance to quinolone as well as other non-related groups of
antibacterials (Cohen et al., 1989). Reduction of the OmpG production has been
reported in P. aeruginosa (Chamberland et al., 1989).
1.6.4.3. Increased Efflux
This mechanism prevents effective intracellular concentrations of the quinolones from
being attained and involves an active efflux system at the inner membrane. Efflux
occurs through the cytoplasmic membrane into the periplasmic space probably via an
energy-dependent active transport system (Bryskier, 1993). Although not identified
for all quinolones, this mechanism occurs in both gram positive and gram negative
microorganisms. Efflux seems to act in conjunction with a second mechanism,
possibly one causing reduced diffusion across the outer membrane through porin
channels (Mayer et al., 1995). In S. aureus, the norA gene encodes for a multiple
antibiotic efflux pump (Neyfakh et al., 1993). In addition, data from a recent study by
Brenwald et al., indicates that a multidrug efflux mechanism may also occur in mutant
strains of S. pneumoniae (Brenwald et al., 1997).
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1.7. Incidence & Spread of Antimicrobial Resistance
1.7.1. Incidence of Resistance in S. pneumoniae
The origins of penicillin-resistant pneumococci remain unclear, and they have
probably emerged on many occasions at diverse geographical locations. They were
first recorded in the late 1960s in Australia, Papua New Guinea and the USA
(Hansman & Bullen, 1967; Hansman et al., 1971; Naraqi et al., 1974). Since then,
penicillin-resistant isolates (with MICs >0.1 mg/L) have been reported worldwide
(Appelbaum, 1987) with particular high incidences among invasive isolates from
Hungary, South Africa and Spain (Klugman, 1990) (Figure 1.8). There has also been
a marked increase in the levels of resistance to penicillin. In Spain more than 15% and
in Hungry more than 48% of the total number of penicillin-resistant isolates are highly
resistant (MICs >1 mg/L) (Fenoll et al., 1991; Marton et al., 1991), and isolates with
MICs of 16 mg/L have been found recently in central Europe.
Until recently the UK was considered to have low prevalence of penicillin-resistant
pneumococci. As recently as 1990, 100% of 7255 strains of pneumococci from 61
centres across the UK were found to be penicillin susceptible (Spencer et al., 1990).
However, there have now been several reports of significant and rising levels of
resistance nationwide (Goldsmith et al., 1997). In Northern Ireland, 3171 strains of S.
pneumoniae were examined, during which time the annual rate of penicillin resistance
was found to increase from <1% to 10.6% (Goldsmith et al., 1997). Similar rates of
penicillin resistance have now been reported from several geographically disparate
regions in the UK (Goldsmith et al., 1997). Clearly both penicillin-resistant and
multidrug-resistant pneumococci are increasing in prevalence in the UK, and this
increase is likely to continue.
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A low incidence of resistance is found in several other countries of Northern Europe
and elsewhere. Continuing surveillance is essential in those countries in which
resistant pneumococci are rare, since these strains can rapidly become entrenched
within a community. A good illustration is provided by studies from Iceland where
penicillin-resistant pneumococci were unknown until 1989 when a multiresistant
serotype 6B pneumococcus appears to have been imported from Spain: within 4
years, 20% of pneumococcal infections in Iceland were due to this multiresistant
strain (Soares et al., 1993). Similarly, in Hong Kong the incidence of penicillin
resistance in pneumococci from sputum has increased from 6.6% in 1993 to 55.8% in
1995 (Lyon et al., 1996). Another example has been observed in the USA. where low
incidence of penicillin resistance appeared in 1980s but recent surveys have shown an
overall incidence of penicillin resistance among invasive isolates to have increased to
25%, with much higher proportions of resistant isolates in some areas (e.g. 70% in
Tennessee). Most of the rise in resistance also appears to be due to the establishment
of imported Spanish multiresistant pneumococci.
Multiple resistance, defined as resistance to at least three different classes of
antibiotic, is frequently encountered in penicillin-resistant isolates (Appelbaum, 1987).
The emergence of multiply-resistant pneumococci was first observed from South
Africa (Jacobs et al., 1978). A strain from a paediatric patient with pneumonia was
resistant to penicillin, erythromycin, tetracycline, chloramphenicol, clindamycin and
TMP-SMZ. A subsequent study in South Africa showed the prevalence of multiple-
resistant pneumococci to be as high as 56.5% in some areas (Koornhof et al., 1978).
In Spain, resistance to chloramphenicol, tetracycline and TMP-SMZ was observed in
83% of the penicillin-resistant isolates causing pneumonia, and also in up to 33% of
the penicillin-susceptible strains isolated from control patients (Pallares et al., 1987).
Other antimicrobial agents, such as erythromycin, TMP-SMZ, tetracycline, and
chloramphenicol may be used to treat pneumococcal infections, but resistance to these
agents usually increases in parallel with penicillin resistance rates, and multiresistant
strains have been problematic in some communities. There is cross resistance among
52
the macrolides, and erythromycin-resistant strains are also resistant to clarithromycin
and azithromycin (Moreno et al., 1995). Vancomycin resistance has not been
described among pneumococci. Early-generation fluoroquinolones are not particularly
active against pneumococci, but newer quinolones such as levofloxacin, and
trovafloxacin are highly active against both penicillin-susceptible and -resistant
pneumococci (Visalli et al., 1996). In contrast to many other antimicrobial agents,
there is usually no association between penicillin resistance and susceptibility to
vancomycin or the quinolones.
1.7.2. Spread of Resistance in S. pneumoniae
Resistance to penicillin in S. pneumoniae has been shown to be entirely due to the
development of altered forms of the high molecular weight PBPs, which have resulted
in a reduction in their affinity for the antibiotic (see section 1.6.2).
Penicillin-binding-protein-mediated resistance to penicillin can spread either by the
dissemination of resistant organisms (clonal spread) or by the dissemination ofmosaic
genes (horizontal spread) (Dowson et al., 1994; Crook & Spratt, 1998). Thorough
analysis of these organisms requires the use of techniques that index both their overall
genetic relatedness (e.g. multilocus enzyme electrophoresis) and the relatedness of
their altered penicillin-binding protein genes (e.g. gene fingerprinting).
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1.7.2.1. Clonal Spread ofDrug-Resistant Pneumococci
The Major Spanish Clones ofAntibiotic-Resistant
Pneumococci
The best characterised, and most globally distributed, penicillin-resistant strains are
those that originated within Spain. Two multiresistant strains become prevalent in
Spain during the 1980s.
One of these, the multiresistant serotype 23F clone (resistant to penicillin,
tetracycline, chloramphenicol and cotrimoxazole) probably arose in Spain at least 15
years ago, and has been identified subsequently in at least six other countries across
three continents (Coffey et al., 1991; Munoz et al., 1991; Sibold et al., 1992) (Figure
1.8). As members of this resistant clone have spread, they have been exposed to new
selective pressures applied by regional variations in usage of the different classes of
antibiotics. This has led to variants of the 23F clone that are resistant to erythromycin
in South Africa (Klugman et al., 1994) and in the USA (McDougal et al., 1992) also,
in the USA, to variants that have increased resistance to extended-spectrum
cephalosporins (McDougal et al., 1995) (Figure 1.8).
The second major multiresistant Spanish serotype 6B clone, has a similar resistance
profile and appears to have spread slightly less than the 23F clone. It has, however,
been found in the UK and several European countries, the Far East and the USA, and
has been particularly successful in Iceland (Soares et al., 1993) (Figure 1.8).
1.7.2.2. Horizontal Gene Transfer in Pneumococci
Analysis of the overall relatedness of isolates and that of their mosaic pbp genes has
revealed the huge diversity of penicillin-resistant pneumococci and the independent
origins of the resistant isolates from Spain and South Africa. The diversity of
penicillin-resistant pneumococci is evident both from an analysis of their mosaic pbp
genes and from the genetic backgrounds in which these genes are found (Dowson et
al., 1997; Crook & Spratt, 1998). Some of the diversity is probably due to the
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multiple origins ofmosaic pbp genes, but a major part within countries may be due to
the distribution of mosaic pbp genes between pneumococcal lineages by horizontal
gene transfer. Horizontal gene transfer has been invoked to explain the presence of
identical mosaic pbp genes in penicillin-resistant pneumococci from genetically
distinct lineage.
A third Spanish clone of serotype 9V, that is resistant only to penicillin and
cotrimoxazole, has also spread globally and possesses the identical penicillin-binding
protein genes (pbpla, 2b and 2x) as the 23F clone, although it has a very different
overall genotype (Coffey et al., 1991). The 9V clone has probably emerged by the
horizontal spread of the altered pbp genes from the 23F clone into a penicillin-
susceptible serotype 9V pneumococcus (Coffey et al., 1991).
1.7.2.3. Serotype Changes Among Penicillin-Resistant
Pneumococci
Several groups have provided evidence that members of a single penicillin-resistant
clone may express distinct capsular polysaccharides. The existence of penicillin-
resistant clinical isolates that are identical in overall genotype, in their antimicrobial
resistance profile, and which posses identical altered forms of the pbpla, 2b and 2x
genes, except capsular type has led to the suggestion that horizontal transfer of genes
involved in capsular biosynthesis may be important in generating penicillin-resistant
clonal variants of differing serotypes. For example, serotype 19F isolates from Spain
and the USA are indistinguishable from members of the multiresistant serotype 23F
clone, except for their capsular type (Coffey et al., 1991; McDougal et al., 1992).
Another example of putative serotype changes among penicillin-resistant
pneumococci was found in isolates from Kenya (Kell et al., 1993).
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1.7.2.4. Global Distribution of Resistant Clones
Several general conclusions can be drawn from the molecular epidemiological studies.
Firstly, even within a single country, there is a considerable diversity of penicillin-
resistant strains. Many penicillin-resistant strains appear to be unique isolates, but
among this diversity there are some strains that are recovered repeatedly, and which in
some cases are spreading globally (Coffey et al., 1995; Tomasz, 1997). Secondly, the
majority of resistant isolates belong to relatively few serotypes, which are those
commonly associated with carriage and disease in children (e.g. 6B, 14, 19A, 19F,
23F) (Klugman, 1990). Thirdly, the resistant strains recovered in different countries
are often unrelated. For example, the multiresistant strains recovered within Spain,
Hungry and South Africa are completely distinct, and almost certainly emerged
separately in each of these countries. This distinction is now becoming slightly blurred
as successful resistant clones are spreading globally, and also does not apply to
neighboring countries which often share the same resistant pneumococci (Klugman,
1990).
1.7.3. Incidence of Resistance in H. influenzae
1.7.3.1. Overall Incidence
Resistance to ampicillin was first documented in Europe in 1972 (Mathies, 1972).
Since then, considerable information has been gathered with regard to its prevalence
throughout the world.
Among the mechanisms mentioned (see section 1.6.3.1) production of TEM-1 (3-
lactamase is by far the most common cause of ampicillin resistance encountered in H.
influenzae globally, especially among H. influenzae type b (Powell et al., 1987;
Jorgensen et al., 1990; Collignon et al., 1992). Among the [3-lactamase producers,
7% produced ROB-1 enzyme in a recent survey in Canada (Scriver et al., 1994), and
8% in a survey in the EISA (Daum et al., 1988) but only about 0.6% in a survey in
France (Joly et al., 1987). Intrinsically ampicillin-resistant H. influenzae accounts for
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<5% of isolates and are more common among non-capsulated organisms (Howard &
Williams, 1988 & 1989; Powell e/ al., 1987).
Since the last decade, the prevalence of P-lactamase production in the UK has
increased significantly from 6.2% in 1986 (Powell et al., 1987) to 8.6% in 1991
(Powell et al., 1992). Similarly, the incidence in the USA has also increased in the
past ten years (Jorgensen et al., 1990; Barry et al., 1994). In Europe, p-lactamase-
producing isolates appear to be confined to certain areas. Machka et al., (1988)
published data on the susceptibility of H. influenzae isolated from nine countries in
1986, which showed that Spain had the highest incidence of P-lactamase-producing
isolates (35%). In other European countries, the incidence of p-lactamase isolates was
27% in Belgium, 11% in France, 6% in Austria, 2% in Germany and 6% in
Switzerland. In addition, the overall rate of P-lactamase production was 16% in
Australia (Collignon et al., 1992) and 28.4% in Canada (Scriver et al., 1994).
During the 1980s, as result of excellent in vitro activity and CSF penetration, third-
generation cephalosporins became the preferred treatment for invasive H. influenzae
disease (Campos & Garcia, 1987). First-generation cephalosporins (e.g., cefaclor and
cephalexin) have limited activity against H. influenzae (Powell et al., 1991). Cefaclor
resistance has a prevalence of 1.4 to 5.5% in the USA and 2% in Europe. Second-
and third-generation oral cephalosporins, cefuroxime axetil, cefixirne and
cfepodoxime proxtil have MICs below 0.5 mg/L. Resistance is generally less than 2%
for cefuroxime and cefamandole, and resistance to newer cephalosporins has not been
documented (Rockowitz & Tunkel, 1995). Cefotaxime, ceftazidime and ceftriaxone
all have excellent CSF penetration and are extraordinarily active against H. influenzae
(Jacobs & Kearns, 1989). P-Lactamase producers are susceptible to P-lactam
antibiotic/p-lactamase inhibitor combinations and many newer cephalosporins. The P-
lactamase inhibitors clavulanate, sulbactam, and tazobactam are active against H.
influenzae harboring TEM-1 and reduce the MIC by 8-to 64-fold.
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In the UK, erythromycin has little activity against H. influenzae. Resistance to
chloramphenicol and tetracycline has been detected, but is currently <5% for each
(Brown et al., 1996). Current resistance level to trimethoprim is 9.6% (Brown et al.,
1996). Although there are a number of isolated reports of the emergence of quinolone
resistance in H. influenzae (Gould et al., 1994), this does not appear to be a
widespread phenomenon and resistance to ciprofloxacin and other quinolones remains
low.
Problems with the therapy of infection due to bacterial isolates with "intermediate"
susceptibility has been shown to occur in S. pneumoniae (Klugman, 1990). If this is
found to be of clinical importance with H. influenzae, there will be major problems in
the therapy of infections caused by such organisms. Moreover, this type of reduced
susceptibility often extended not only to co-amoxiclav, but also to other P-lactams.
1.7.3.2. Incidence in Capsulated and Non-Capsulated
H. influenzae
H. influenzae type b isolates were statistically much more likely to be P-lactamase-
positive than the non-capsulated isolates, this is in agreement with the results of the
UK surveys of 1986 (Powell et al., 1987) and 1991 (Powell et al., 1992). These
patterns have also been described elsewhere (Doern et al., 1988; Collignon et al.,
1992). In concordance with the findings of these authors, type b isolates were
statistically more likely to be isolated from body fluids than from other sources and
were more often isolated from patients under the age of five than from other age
groups (Nazareth et al., 1992).
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1.7.3.3. Incidence in Non-p-Lactamase-Mediated
Resistance
The incidence of non-P-lactamase-mediated-resistance to ampicillin (MIC >1 mg/L) in
H. influenzae isolates has continued to rise in the last few years in the UK; from 4%
in 1986 (Powell et ah, 1987) to 5.8% in 1991 (Powell et al., 1992). Among other
international studies, only Australia has previously reported a high resistance rate,
where 7% of isolates were resistant to ampicillin in the absence of (3-lactamase
production (Bell & Plowmann, 1980). Such strains remain rare, accounting for fewer
than 1% of all isolates elsewhere (Barry et al., 1994; Scriver et al., 1994). However,
many authors only included those isolates for which the ampicillin MIC exceeded 1
mg/L as resistant, and isolates for which the MIC was 1 mg/L as intermediate. If an
ampicillin breakpoint MIC of >2 mg/L were applied, the present rate of non-(3-
lactamase-mediated isolates with reduced susceptibility to ampicillin would fall to
2.7%, which is more closely in agreement with data from elsewhere.
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1.8. Application of Techniques to Determine the Incidence,
Mechanism and Spread of Resistance
To be a useful epidemiologic tool, a typing system must give an unambiguous result
for each isolate (typeability), give the same result each time the same isolate is tested
(reproducibility), and differentiate among epidemio logically unrelated strains
(discriminatory power). The earliest typing methods used for epidemiologic purposes
were phenotypic methods. Phenotypic methods detect characteristics expressed by
microorganisms in response to antibiotics or other inhibitors, as a product of one of
their enzymes, or as a protein on their cell surface. Phenotypic methods are not as
stable as DNA-based methods. In addition, phenotypic methods tend to lump isolates
together in large groups, and thus, do not discriminate between strains as well as
DNA-based methods. Genotypic typing methods that evaluate differences at the DNA
level are used more commonly because they are more discriminatory than phenotypic
methods. In addition, all isolates should be typeable by tests evaluating the
chromosomal DNA and the results are usually reproducible, which cannot be said of
phenotypic methods.
1.8.1. p-Lactam Resistance Mediated by Changes in PBPs
PBP-mediated resistance occurs when the resident PBPs are altered to forms where
they have a substantially reduced affinity for penicillin or other (f-laetams, as in the
evolution of penicillin-resistant strains ofS. pneumoniae and H. influenzae.
1.8.1.1. Detection of Resistance to p-Lactams
The upward trend of P-lactam resistance in S. pneumoniae emphasises the need for a
reliable and convenient method for its detection. For the routine testing of penicillin
susceptibility of pneumococci, the use of 1 jag oxacillin discs is thought to be a
reliable method, and its currently recommended by the National Committee for
Clinical Laboratory Standards (NCCLS, 1990) and the British Society for
Antimicrobial Chemotherapy (BSAC, 1998). This method does not give a truly
quantitative susceptibility determination, and it is difficult to distinguish between the
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transitions from low-level penicillin resistance, to intermediate-level resistance, and to
high-level resistance. Such distinctions are clinically important for treatment decisions
for pneumococcal infections (Paris et al., 1995). The E-test is thought to be one of
the most accurate of the commercial tests that are available (Tenover et al., 1996),
and a reliable alternative to agar or broth dilution methods.
Several DNA amplification-based techniques have been described that use pbp gene
PCRs as targets (Ubukata et al., 1996; Jalal et al., 1997). Alternatively, a restriction
fragment length polymorphism (RFLP) strategy has also been investigated and has
been shown to be valuable in differentiating between penicillin-susceptible and -
resistant pneumococcal strains and can be used to complement PCR diagnosis (O'Neill
etal., 1999).
1.8.1.2. Detection of PBPs & Their Affinity for (3 -Lactams
PBPs profiles can be detected by incubating whole cells or membrane preparations
either directly with radiolabelled penicillin, or in competition with unlabelled
compounds, then resolving them in SDS-PAGE and visualising them by fluorography
(Spratt, 1977). This technique does not look directly at the PBP genes but the
proteins that they encode, revealing any variation in the number and molecular size on
SDS-PAGE. This technique has different limitations, is time consuming and requires
usage of radiolabelled compounds. In addition, several earlier studies were unable to
resolve each of the PBPs and, hence, this makes the results difficult to interpret.
Reproducibility between different results requires a strict adherence to protocol as
even a change in the manufacturer of the SDS used for PAGE can alter the final
fluorogram. Apart from this, altered low-affinity PBPs can migrate either fast or slow
to give an apparently altered molecular weight when compared with their high affinity
forms (Markiewicz & Tomasz, 1989).
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1.8.1.3. Epidemiologic Investigation
In species where recombination is common, as in S. pneumoniae, one has to be
careful in attributing inappropriate epidemiologic weight to phenotypic methods such
as serotyping or antibiotic resistance patterns when trying to determine whether
resistance has spread clonally or by horizontal gene transfer. This distinction can be
achieved using a combination of methods such as multilocus enzyme electrophoresis
(MLEE), ribotyping, pulsed-field gel electrophoresis (PFGE) and gene fingerprinting
or partial gene sequencing that are able to index either the overall genetic relatedness
between isolates or the relatedness of their resistance determinants. Resistant
pneumococci, that are not closely related, can possess identical altered pbp genes and
isolates that are apparently genetically identical can possess different pbp genes
(Dowson & Coffey, 1998).
1.8.2. p-Lactam Resistance Mediated by Production of
p-Lactamases
P-Lactamases confer resistance to p-lactam antibiotics, which are the most widely
used family of antibiotics. It is, therefore, essential that one can identify the
production of P-lactamases by clinical isolates and have effective ways of
distinguishing the different enzymes. This is necessary for epidemiologic surveys,
predicting future resistance trends, and to ensure that patients receive the appropriate
p-lactam or alternative therapy.
1.8.2.1. Biochemical Application for Characterisation of
p-Lactamases
For the past 20 years thin-layer polyaerylamide isoelectric focusing (IEF) has played a
major role in the identification and characterisation of p-lactamases (Matthew el al.,
1975). IEF is able to distinguish enzymes that focus only 0.05 pi apart (Payne et al.,
1989), but the exponential increase in the numbers of P-lactamases discovered over
the last 10 years (>200 P-lactamases) has meant that this method no longer provides
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sufficient resolution to distinguish the majority of P-lactamases. Today the pi of a p-
lactamase is still an essential determinant that must be used in combination with a
variety of other data. Moreover, the IEF of P-lactamases is now entering a new era as
this technique can be adapted to provide important biochemical information on p-
lactamases other than simply their pi values (Payne & Farmer, 1998).
1.8.2.2. Molecular Approaches for the Detection &
Identification of p-Lactamases
Molecular techniques have become very effective for identifying different P-
lactamases (Payne & Thomson, 1998). However, in some cases this approach must
still be combined with kinetic and IEF data to identify a P-lactamase.
The first indication of the presence of P-lactamases is usually the observation of
increased levels of resistance in clinical isolates as detected by routine susceptibility
testing. In some species, like H. influenzae, the presence of a P-lactamase in itself is
enough information to make a judgment on treatment options. IEF then can be used
to characterise the P-lactamase produced. However, the whole approach is time
consuming, in terms of enzyme extract preparation and running electrophoresis, and
the need for large amount of cells for enzyme extraction.
PCR has been extensively used in the detection and analysis of resistance genes in
bacterial isolates (Jalal et al., 1997) and in the detection of specific microorganism
directly in clinical and environmental specimens (Shirai et al., 1991). However, it is
only relatively recently that the possibility of employing PCR in the direct detection of
resistance genes in clinical specimens has been investigated. PCR has been used to
detect ampicillin resistance genes in CSF samples containing H. influenzae (Tenover
et al., 1994). PCR primers were used that were specific for the Wotem and blazon
genes. Correlation was obtained between the result of MIC testing, P-lactamase
production as determined by nitrocephin and PCR testing. The primary advantage of
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PCR is that it detects and amplifies very small amounts ofDNA in a short amount of
time. However, any contaminating DNA can produce false-positive results.
1.8.3. Molecular Characterisation ofQuinolone Resistance
Unlike the p-lactams, it is not possible to examine the resistance pattern to a cohort of
quinolones and predict the resistance mechanism. Resistance to one of the group is
almost always accompanied by a proportional increase in resistance to the others,
which means that distinction cannot be made by observing differential increases in
resistance.
Recently, PCR has been used to amplify the quinolone resistance-determining region
(QRDR) of the gyrA gene and, more latterly, the parC gene. This takes
oligonucleotides that match conserved sequence and part of the gene, of known and
measurable size, is amplified. Subsequently, it is possible to separate the DNA strands
and directly sequence them. This is not feasible in a diagnostic laboratory as, although
fairly rapid nowadays, the use of a radiolabel, for sequencing, and the time taken for
analysis makes it impractical. If a suitable restriction site is found, then it is possible to
distinguish alterations in a specific codon. This is much more practicable, and it is
quite possible to prepare amplified DNA and examine the RFLP within one day.
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1.9. Prevention-2
Antibiotic Usage Control & Surveillance
Excess usage of antibiotics is seen as a major factor in the emergence of resistant
bacteria (Courcol et al., 1989). The hope is that control of antibiotic usage will
contain the rise in antibiotic resistance or even reverse the trend (Cohen, 1994).
Though plausible, this still needs to be proven as a reliable public health approach to
the control of resistance without the disadvantage of under treating infectious
disorders. The recognition and impact of resistant bacteria on the burden of bacterial
disease can only be determined by rigorous population based and active surveillance
(Hughes & Tenover, 1997). Such data would also potentially provide information
useful in devising and modifying strategies of antibiotic usage control or even
recognising alternative approaches to limiting the spread and impact of resistant
bacteria.
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1.10. Aims of this Thesis
Streptococcus pneumoniae
1. What is the level of penicillin resistance in Streptococcus pneumoniae isolates and
how does this correlate with resistance to other antibiotics?
2. What is the relationship between classical serotyping ofStreptococcus pneumoniae
and more exacting molecular typing procedure?
3. In the emergence of penicillin resistance, is this caused by the clonal spread of a
few "epidemic" strain or results from spontaneous emergence in individual patients?
4. What effect does resistance in Streptococcus pneumoniae have on the ability to
treat with fluoroquinolones?
Haemophilus influenzae
1. What is the level of amoxycillin resistance in Haemophilus influenzae isolates?
2. What are the mechanisms of penicillin resistance in amoxycillin-resistant isolates of
Haemophilus influenzae?





The bacterial strains used in this study are shown in Table 2.1. The purity and integrity of
the S. pneumoniae and H. influenzae strains were initially verified by colony morphology
and then by standard microbiological tests.
The clinical isolates of S. pneumoniae and H. influenzae were collected from the
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Table 2.1. Bacterial strains used in this study
Bacterial Strain Source
70 S. pneumoniae strains
Clinical isolates were collected from centres
throughout the UK between October 1995 and
February 1996 by Bayer pic (Newbury, Berkshire)
(see text for the list of centres)
231 H. influenzae strains
Clinical isolates were collected from centres
throughout the UK between October 1995 and
February 1996 by Bayer pic (Newbury, Berkshire)








Penicillin-resistant clinical isolates collected from
the Royal Infirmary of Edinburgh (RIE) Hospital in
1996
R6 S. pneumoniae strain
Penicillin-susceptible, non-capsulated strain from
Dr. P. V. Adrian, Department of Medical
Microbiology, University of the Witwatersrand,
Johannesburg, South Africa
Laboratory Standards:
S. aureus NCTC 6571
E. coli NCTC 10418
P. aeruginosa NCTC 10662
S. pneumoniae NCTC 7465
H. influenzae NCTC 11931
National Collection ofType Cultures, London
j, Sensitive to all common antibiotics
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2.2. Storage of Cultures
Bacterial strains were stored at -70°C in Brain Heart Infusion broth (Oxoid, UK) with
50% glycerol. Strains were always subcultured from the stock on solid media and were
not passaged.
2.3. Growth Media
All growth media were sterilised by autoclaving at 121 °C for 15 min at 15 pounds per
square inch. All media were obtained from Oxoid (Oxoid, UK) as dry powders, and
prepared as single strength solutions as recommended by the manufacturer unless
otherwise stated.
2.3.1. Blood Agar
S. pneumoniae strains were grown in Blood Agar plates. Columbia agar was prepared
according to the manufacturer's instructions. The media was cooled below 55°C prior to
the addition of 5% defibrinated horse blood and incubated at 37°C in a 5% C02
atmosphere overnight.
2.3.2. Chocolate Blood Agar
H. influenzae strains were grown in Chocolate Blood Agar plates. Columbia agar
prepared was cooled to 65°C prior to the addition of 5% defibrinated horse blood and
incubated at 37°C in a 5% C02 atmosphere overnight.
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2.3.3. Brain Heart Infusion Broth
Bacterial strains were grown overnight in Brain Heart Infusion (BHI) broth
(supplemented with 10 pg/ml Haemin and 10 pg/ml NAD, for H. influenzae) at 37°C in
5% C02.
2.4. Chemical Reagents




Antimicrobial Susceptibility of S. pneumoniae
and H. influenzae Clinical Isolates
3.1. Introduction
Antimicrobial resistance is an ever-present and ever-changing problem with organisms
that cause serious diseases (Amyes, 1999). It is essential that there are well-controlled
periodic surveys to monitor any changes in rates of resistance to the antimicrobial
agents used traditionally as therapy for S. pneumoniae and H. influenzae and to
determine whether resistance is developing to the newer agents that are currently
active against these organisms.
An ideal antimicrobial agent should be effective, available in both oral and intravenous
formulations, well distributed in the respiratory tract, well tolerated and safe, and
inexpensive. Currently, there is no one drug that meets this profile. (1-Lactams and
macrolides are the most frequently used antibiotics in respiratory tract infections
(Jacobs, 1997). However, macrolide resistance is increasing in S. pneumoniae and
some macrolides have been found to have limited activity against penicillin-
intermediate and penicillin-resistant strains of S. pneumoniae (Jacobs, 1997).
Amoxycillin/clavulanate and cefiiroxime axetil retain high levels of activity against |3-
lactamase producing strains of H. influenzae and penicillin-intermediate strains of S.
pneumoniae.
The present study attempted to determine the prevalence of antimicrobial resistance
among clinical isolates ofS. pneumoniae and H. influenzae in the UK.
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3.2. Materials & Methods
3.2.1. Bacterial strains
A total of 70 S. pneumoniae and 231 H. influenzae clinical isolates were obtained
from centres throughout the UK. In addition, 10 penicillin-resistant S. pneumoniae
isolates from the Royal Infirmary ofEdinburgh were added to this study.
The following strains were also used for quality control and tested each time
susceptibility testing was performed: E. coli NCTC 10418, S. aureus NCTC 6571, P.
aeruginosa NCTC 10662, S. pneumoniae NCTC 7465 and H. influenzae NCTC
11931.
3.2.2. Antimicrobial Susceptibility Tests
Antimicrobial Agents
Antimicrobial agents were supplied as sterile powders of known potency from
different suppliers (Table 3.1). Clavulanic acid was supplied by SmithKline Beecham.
Drugs were stored as dry powders in darkness at 4°C. The antimicrobial solutions
were freshly prepared with sterile MilliQ water when required.
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Imipenem Merck Sharp & Dohme
Meropenem Zeneca Pharmaceutical
Cefaclor Sigma Chemicals
Erythromycin David Bull Laboratories
Tetracycline Lederle Laboratories
Trimethoprim Glaxo-Wellcome
Minimum Inhibitory Concentration (MIC) Determination
Minimum inhibitory concentrations were determined by agar dilution as described in
the standard guidelines of the British Society of Antimicrobial Chemotherapy (BSAC)
(Philips et al., 1991).
For the preparation of agar plates containing antimicrobial agents, doubling dilution of
each antimicrobial agents were freshly made with sterile MilliQ water in Iso-Sensitest
Agar plates supplemented with 5% defibrinated horse blood. The media containing
antimicrobial agents were used within 24 h.
Bacterial strains were grown overnight in Iso-Sensitest Broth (Oxoid, UK)
(supplemented with 10 pg/ml Haemin and NAD, for H. influenzae) at 37°C with
continuous shaking. Plates containing antimicrobial agents were inoculated by
transferring 2 pi volume of the freshly diluted bacterial suspension (104 cfu/ml) from
overnight culture to the surface of the agar with a mulipoint inoculator (Denly,
Billinghurst, UK). A plate with no added antibiotic was inoculated as a positive
control. All plates were incubated at 37°C in 5% CO2 for 18-24 h. The lowest
concentration of the antimicrobial agents to inhibit all visible growth was determined
as the MIC (mg/L).
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3.2.3. Investigation of the Effect of Incubation Conditions
on Trimethoprim MIC Results
i) Agar Dilution Method
Seventy pneumococcal strains were re-examined to determine their susceptibility to
trimethoprim by an agar dilution method (as described above). MIC plates containing
trimethoprim were incubated aerobically and in CO2 at 37°C for 18-24 h and the MIC
recorded.
ii) The E-test Method
High trimethoprim MICs against pneumococcal strains were further investigated using
the E-test (Cambridge Diagnostics Services LTD, UK). Four Iso-Sensitest agar plates
supplemented with 5% horse blood were prepared. Two plates were incubated at
37°C aerobically (Ai & A2) and the other two were incubated at 37°C in 5% CO2 (Ci
& C2) without inoculating the pneumococcal strain. At the same time, the test
pneumococcal strain (with trimethoprim MIC of 4 mg/L) was grown overnight in Iso-
Sensitest Broth at 37°C with continuous shaking. After overnight incubation, loopfiils
of diluted bacterial suspension (104 cfu/ml) were streaked into the surface of the four
pre-incubated Iso-Sensitest agar plates supplemented with 5% horse blood. The E-
test trimethoprim strips were applied to each plate. Plates At and Ci were re-
incubated at 37°C aerobically, and plates A2 and C2 were re-incubated at 37°C in 5%
C02 for 18-24 h. After overnight incubation the MIC results were recorded.
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3.3. Results
3.3.1. Prevalence of Antimicrobial Resistance in
S. pneumoniae
Of the 70 pneumococcal isolates tested, 8 (11.4%) strains were resistant to penicillin
(MIC >0.12 mg/L). Two of these showed intermediate resistance (MIC 0.12-1 mg/L)
to penicillin and 6 were resistant (MIC >1 mg/L). The rate of resistance to other
antibiotics were as follows: 7.1% amoxycillin, 4.3% co-amoxiclav, 12.9%
erythromycin, 10% tetracycline, 10% cefuroxime and interestingly 94.2% of the
isolates were resistant to trimethoprim. All the pneumococcal isolates were
susceptible to imipenem and meropenem (Table 3.2).
The other 10 penicillin-resistant S. pneumoniae isolates from the Royal Infirmary of
Edinburgh hospital were added to the 8 penicillin-resistant S. pneumoniae isolates
from the UK. These 18 penicillin resistant S. pneumoniae isolates from UK were
further examined. In this new group, 8 isolates were intermediate resistant to penicillin
and the remaining 10 isolates were highly resistant.
Fully susceptible strains of S. pneumoniae have MICs of penicillin of 0.008 to 0.06
mg/L, and strains exhibit a normal distribution around an MIC of 0.016 mg/L (Figure
3.1). Intermediate strains have penicillin MICs of between 0.12 and 1 mg/L, while
strains with MICs over 1 mg/L are considered resistant. In contrast to penicillin,
strains tended to be either highly susceptible or highly resistant to the macrolides
(Figure 3.2.) when a susceptible breakpoint of <0.25 mg/L was used for erythromycin
(Jacobs & Appelbaum, 1995).
The pattern ofmulti-resistance observed is summarised in Table 3.3. The results show
that there is a significant relationship between penicillin-resistance and cross-
resistance to tetracycline, trimethoprim and erythromycin.
75
Table 3.2. Prevalence of antimicrobial resistance among 70 clinical
isolates of S. pneumoniae collected from the UK
Antimicrobial Agent












Penicillin >0.12 0.008 0.016 11.4 (8) 0.008-8
(0.008-8)
Amoxycillin >1 0.008 0.016 7.1 (5) 0.008-2
(0.008-8)
Co-amoxiclav >1 0.008 0.016 4.3 (3) 0.008-2
(0.008-8)
Cefuroxime >1 0.008 0.016 10(7) 0.004-4
(0.008-8)
Imipenem >4 0.004 0.004 0 0.004-0.12
(0.004-16)
Meropenem >4 0.004 0.004 0 0.004-0.25
(0.004-16)
Tetracycline >1 0.12 0.25 10(7) 0.03-128
(0.03-128)
Erythromycin >0.5 0.06 0.12 12.9(9) 0.06-16
(0.06-8)
Trimethoprim >0.5 2 8 94.2 (66) 0.12-128
(0.12-128)
* Figures adopted from Philips et al. (1991).
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Table 3.3. Pattern of resistance in three groups of S. pneumoniae strains
delineated by penicillin susceptibility
Also Penicillin Susceptibility









Tetracycline 8(5) 62.5 (5) 30(3)
Erythromycin 8(5) 62.5 (5) 50(5)
Trimethoprim 32.3 (20) 62.5 (5) 80 (8)
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3.3.2. Effect of Incubation Conditions on Trimethoprim
MICs
i) Trimethoprim MIC Results by Agar Dilution Method
Trimethoprim MICs were reexamined for the 70 pneumococcal strains to determine
the effect of air and CO2 incubation in trimethoprim susceptibility. MIC plates
incubated in 5% CO? gave high MIC results. However, there was a substantial
decrease in the MICs of trimethoprim when plates were incubated aerobically in
which 67.1% (47) of isolates were resistant to trimethoprim compared to 94.2% (66)
of isolates were resistant when plates were incubated in 5% CO2.
ii) Trimethoprim MIC Results by the E-test
The high trimethoprim MIC for pneumococcal strains when the MIC plates were
incubated in 5% CO2, was further investigated using the E-test (Table 3.4). Plates Ai
and Ci showed MIC of 4 mg/L for trimethoprim. On the other hand, plates A2 and C2
showed high MIC results (MIC >32 mg/L). The results suggested that the
microaerophilic condition rather than changes in pH of the medium antagonise
trimethoprim and that preincubation had no effect on trimethoprim MIC results.
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3.3.3. Prevalence of Antimicrobial Resistance in
H. influenzae
Of the 231 H. influenzae isolates tested, 46 (20%) strains were resistant to
amoxycillin (MIC >1 mg/L) and 9 (3.9%) isolates were also resistant to co-amoxiclav
(MIC >1 mg/L).
The rate of resistance to other antibiotics was as follows: 97% erythromycin, 3.9%
tetracycline, 5.2% cefuroxime and 9.5% of the isolates were resistant to trimethoprim.
All the H. influenzae isolates were susceptible to ciprofloxacin (Table 3.5).
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Table 3.5. Prevalence of antimicrobial resistance among 231 clinical
isolates of H. influenzae collected from the UK
Antimicrobial Agent












Amoxycillin >1 0.05 4 20 (46) 0.03-64
(0.03-128)
Co-amoxiclav >1 0.5 1 3.9 (9) 0.03-4
(0.03-16)
Cefuroxime >1 0.5 1 5.2 (12) 0.25-4
(0.25-16)
Cefaclor >8 4 16 10(23) 0.5-32
(0.12-128)
Tetracycline >1 0.5 1 3.9 (9) 0.016-8
(0.06-128)
Erythromycin >0.5 4 16 97 (224) 0.12-32
(0.12-128)
Trimethoprim >0.5 0.12 0.5 9.5 (22) 0.016-16
(0.016-128)
Ciprofloxacin >1 0.008 0.016 0(0) 0.008-0.5
(0.004-5)
* Figures adopted from Philips et al., (1991).
82
3.4. Discussion
S. pneumoniae and H. influenzae are responsible for systematic as well as upper and
lower respiratory tract infections. In addition, S. pneumoniae and H. influenzae are
frequently implicated in bacterial meningitis (Nazareth et al., 1992; Schelch et al.,
1985). Treatment of these potentially serious infections has become problematic
because of increasing global antimicrobial resistance (Gruneberg & Felmingham,
1996). Since the prevalence and resistance patterns continue to change, ongoing
surveillance is required.
The prevalence of penicillin-resistant pneumococci is increasing worldwide, and is
greater than 20% in many parts of the world (Dowson et al., 1994), similarly,
macrolide-resistant strains are usually in the range of 10 to 20% (Appelbaum, 1992).
In H. influenzae, resistance rates to certain (3-lactams (e.g. amoxycillin-clavulanate
and cefixime) are low, whereas resistant rates to cefaclor and cefprozil are higher
(>5%) (Jones et al., 1997). The use of macrolides against H. influenzae is limited by
their marginal activity. Azithromycin is the most potent macrolide compared with
erythromycin and clarithromycin. No high-level resistance to the macrolides has been
detected in H. influenzae.
Until recently the UK was considered to have a low prevalence of penicillin-resistant
pneumococci. As recently as 1990, 100% of 7255 strains of pneumococci from
centres across the UK were found to be penicillin susceptible (Spencer et al., 1990).
However, there have now been several reports of significant and rising levels of
resistance nationwide (Goldsmith et al., 1997).
The results indicated that the UK has fewer problems with regards to antibiotic
resistance in S. pneumoniae and H. influenzae than many other countries.
Nevertheless, there is a continuing increase in resistance to certain antibiotics and
therapy with these antibiotics would be expected to encounter more problems with
drug resistance than a decade ago.
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Chapter Four
Molecular Typing and Analysis of Penicillin-
Binding Protein Alterations in Penicillin-
Resistant Clinical Isolates of S. pneumoniae
4.1. Introduction
Infections caused by S. pneumoniae contribute significantly to morbidity and mortality
world-wide (Klugman, 1990). Although penicillin was the treatment of choice for S.
pneumoniae infections, the development of penicillin resistance has complicated
treatment strategies and resulted in alternative agents being used. Resistance to
penicillin and other (flactam antibiotics in S. pneumoniae results from alteration of
penicillin binding proteins (PBPs) la, lb, 2x, 2a and 2b which reduce P-lactam affinity
(Hakenbeck et al., 1980). The overall resistance of an individual strain is dependent
on the pattern of PBP alterations. The nucleotide sequences of genes coding for the
native and altered PBP (2b, 2x and la) of both penicillin-resistant and penicillin-
susceptible S. pneumoniae have been reported (Dowson et al., 1989a; Laible et al.,
1991, Martin et al., 1992).
Penicillin resistance in S. pneumoniae results in the use of alternative agents and it has
been observed that the emergence of penicillin resistance in S. pneumoniae is often
followed by an increase in strains resistant to other antibiotics leading to multidrug
resistance which is defined as resistance to three or more different classes of
antibiotics (Appelbaum, 1992). There are distinct differences in the incidence of
penicillin resistance in S. pneumoniae in different countries. Within Europe the highest
rates have been found in Spain and Hungary with levels in excess of 50% reported
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(Marton et al., 1991). Until recently penicillin resistance in S. pneumoniae in UK was
unusual, however, the situation is changing and reports of penicillin resistance in S.
pneumoniae have been made from a number of centres (Goldsmith et al., 1997). The
factors that contribute to the overall levels of penicillin resistance are complex: a
correlation between penicillin resistance and the usage of penicillin has been
demonstrated (Baquero, 1996) but equally the importation of resistant isolates from
other areas followed by the clonal spread of these organisms has been shown to be
important in other countries (Munoz et al., 1992; Soares et al., 1993). Recently the
evolution of penicillin resistance in S. pneumoniae has been modelled, predicting a
slow emerging phase of resistance development followed by exponential increases in
resistance over a ten year period to a stationary phase level of around 50% resistance
(Baquero, 1996). It has been speculated that the United Kingdom may be at the start
of the exponential growth phase of penicillin resistant S. pneumoniae (Goldsmith et
al., 1997).
It is essential therefore that the emergence of penicillin resistance in S. pneumoniae in
the UK be monitored closely. In this study, clinical respiratory isolates of penicillin-
resistant S. pneumoniae from centres in the UK have been molecularly typed by
pulsed-field gel electrophoresis (PFGE) and screened for alterations, in the genes
encoding PBP 2B, 2X and 1A by the polymerase chain reaction (PCR). Also
restriction by HinQ. of entire pbp2x, 2b and la genes amplified by PCR have been
used. This data will allow us to determine if increasing penicillin resistance in the UK
results from clonal spread of particular strains or is emerging independently.
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4.2. Materials & Methods
4.2.1. Bacterial Strains
Eighteen penicillin-resistant S. pneumoniae clinical isolates with penicillin G MICs of
> 0.12 mg/L were used in this study (See section 3.3.1). All isolates were grown on a
Columbia agar supplemented with horse blood (5%) at 37° C in 5% CO2.
4.2.2. Capsular Serotyping
S. pneumoniae penicillin-resistant isolates were serotyped on the basis of capsular
swelling (Quellung reaction) with type-specific antisera (Statens Serum Institute,
Copenhagen) by the Central Public Health Laboratory Service (PHLS, Colindale,
London).
4.2.3. Pulsed-Field Gel Electrophoresis (PFGE)
Preparation of Intact Chromosomal DNA in Agarose Plugs
The preparation of intact chromosomal DNA in agarose plugs was by the method of
Hall el al. (1996) with some modifications. S. pneumoniae strains were inoculated
into Brain Heart Infusion broth (BHI) and were grown to an optical density of 0.3 to
0.5 at 560 nm in 37°C incubator with 5-10% C02 overnight. The cells were
centriluged at 4°C at 3,000 rpm in a centrifuge for 10 min. The cell pellets were
resuspended in 0.5 ml TO buffer [10 mM Tris-HCl (pH 7.6), 1 M NaCl],
recentrifuged, resuspended finally in fresh TN buffer and held at 37°C. Each 0.5 ml
cell suspension was then mixed with 0.5 ml of molten 2% low-melt preparative grade
agarose (Bio-Rad, UK) in distilled water. The mixture was micropipetted immediately
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into the wells of a perspex plug mould (Bio-Rad, UK) and cooled to 4°C to allow the
agarose to set. Each set of plugs was then ejected from the mould into bijou bottles
containing 2 ml of lysis buffer [6 mM Tris-HCl (pH 7.6), 1 M NaCl, 100 mM
disodium EDTA, 0.5% polyxythylene 20 cetyl ether, 0.2% sodium deoxycholate,
0.5% tf-lauroylsarcosine, 20 pg/ml ribonuclease A, and 100 pg/ml lysozyme] and the
bottles were incubated overnight at 37°C. The lysis buffer was then replaced with 2
ml of EL buffer [0.5 M disodium EDTA (pH 9.0), 1% n-lauroylsarcosine, 50 pg/ml
proteinase K] and incubated at 55°C for 48 h. At the end of this period, the EL buffer
was replaced with 2 ml ofTE buffer [10 mM Tris-HCl, 0.1 mM disodium EDTA] and
incubated at 4°C for 30 min. This wash step was repeated twice with fresh TE buffer
for a minimum of 30 min each. The plugs were then stored at 4°C in TE buffer until
required.
Digestion of Chromosomal DNA in Agarose Plugs
Generally, digests were performed with DNA contained in about one-third of a
complete plug. Each plug portion was transferred to a sterile microcentrifuge tube and
equilibrated at 4°C in 100 pi of the Smal digestion buffer (Promega, UK). After 1 h.
the buffer was replaced with 100 pi of fresh digestion buffer and 12 U of Smal
(Promega, UK) was added. After 4-6 h digestion at 37°C, the buffer-enzyme mixture
was replaced with 100 pi of inactivation buffer [0.5 M EDTA (pH 9.0), 1% n-
lauroylsarcosine] and kept at 4°C until ready for electrophoresis.
Electrophoresis
DNA macrorestriction fragments were separated on 1% agarose gel by PFGE
employing a CHEF-DR II system (Bio-Rad, UK) at 6 V/cm for 18 h with a switching
time of 1-15 sec at 12°C. The gels were stained with 1 pg/ml of ethidium bromide and
were destained in water for lh before photography.
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Gelcompar Software
The PFGE patterns were analysed by Gelcompar software (Applied Math, Kortrijk,
Belgium). The PFGE patterns were compared by the UPGMA (unweighted pair
group method with arithmetic averages) clustering method employing the Dice
coefficient (Shi et al., 1996). A tolerance in the band position of 1.2% was applied
during the comparison ofPFGE fingerprinting patterns.
4.2.4. Isolation of Chromosomal DNA
S. pneumoniae strains were cultivated on Columbia agar supplemented with 5% horse
blood and incubated in 5-10% C02 at 37°C overnight. Colonies were emulsified in 50
pi sterile MilliQ water in a microcentrifuge tube and boiled for 5 min; the supernatant
containing DNA was used for PCR analysis.
4.2.5. DNA Amplification by Polymerase Chain Reaction
The PCR protocol was a modification of that used by Jalal et al (1997). The primers
used (Table 4.1) were supplied high-pressure liquid chromatography (ELPLC) purified
by Oswel DNA Services (Southhampton, UK). Primers derived from sequences
encoding the penicillin-binding domain of PBPs were used to amplify susceptible
genotypes ofpbp2b and 2x, and resistant genotype ofpbp la genes.
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Table 4.1. Primers sequence used in PCR to amplify
part ofpbp2b, 2x and la genes in S. pneumoniae







All the PCR reagents were supplied by Advanced Biotechnologies Ltd., UK. The
optimal reaction mix included 0.5 pi of Taq DNA Polymerase (5 U/pl), 10 pi of 1 Ox
Reaction buffer [200 mM (NH^SCb, 750 Mm Tris-HCl (pH 8.8), 0.1% Tween®20],
5 pi dNTP Mix (20 mM), 3 pi MgCh (25 mM), 1 pi primers Mix (10 pmole/pl), 5 pi
of DNA template, and sterilised MilliQ water to a final volume of 100 pi. This was
overlaid with sterile mineral oil and processed on Techne Thermal Cycler (Techne
Cambridge Ltd., UK). The optimal PCR cycling conditions were as follows: 1 cycle of
94°C for 3 min followed by 35 cycles of 94°C for 30 s, 60°C for 30 s and 72° C for 2
min followed by a final cycle of 72° C for 7 min. Two controls were included in each
PCR run: S. pneumoniae R6 control strain and a negative control where DNA was
replaced by an equal amount of sterilised MilliQ water. PCR products were analysed
by electrophoresis through a 1.8 % agarose-ethidium bromide-containing gel with 100
bp DNA ladder (GibcoBRL Life technologies) as marker and bands visualised with
UV transillumination.
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4.2.6. PCR-Restriction Fragment Length Polymorphism
(PCR-RFLP)
Amplification of the Entire pbp2b, 2x and la Genes by
Polymerase Chain Reaction
The PCR protocol was a modification of that used by Gillespie et al (1997). The
primers used (Table 4.2) were supplied high-pressure liquid chromatography (HPLC)
purified by Oswel DNA Services (Southhampton, UK). Primers used were designed
to amplify the entire pbp2x, 2b and la genes.
Table 4.2. Primers sequence used in PCR to amplify
the entire pbp2b, 2x and la genes in S. pneumoniae







The optimal reaction mixtures for PCR were as described above (see section 4.2.4).
The cycling conditions were as follows: 95°C for 5 min, followed by 1 min of
denaturation at 94° C, 2 min of annealing at 55° C, and 3 min of extension at 72° C
for 30 cycles and a final extension for 7 min at 72° C in the same thermocycler with
appropriate controls as described above.
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Restriction Fragments Length Polymorphism with HinSX
Restriction of the pbp2x, 2b and la PCR products was performed using Hinil
(Promega, UK). The digestion mixture consisted of 1 pi ofHinil enzyme (10 U/pl) in
10 mM Tris-HCl (pH 7.5), 60 mM NaCf, 7 mM MgCh, 0.1 mg bovine serum albumin
per liter in 50 pi volume. A total of 20 pi ofPCR product was added to 2 pi of buffer
and 1 pi of Hinil enzyme. Digestion proceeded for 4 h at 37°C in waterbath, and the




Of the 18 penicillin-resistant clinical isolates tested: nine isolates were serotype 9, four
isolates were serotype 6, two isolates were serotype 19, two isolates were serotype 23
and one isolate was serotype 29. Interestingly, 7/9 isolates that exhibited serotype 9
had a high MIC ofpenicillin (>2 mg/L).
4.3.2. Pulsed-Field Gel Electrophoresis (PFGE)
The PFGE patterns of 18 isolates from the UK are shown in Figure 4.1. These
patterns were classified into groups alphabetically. PFGE fingerprinting of the 18
isolates analysed by Gelcompar revealed that only 2 of the isolates were identical.
Taking a cut-off value of 80% similarity produced 4 clusters of isolates (A to D)
within 10 strains from the total of 18 strains examined. The remaining 8 isolates were
unrelated and demonstrated 8 distinct types (E to L).
A dendrogram was constructed to show the degree of relatedness among the strains
of clusters from the UK (Figure 4.2.). Cluster A included four isolates. Three
genetically related subtypes were identified among these four isolates. The two
identical isolates were of subtype Ai (RIE-11080 & BRI-251). The remaining two
isolates were subtypes A2 & A3 (NMH-285 & D-774, respectively). Cluster B
included two isolates (RIE-13593 & NMH-158) and were subtyped Bi and B2,
respectively. Cluster C included two isolates (RIE-12825 & BRI-249) and were
subtyped Ci and C2, respectively. Cluster D also included two isolates (RIE-919 &
RIE-8442) and were subtyped Di and D2, respectively.
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4.3.3. PCR Amplified pbp2\, 2b and la genes
Chromosomal DNA from S. pneumoniae strains was used as a template for PCR to
amplify susceptible genotypes of pbp2b and 2x, and resistant genotype of pbpla
genes. Oligonucleotide primer pairs allowed amplification and isolation of 277, 359
and 423 bp of pbp2x, 2b and la products, respectively (Figure 4.3).
The isolates tested displayed six patterns ofpbp genes when screened by PCR (Table
4.3 & Figure 4.3) and a Roman numeral was assigned to each pattern. Pattern type f
consisted of alterations in the genes encoding PBP 2b, 2x and la and was detected in
6 isolates all of which were highly resistant to penicillin (MIC 2 mg/L). Four isolates
with MICs ofpenicillin ranging from 1-8 mg/L showed a different pattern termed type
If with alterations at pbp genes 2b and la only. Three isolates with intermediate levels
of penicillin resistance (MIC 0.12-0.25 mg/L) had alterations in only pbp gene 2b
(Pattern III). Two further isolates with intermediate penicillin resistance had
alterations in pbp2x and la (Pattern IV). Pattern V was shown by only a single isolate
with a high level of penicillin resistance (MIC 2 mg/L) and an alteration at only in
pbpla. Finally two isolates with intermediate levels of penicillin resistance (MIC 0.12-
0.25 mg/L) had no detectable change in the genes encoding pbp2b, 2x or la (Pattern




III IV V VI
PBP2x + - + - -
PBP2b + + + - -
PBPla + + + + -














100 bp lambda DNA ladder marker
negative control (without template DNA)
R6 penicillin-susceptible S. pneumoniae strain
PCR Patterns
Presence and absence ofaltered PBPs, respectively.
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Table 4.3. Relationship of PBP alterations in 18 penicillin-
resistant S. pneumoniae isolates from the UK
Penicillin PCR PBP
Strain MIC Pattern genotype
mg/L
2X 2B 1A
RIE-11825 2 I + + +
RIE-12825 2 + + +
BRI-249 2 + + +
BRI-251 2 + + +
NMH-285 2 + + +
D-774 2 + + +
RIE-2905 1 II - + +
RIE-13593 2 - + +
RIE-13678 2 - + +
NMH-158 8 - + +
RIE-919 0.12 III - + -
RIE-6083 0.25 - + -
RIE-8442 0.12 - + -
RIE-11080 0.25 IV + - +
WH-563 1 + - +
WH-565 2 V - - +
RIE-7184 0.25 VI - - -
D-680 0.5 - - -
PFGE Pulsed-field gel electrophoresis, PCR Polymerase chain reaction,
PBP Penicillin binding protein, (+)altered pattern, (-)not altered pattern.
4.3.4. PCR-Restriction Fragment Length Polymorphism
(PCR-RFLP)
Chromosomal DNA from S. pneumoniae strains was used as a template for PCR to
amplify the entire pbp2x, pbp2b and la genes. Oligonucleotide primer pairs allowed
amplification and isolation of 1.5 bp pbp2b products and 2.0 bp pbp 2x products
(Figure 4.4). However, the pbpla gene did not amplify.
The restriction patterns of the pbp2b and 2x genes of all strains with an MIC of
penicillin of 1 mg/L or above were different from the penicillin-susceptible strain R6
(Figures 4.5). In addition, strains with an MIC less than 1 mg/L showed
heterogeneous patterns of restriction.
All strains with an MIC of penicillin of 1 mg/L or above had the same restriction
pattern for both pbp2b and 2x, except strains WH-563 and BRI-249. All strains with
an MIC for penicillin of less than 1 mg/L had the same pattern as penicillin-susceptible
strain R6 for both pbp2b and 2x, except strains RLE-11080, RIE-2905 and WH-563.
Interestingly, the same pattern of restriction ofpbp2b and 2x genes was observed in
two isolates with serotype 23, and 7 of the 9 isolates with serotype 9.
S. pneumoniae strains with an MIC of penicillin of 1 mg/L or above exhibited
considerable homogeneity in pbp2b and 2x RFLP. However, strains with an MIC less
than 1 mg/L gave a more heterogeneous pattern.
The relationship of RFLP patterns, PFGE patterns, capsular serotypes and MICs of
18 penicillin-resistant S. pneumoniae clinical isolates from the UK is shown in Table
4.4.
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Lane M ADNA/i/wdlll molecular size marker
Lane 1 pbp2b PCR product
Lane 2 pbp2x PCR product
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4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
R6* RIE-919 RIE-8442 RIE-6083 RIE-11080 RIE-7184 D-680 RIE-2905 WH-563 RIE-11825 RIE-12825 BRI-249 BRI-251 NMH-285 D-774 RIE-13593 RIE-13678 WH-565 NMH-158
0.12 0.12 0.25 0.25 0.25 0.5 1 1
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Table 4.4. Relationship ofRFLP patterns, PFGE patterns, capsular
serotypes and MICs of 18 penicillin-resistant S. pneumoniae clinical










rie-919 0.12 6 d, III I. Ii
rie-8442 0.12 6 d2 III h Ii
rie-6083 0.25 29 h III Ii I,
rie-11080 0.25 6 a, IV H2 I2
rie-7184 0.25 19 k VI Is Ii
d-680 0.5 9 l VI Ii I.
rie-2905 1 19 f II II. I2
wh-563 1 9 I IV II2 Ii
rie-11825 2 9 e I Hi Hi
rie-12825 2 9 c, I Hi Hi
bri-249 2 6 c2 I II2 Hi
bri-251 2 9 a, I Hi Hi
nmh-285 2 9 a2 I Hi II.
d-774 2 9 a3 I Hi II.
rie-13593 2 23 b, II Hi Hi
rie-13678 2 23 G II Hi II.
wh-565 2 9 j V Hi II.
nmh-158 8 9 b2 II Hi II.
PFGE Pulsed-field gel electrophoresis, RFLP Restriction fragment length
polymorphism, PBP Penicillin binding protein.
+ altered pattern, - not altered pattern.
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4.4. Discussion
The acquisition and spread of resistance in S. pneumoniae are complex processes,
involving clonal spread, DNA horizontal transfer and point mutations. Molecular
techniques have been used to analyse the nature of penicillin- and multiresistant
pneumococci recovered in different countries. Thorough analysis of these isolates
requires the use of techniques that index both their overall genetic relatedness and the
relatedness of their altered pbp2b, 2x and la genes (Dowson & Coffey, 1998). The
variation in both the overall genotype and the three pbp genes allows the distinction
between clonal spread of resistant pneumococci, and the generation of novel resistant
clones by horizontal gene transfer, indicated by the presence of the same pbp gene(s)
in strains that have different overall genotypes.
Several different approaches have been used for the molecular analysis of penicillin
resistance in pneumococci. Jalal et al. (1997) used a PCR protocol to amplify
susceptible genotypes ofpbp2b and 2x genes, and resistant genotype ofpbpla gene.
Gillespie et al. (1997) used a gene fingerprinting or RFLP analysis of amplified pbp2x,
2b and la genes but O'Neill et al. (1999) have used RFLP of amplified pbp2b only to
detect penicillin susceptibility. PFGE macrorestriction pattern of chromosomal DNA
was also used to evaluate the genetic relatedness of S. pneumoniae isolates (Hall et
al, 1996).
PFGE is a popular technique and has been widely used to compare genetically
pneumococci isolated worldwide. Disadvantages of PFGE include the long and
delicate procedure that is required for isolating and digesting high molecular weight
genomic DNA, the need for expensive sophisticated equipment and the need for
extended electrophoresis times. Restriction enzyme analyses of pbp2b, 2x and la
genes are often used to assist in the epidemiological analysis of pneumococci or as a
method to detect penicillin susceptibility by pattern analysis. These methods prove to
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give more precise information than serotyping and are very useful for the
epidemiological investigation ofpenicillin resistance in pneumococci.
In the current study, the usefulness of PFGE macrorestriction with the Smal enzyme
of chromosomal DNA and DNA restriction patterns of amplified pbp2b, 2x and la
genes were determined. Eighteen penicillin-resistant strains were typed by PFGE.
Cluster analysis of patterns produced by PFGE of chromosomal DNA digested with
Smal revealed that only 2 of the isolates were identical. Taking a cut-off value of
80% similarity produced 4 clusters of isolates containing 4, 2, 2 and 2 strains
respectively; the remaining 8 isolates were unrelated. Also isolates of related
genotypes were found in a variety of geographic locations. It appears, therefore, that
penicillin resistance was not simply the result of clonal spread but rather because of
the presence of several genotypes. Our data also clearly showed that pneumococcal
strains with the same serotype might show quite different PFGE patterns. This
confirms that capsular serotyping is not a good criterion for genetic relatedness and
PFGE is a more discriminative method.
Screening for changes in PBPs showed that there was a correlation between resistance
and alteration in PBP. All 10 strains with an MIC of penicillin of 2 mg/L or above had
changes in pbpla and all, but 1, also had a change in pbp2b. In contrast only 6 had
alterations in pbp2x. Isolates with MICs of penicillin less than 1 mg/L showed a more
heterogeneous pattern of PBP changes and 2 isolates had no change in pbpla, 2x or
2b. This approach had difficulty in detecting resistant isolates, simply because the
sequence of these strains are not recognised by primers used in PCR and gave false
negative results.
To overcome this problem, restriction enzyme analysis of pbp2b, 2x and la genes
have been used. In this approach primers are designed to amplify the whole genome of
pbp2x, 2b and la and the PCR products were restricted by Hinil endonuclease. S.
pneumoniae strains with an MIC of penicillin of 1 mg/L or above exhibited
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considerable homogeneity in pbp2b and 2x RFLP. However, strains with an MIC less
than 1 mg/L gave more heterogeneous patterns. The pbpla gene failed to amplify.
These results suggest that penicillin resistance in S. pneumoniae in the UK is evolving
in different strains and this is a cause for concern. Also it demonstrates the importance




Activity of Quinolones against Penicillin
Susceptible and Penicillin-Resistant Clinical
Isolates of S. pneumoniae
5.1. Introduction
S. pneumoniae is an important pathogen and a major aetiologic agent of respiratory tract
infections. Effective treatment of pneumococcal infections has until recently relied upon
the use of P-lactam antibiotics, but with the emergence of antibiotic resistance, their use
is now increasingly compromised (Baquero, 1995; Appelbaum, 1997). There is
considerable interest in alternative antimicrobials, such as the fluoroquinolones. The
quinolones developed over the past 10 to 15 years exhibit a broad spectrum of in vitro
activity against a wide range of microorganisms (Wolfson & Hooper, 1989). Both the
potencies and spectra of activity of the older quinolones have been increased with the
introduction of newer agents.
Although presently available fluoroquinolones, such as ciprofloxacin and ofloxacin, are
limited in their effectiveness against S. pneumoniae strains (Korner et al., 1994;
Bauernfeind, 1997), newer developmental compounds show greater promise (Barry et
al., 1996; Brueggemann et al., 1997). Sparfloxacin has excellent activity against both
penicillin-resistant and erythromycin-resistant strains of S. pneumoniae (Goa et al.,
1997). The two new quinolones moxifloxacin and trovafloxacin have similar activities and
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are the most active of the current quinolones (Brueggemann et al., 1997; Klugman &
Gootz, 1997).
In this study I examined the activity of ciprofloxacin and four newer fluoroquinolones
(Moxifloxacin, trovafloxacin, sparfloxacin and grepafloxacin) against 11 penicillin-
susceptible and 18 genetically characterised penicillin-resistant S. pneumoniae isolates
from the UK (see Chapter 4).
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5.2. Materials & Methods
5.2.1. Bacterial Strains
Eleven penicillin-susceptible and 18 penicillin-resistant S. pneumoniae clinical isolates
from the UK were examined for their susceptibility against five quinolones. Control
strains included were: S. aureus NCTC 6571, E. coli NCTC 10418, P. aeruginosa
NCTC 10662 and S. pneumoniae R6.
5.2.2. Antimicrobial Agents
Antimicrobial agents were supplied as sterile powders from different suppliers (Table
5.1). Drugs were stored as dry powders in darkness at 4°C. The antimicrobial solutions
were freshly prepared with sterile MilliQ water when required.








5.2.3. Antimicrobial Susceptibility Testing
Antimicrobial susceptibility tests were performed on Iso-Sensitest agar plates
supplemented with 5% horse blood. MICs were determined by agar dilution of the
antibacterial agents. Stock solutions of antibiotics were prepared immediately prior to use
and two-fold dilutions of each antibiotic were prepared in agar plates. The media
containing antimicrobial agents were used within 24 h.
Bacterial strains were grown overnight in Iso-Sensitest Broth (Oxoid, UK) at 37°C with
continuous shaking. Plates containing antimicrobial agents were inoculated by
transferring 1 pi of the undiluted overnight culture to the surface of the agar with a
mulipoint inoculator (Denly, Billinghurst, UK) to give a final inoculum size of 104 CFU.
A plate with no added antibiotic was inoculated as a positive control. All plates were
incubated at 37°C for 18-24 h. The lowest concentration of the antimicrobial agents to
inhibit all visible growth was determined as the MIC (mg/L).
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5.3. Results & Discussion
S. pneumoniae no longer has predictable antibiotic susceptibility since isolates with
increased resistance to penicillin and other antibiotics have become more common. There
is a need for antimicrobial agents that can be used for oral and parental therapy of
infections caused by penicillin-resistant pneumococci.
The current study examined the activity of ciprofloxacin and other new quinolones
against a range of penicillin-susceptible and -resistant S. pneumoniae clinical isolates from
centres throughout the UK. Table 5.2 shows the MICs results of ciprofloxacin,
moxifloxacin, trovafloxacin, sparfloxacin and grepafloxacin.
Newer quinolones were the most active against these isolates. Ciprofloxacin had the
lowest activity with MICs 4 to -16 fold higher than other quinolones. As observed with
penicillin-susceptible pneumococci, all quinolones are generally 2 to 14-fold more active
than against penicillin-resistant strains. Making the assumption that the breakpoint for the
newer quinolones will be 2mg/L (it has not yet been decided), susceptibilities to newer
quinolones were 100% for both penicillin-susceptible and -resistant isolates. Three
penicillin-resistant isolates had high MICs of ciprofloxacin of > 2 mg/L (strains D-680,
RIE-11080 and BRI-251) and were selected for more investigation into the possible
cause ofelevated MIC to ciprofloxacin (see Chapter 6).
Table 5.3 shows the distribution of different quinolone MIC results over the PFGE
patterns and capsular serotypes for the 18 penicillin-resistant isolates. Analysis of these
results showed no correlation between particular genetic types and levels of quinolone
susceptibility.
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Table 5.2. MICs of 11 penicillin-susceptible and 18 penicillin-resistant
S. pneumoniae strains to quinolones antimicrobial agents
Drug mic Range(mg/L) micso mic90
Penicillin-susceptible
Ciprofloxacin 0.008-0.5 0.5 0.5
Moxifloxacin 0.004-0.25 0.008 0.25
Trovafloxacin 0.004-0.25 0.004 0.25
Sparfloxacin 0.004-0.25 0.06 0.25
Grepafloxacin 0.004-0.12 0.004 0.12
Penicillin-resistant
Ciprofloxacin 0.12-4 0.5 2
Moxifloxacin 0.016-0.5 0.12 0.25
Trovafloxacin 0.008-1 0.12 0.5
Sparfloxacin 0.03-1 0.12 0.25
Grepafloxacin 0.03-1 0.12 0.25
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Table 5.3. Relationship between penicillin MICs, quinolone MICs,
PFGE patterns and capsular serotypes of 18 penicillin-resistant S.
pneumoniae clinical isolates from the UK
Starin Serotype PFGE MIC (mg/L)
Pen Cipr Trov Spar Grep Moxi
RIE-919 6 D(D 0.12 0.12 0.12 0.12 0.12 0.016
R1E-8442 6 D(2) 0.12 0.25 0.008 0.25 0.25 0.03
RIE-6083 29 H 0.25 0.5 0.12 0.12 0.12 0.016
RIE-11080 6 A(i) 0.25 2 0.5 0.25 0.25 0.25
RIE-7184 19 K 0.25 0.5 0.12 0.25 0.12 0.12
D-680 9 L 0.5 4 1 1 1 0.5
RIE-2905 19 F 1 0.5 0.008 0.03 0.12 0.06
WH-563 9 I 1 0.5 0.06 0.06 0.03 0.12
RIE-11825 9 E 2 0.25 0.008 0.03 0.25 0.03
RIE-12825 9 C(i) 2 0.5 0.008 0.03 0.12 0.12
BRI-249 6 C(2) 2 0.5 0.12 0.12 0.12 0.12
BRI-251 9 A(i) 2 2 0.5 0.25 0.25 0.25
NMH-285 9 A(2) 2 0.5 0.25 0.12 0.5 0.25
D-774 9 A(3) 2 0.25 0.03 0.06 0.06 0.06
RIE-13593 23 B(i) 2 0.5 0.06 0.12 0.25 0.12
RIE-13678 23 G 2 0.5 0.12 0.06 0.12 0.06
WH-565 9 J 2 1 0.25 0.25 0.25 0.12
NMH-158 9 B(2) 8 0.5 0.06 0.06 0.12 0.12
MIC Minmum inhibitory concentration, Pen Penicillin, Cipr Ciprofloxacin, Moxi Moxifloxacin,
Trov Trovafloxacin, Spar Sparfloxacin, Grep Grepafloxacin, PFGE Pulsed-field elelectrophoresis
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Fuchs et al. (1997) recently reported that there was no correlation between quinolone
susceptibility in S. pneumoniae and penicillin resistance. Similar observations were
recently reported from the Alexander Project Collaborative Group (Goldstein et al.,
1996). No theoretical link has been proposed between penicillin and quinolone
susceptibility, and the mechanisms of resistance to the two drugs are quite distinct.
Contrasting data from the Northern Ireland Public Health Laboratory in Belfast are
recently reported (Goldsmith et al., 1998). The ciprofloxacin susceptibility of 42
penicillin-resistant pneumococci were compared to those of 122 penicillin-susceptible
isolates, isolated since 1994. Only one of the 42 penicillin-resistant (2.4%) was
susceptible to ciprofloxacin (MIC <1 mg/L) and 18 (42.9%) were fully resistant (MIC >4
mg/L). In comparison 84 out of 122 (68.8%) penicillin-susceptible were ciprofloxacin
susceptible and only 7 (5.7%) were fully resistant. Thus ciprofloxacin resistance in
pneumococci isolated in Belfast appears to be more common in penicillin-resistant strains
than in penicillin-susceptible strains. It would appear, therefore, that there may be two
phenomena occurring in Northern Ireland to explain the increased resistance to
ciprofloxacin in local pneumococci generally and in penicillin-resistant strains in particular
(Goldsmith et al., 1998): the frequency of prescription of ciprofloxacin is higher than that
in the rest of the UK or may be that ciprofloxacin-resistant pneumococci have spread
clonally more quickly than ciprofloxacin-susceptible strains. However, strains have not
yet been examined for possible clonal spread nor the activity of newer quinolone have
been detected.
In summary, ciprofloxacin has been reported to be marginally active against
pneumococcal (Fuchs et al., 1997). Consequently, it should not be used as first-line
treatment for pneumococcal infections. In contrast, the newer quinolones may be
promising therapeutic options in patient populations that are likely to be infected with
multiply resistant pneumococci (Brueggmann et al., 1997).
112
Chapter Six
Molecular Characterisation ofMutations in the
QRDRs ofgyrA and parC Genes in
S. pneumoniae Clinical Isolates with High MICs
to Ciprofloxacin
6.1. Introduction
A problem associated with the use of fluoroquinolones is the selection of spontaneous
resistant mutants. Recent studies of S. pneumoniae have defined the appearance of
ciprofloxacin-resistant pneumococci in vitro and in vivo (Tankovic el al., 1996).
Several studies with pneumococci have shown that low-level resistance (MIC 4-8
mg/L) can result from mutations inparC (Pan & Fisher, 1996; Munoz & de la Campa,
1996; Janoir et al., 1996), while increased levels of resistance (MIC 16-64 mg/L)
occur following the acquisition of additional mutations in gyrA (Pan et al., 1996;
Munoz & de la Campa, 1996; Janoir et al., 1996). More recently a further resistance
mechanism has been described in pneumococci involving the efflux of hydrophilic
fluoroquinolones which shows a low-level of resistance (Brenwald et al., 1997; Zeller
et al., 1997). Like the multi-drug efflux pumps NorA in S. aureus (Neyfakh et al.,
1993) and Bmr in Bacillus subtilis (Ahmed et al., 1995), the efflux-mediated
resistance described in pneumococci causes reduced susceptibility to several
fluoroquinolones as well as variety of unrelated compounds (Brenwald et al., 1997;
Zeller et al., 1997). Recently, Brenwald et al. (1998b) showed that efflux-mediated
resistance in pneumococci is common amongst clinical isolates and involves a gene
encoding a 399 amino-acid protein, which shows homology to NorA and Bmr.
Reserpine was used as an inhibitor of the putative efflux pump of S. pneumoniae to
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determine the presence or absence of this mechanism of resistance to fluoroquinolones
(Brenwald et al., 1997).
The location of gyrA and parC genes in the S. pneumoniae genome was revealed
(Munoz & de le Campa, 1996). Chromosomal DNA prepared from strain R6 was
digested with different restriction endonucleases and was subjected to PFGE, and the
resulting fragments were blotted and hybridised with probes specific for parC, gyrA
and gyrB. The results indicate that gyrA is located in a region different from the
region where gyrB and parC are located, according to the published S. pneumoniae
R6 chromosomal map (Gasc et al., 1991).
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6.2. Materials & Methods
6.2.1. Bacterial Strains
The S. pneumoniae strains used in this study are part of the penicillin-resistant clinical
isolates from the UK (see Chapter 5, Table 5.3). Three wild-type strains (RIE-11080,
RIE-251 and D-680) with ciprofloxacin MIC of >2 mg/L were used. Also two wild-
type ciprofloxacin-susceptible strains (R6 and RIE-919) were used for comparison.
6.2.2. Selection of Mutants
The wild-type ciprofloxacin-resistant D-680 strain was used for selection of
ciprofloxacin-resistant mutants by stepwise selection. First-step mutants of S.
pneumoniae D-680 were selected by incubating 108 CFU onto Columbia agar (Oxoid,
UK) supplemented with 5% horse blood and containing ciprofloxacin (Brenwald et
al., 1998). Following incubation at 37°C in an atmosphere of 5-10% CO2 for 3 days,
mutants were subcultured onto ciprofloxacin-free medium.
6.2.3. MIC Determination for Ciprofloxacin and
Norfloxacin in the Presence or Absence of Reserpine
Reserpine was used as an inhibitor of the putative efflux pump of S. pneumoniae to
determine the presence or absence of efflux pump mechanism of resistance to
fluoroquinolones. The susceptibility to ciprofloxacin (Bayer,UK) and norfloxacin
(Sigma, UK) in the presence or absence of 20 pg/ml of reserpine (Sigma, UK) were
determined by an agar dilution method with Iso-Sensitest agar (Oxoid, UK)
supplemented with 5% horse blood with an inoculum of 104 CFU/spot (Brenwald et
al., 1998a). Reserpine was freshly prepared before use, and media containing it were
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used immediately. After incubation at 37°C in 5-10% C02 for 18 h, the MIC was
recorded as the lowest antibiotic concentration inhibiting growth.
6.2.4. Isolation of Chromosomal DNA
S. pneumoniae strains was cultivated on Columbia agar (Oxoid, UK) supplemented
with 5% horse blood and incubated in 5-10% C02 at 37°C overnight. Colonies were
emulsified in 50 pi sterile MilliQ water in a microcentrifuge tube and boiled for 5 min;
after centrifugation the supernatant contained the DNA which was used for PCRs.
6.2.5. DNA Amplification by Polymerase Chain Reaction
The PCR protocol used to amplify the QRDRs of gyrA and parC genes was a
modification of that used by Pan et al (1996). The primers used (Table 6.1) were
supplied high-pressure liquid chromatography (HPLC) purified by Oswel DNA
Services (Southhampton, UK).
Table 6.1. Primers sequence used in PCR to amplify
the QRDRs ofgyrA & parC in S. pneumoniae






All the PCR reagents were supplied by Advanced Biotechnologies Ltd.. UK. The
optimal reaction mix included 0.5 pi of Taq DNA Polymerase (5 U/pl), 10 pi of lOx
Reaction buffer [200 mM (NTL^SCL, 750 Mm Tris-HCl (pH 8.8), 0.1% Tween®20],
5 pi dNTP Mix (20 mM), 3 pi MgCL (25 mM), 1 pi primers Mix (10 pmole/pl), 5 pi
of DNA template, and sterilised MilliQ water to a final volume of 100 pi. This was
overlaid with sterile mineral oil and processed on Techne Thermal Cycler (Techne
Cambridge Ltd., UK). The optimal PCR cycling conditions were as follows: 1 cycle of
95°C for 5 min followed by 30 cycles of 94°C for 1 min, 55°C for 2 min and 72°C
for 3 min followed by a final cycle of 72°C for 7 min. A negative control was included
in each PCR run where DNA was replaced by an equal amount of sterilised MiliQ
water. PCR products were analysed by electrophoresis through a 1.8 % agarose-
ethidium bromide-containing gel with 100 bp DNA ladder (GibcoBRL Life
technologies) as marker and bands visualised with UV transillumination.
6.2.6. Restriction Fragments Length Polymorphism with
Hinfl
Restriction of the gyrA and parC PCR products was performed using Hinfl
(Promega, UK). The digestion mixture consisted of 1 pi ofHinfl enzyme (10 U/pl) in
10 mM Tris-HCl (pH 7.5), 60 mM NaCL, 7 mM MgCf, 0.1 mg bovine serum albumin
per liter in 50 pi volume. A total of 20 pi of PCR product was added to 2 pi of buffer
and 1 pi ofHinfl enzyme. Digestion proceeded for 4 h at 37°C in a waterbath, and the
products were run on a 1.8% agarose gel as described above.
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6.2.7. DNA Sequencing
To identify mutations at the nucleotide sequence level, gyrA and parC PCR products
were sequenced and analysed in an automatic DNA sequencer. Purified DNA samples
were processed and analysed in the Department of Haematology in the Royal
Infirmary of Edinburgh.
6.2.8. Pulsed-field Gel Electrophoresis (PFGE)
Chromosomal DNA embedded in agarose plugs was prepared from S. pneumoniae
R6, D-680 wild-type and first-step mutant strains as described previously (see
Chapter 4, section 4.2.3). PFGE was carried out after microrestriction of the
chromosomal DNA with Smal endonuclease.
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6.3. Results & Discussion
6.3.1. MIC Determination in the Presence of Reserpine
Reserpine had no effect on ciprofloxacin nor norfloxacin activity against the S.
pneumoniae strains tested (Table 6.2). This suggests that no efflux pump mechanism
was present in these strains.
6.3.2. Amplification of QRDR in gyrA and parC by PCR
Chromosomal DNA from S. pneumoniae strains was used as a template for PCR to
amplify the QRDR of the gyrA and parC genes. Oligonucleotide primer pairs allowed
amplification and isolation of 382 bp gyrA products (encoding residues 46 to 172) and
366 bp parC products (encoding residues 36 to 157), respectively)(Figure 6.1).
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Figure 6.1. Agarose gel electrophoresis of GyrA and ParC PCR
products from S. pneumoniae 680 wild-type strain
Lane M 100 bp DNA ladder marker
Lane 1 GyrA PCR product (382 bp)
Lane 2 ParC PCR product (366 bp)
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6.3.3. RFLP by HinflofgyrA andparC PCR Products
Initially, the status of the gyrAand parC QRDRs was examined by digesting PCR
products with Hirtflandexamining the resulting DNA fragments by electrophoresis.
The 382 bp gyrA PCR product from all strains underwent cleavage at a single Hinfl
site (overlapping the coding sequence for the conserved Ser codon which is equivalent
to the resistance hot spot Ser-83 in E. coli), generating 110 and 272 bp fragments
(Figure 6.2). The gyrA PCR product from the first-step mutant of strain D-680 was
also cleaved by Hinfl,indicating that there is no mutation at either codon 82 nor 83.
The 366 bp parC product from the wild-type gene has sites at nucleotide
position 232 and 288 and on digestion with generated 183, 127 and 56 bp
fragments. Acquisition of a quinolone resistance mutation altering mutational hot spot
at Ser-79 in ParC leads to a loss of the position 232 site and generation of two
183 bp fragments. The parC genes of S. pneumoniae strains in each case retained all
their Hinflsites, which is consistent with the absence of Ser-79 codon changes
(Figure 6.3). However, analysis by parC Hinfl RFLP of the first-step mutant of D-
680 revealed that it gave a single 183 bp band suggesting acquisition of a Ser-79
change (Figure 6.3).
The RFLP analysis provided evidence for parC mutation in the first-step mutant and
the absence of gyrA mutation. However, these observations did not exclude the
presence ofmutations at other positions in the QRDR ofgyrA and parC genes.
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Figure 6.2. A & B. Agarose gel electrophoresis ofHinfl restricted













Lane M 100 bp DNA ladder marker
Lane 1 GyrA PCR product from D-680 wild-type strain
Lane 2 Hint1 restricted GyrA PCR product from D-680 wild-type
strain
Lane M 100 bp DNA ladder marker
Lane 1 GyrA PCR product from D-680 first-step mutant
Lane 2 HinQ restricted GyrA PCR product from D-680 first-step
mutant
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Figure 6.3. Agarose gel electrophoresis of restricted ParC PCR
product from S. pneumoniae D-680 wild-type strain and first-step
mutant
Lane M 100 bp DNA ladder marker
Lane 1 Hinfl restricted ParC PCR product from D-680 wild-type strain
Lane 2 Hinfl restricted ParC PCR product from D-680 first-step mutant
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6.3.4. Sequencing of the QRDR in gyrA andparC
To analyse the respective QRDRs at the nucleotide level, PCR products from all S.
pneumoniae strains and the first-step mutant were subjected to automated DNA
sequencing (Figures 6.4 & 6.5). Consistent with the RFLP data, all wild-type strains
showed no mutations in the HinfLrestriction site in and parC QRDRs.
However the first-step mutant derived from D-680 strain had acquired mutations in
gyrA and parC QRDRs at Glu-87 (GAA)-to-Lys (AAA) and at Ser-79 (TCT)-to-Tyr
(TAT), respectively. These genetic changes are consistent with the parC RFLP
results, but not with gyrA results, and are associated with 8-fold increases in
ciprofloxacin MIC in the first-step mutant compared with that for the wild-type D-680
strain. Interestingly, the cross-resistance profile of ciprofloxacin-selected mutants
against the newer quinolones (Table 6.2) showed that the single mutations selected
by stepwise drug challenge are identical to those at the equivalent positions of gyrA
andparC mutations which are known to cause quinolone resistance in other species.
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6.3.4.1. Results ofgyrA QRDR sequence of pneumoniae
Figure 6.4. A, B & C
A partial 382-base region ofpartial gyrA gene was sequenced and amino acid residues
at position 46 to 172 including QRDR are shown below. The Hinfi. restriction site are
grey boxed. Letters under the nucleotide sequence show the deduced protein
sequence. Amino acid residues are numbered under the letters by analogy with E. coli
GyrA protein. Red letters in the sequence indicate nucleotides and amino acids
different from that of S. pneumoniae ciprofloxacin-susceptible R6 strain and only the
section where nucleotide changes occur is shown.
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Figure 6.4.A. gyrA QRDR sequence of S. pneumoniae ciprofloxacin-
susceptible R6 strain, as listed in GENBANK (AF053121), with MIC
of 0.5 mg/L (Balas et al., 1998).
261 c cgt cgc att etc tat gga atg aat gaa ttg ggt gtg
R R I L Y G M N E L G V
46
298 acc cca gac aaa ccc cat aaa aaa tct get cgt att
T P D K P H K K S A R I
334 aca ggg gat gtc atg ggt aaa tac cac cca cac ggg
T G D V M G K Y H P H G
370 gat tcc tct att tat gaa gcc atg gtc cgt atg get
D S S I Y E A M V R M A
83 87
406 caa tgg tgg age tac cgt tac atg ctt gta gat ggt
Q W W S Y R Y M L V D G
442 cat ggg aat ttt ggt tcc atg gat gga gat agt get
H G N F G S M D G D S A
478 gcc get caa cgt tat acc gag gca cgt atg age aag
A A Q R Y T E A R M S K
514 att get ctg gaa atg ctt cgt gat ate aac aaa aat
I A L E M L R D I N K N
550 aca gtt gat ttc gtt gat aac tat gat gcc aat gaa
T V D F V D N Y D A N E
586 egg gaa ccc ttg gtc ttg cca gcg cgt ttt cca aac
R E p L V L P A R F P N
622 ctt ttg gtt aat gga gca act 642
L L V N G A T
172
Single-letter amino acid codes
A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine,
H histidine, I isoleucine, K lysine, L leucine, M methionine, N aspargine, P proline,
Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine.
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Figure 6.4.B. Four gyrA QRDR sequences of S. pneumoniae strain
RIE-919 (MIC 0.12 mg/L), RIE-11080, BRI-251 and D-680 (MIC 2,
2 and 4 mg/L, respectively)
-All together only one nucleotide was altered resulting in no change of the amino acid.
This altered nucleotide is also present at this sequence if it is compared with gyrA
ORDR sequence of S. pneumoniae ATCC 49619 (GENBANK AF065152) or S.
pneumoniae NCTC 7465 (GENBABK SPU37560).
334 aca ggg gat gtc atg ggt aaa tat cac cca cac ggg
TGDVMGKYHPHG
370 gat tcc tct att tat gaa gcc atg gtc cgt atg get
DSSIYEAMVRMA
83 87
406 caa tgg tgg age tac cgt tac atg ctt gta gat ggt
QWW SYRYMLVDG
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Figure 6.4.C. gyrA QRDR sequence of ciprofloxacin-resistant
S. pneumoniae first-step mutant of strain D-680 with an MIC
of 32 mg/L
-Two nucleotides within QRDR were altered resulting in 1 amino acid mutation:
Glu-87-Lys.
334 aca ggg gat gtc atg ggt aaa tat cac cca cac ggg
TGDVMGKYHPHG
370 gat tcc tct att tat aaa gcc atg gtc cgt atg get
DS S I YKAMVRMA
83 87
406 caa tgg tgg age tac cgt tac atg ctt gta gat ggt
QWWSYRYMLVDG
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6.3.4.2. Results ofparCQRDR sequence of S. pneumoniae
Figure 6.5. A. B & C
A partial 366-base region ofpartialparC gene was sequenced and amino acid residues
at position 36 to 157 including QRDR are shown below. The Hinfl restriction site are
grey boxed. Letters under the nucleotide sequence show the deduced protein
sequence. Nucleotides and amino acids are numbered by taking the first parC
nucleotide as nucleotide 1 and the first ParC residue as number 1. Red letters in the
sequence indicate nucleotides and amino acids different from that of S . pneumoniae
ciprofloxacin-susceptible R6 strain and only section where nucleotide changes occur is
shown.
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Figure 6.5.A. parCQRDR sequence of S. pneumoniae ciprofloxacin-
susceptible R6 strain, as listed in GENBANK (X95717), with MIC of
0.5 mg/L (Munoz & de la Campa, 1996)
105 t ggg ttg aag ccg gtt caa cgc cgt att ctt tat
GLKPVQRRI LY
36
139 tct atg aat aag gat age aat act ttt gac aag
SMNKDSNT FDK
172 age tac cgt aag teg gee aag tea gtc ggg aac
SYRKSAKSVGN
205 ate atg ggg aat ttc cac cca cac ggg gat tct
IMGNFHPHGDS
79
238 tct ate tat gat gcc atg gtt cgt atg tea cag
SIYDAMVRMSQ
83
271 aac tgg aaa aat cgt gag att eta gtt gaa atg
NWKNRE I LVEM
304 cac ggt aat aac ggt tct atg gac gga gat cct
HGNNGSMDGDP
337 cct gcg get atg cgt tat act gag gca cgt ttg
PAAMRYTEARL
370 tct gaa att gca ggc tac ctt ctt cag gat ate
SEIAGYLLQDI
403 gag aaa aag aca gtt cct ttt gca tgg aac ttt
EKKTVPFAWNF






Figure 6.5.B. Four parCQRDR sequences of S. pneumoniae strain
RIE-919 (MIC 0.12 mg/L), RIE-11080, BRI-251 and D-680 (MIC 2,
2 and 4 mg/L, respectively)
-All together only one nucleotide was altered resulting in no change of the amino acid.
172 age tac cgt aag teg gee aag tea gtc ggg aac
SYRKSAKSVGN
205 ate atg ggg aat ttc cac cca cac ggg gat tct
IMGNFHPHGDS
79
238 tct ate tat gac gee atg gtt cgt atg tea cag
S IYDAMVRMSQ
83
271 aac tgg aaa aat cgt gag att eta gtt gaa atg
NWKNRE I LVEM
131
Figure 6.5.C. parCQRDR sequence of ciprofloxacin-resistant
S. pneumoniae first-step mutant of strain D-680 with an MIC
of 32 mg/L
-Two nucleotide within QRDR was altered resulting in 1 amino acid mutation:
Ser-79-Tyr. This led to the loss of the position 232 restriction site.
172 age tac cgt aag teg gee aag tea gtc ggg aac
SYRKSAKSVGN
205 ate atg ggg aat ttc cac cca cac ggg gat tat
IMGNFHPHGDY
79
238 tct ate tat gac gee atg gtt cgt atg tea cag
SIYDAMVRMSQ
83




The comparison of patterns of fragments generated by PFGE of chromosomal DNA
from D-680 wild-type and first-step mutant strains showed identical restriction
patterns (Figure 6.6). This suggested that no point mutation or DNA rearrangement
had occured in the first-step mutant during the selection step by ciprofloxacin from
the wild-type strain.
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Chapter Seven
Molecular Typing and P-Lactamase Analysis of
Amoxycillin-Resistant Clinical Isolates of
H. influenzae
7.1. Introduction
H. influenzae is one of the most common pathogens responsible for respiratory tract
infections, p-lactams are widely used to treat such infections. Resistance to ampicillin was
first documented in Europe in 1972 (Mathies, 1972). Since then, ampicillin resistance has
risen steadily to the present level of 10-30% reported by most centres (Machka el al.,
1988).
The major mechanism of resistance to P-lactams drugs in H. influenzae is the production
of p-lactamases, and the prevalence of p-lactamase-producing isolates has increased over
the last 20 years (Powell et al., 1987 & 1992; Barry et al., 1994). The extent of non-P-
lactamase-mediated resistance has always been difficult to assess and it is possible that p-
lactamase production may be missed by routine testing (Scriver et al., 1994). P-lactam
resistance in strains apparently negative for p-lactamase production has been attributed to
changes in penicillin binding proteins or alterations in permeability (Reid et al., 1987).
The most common P-lactamase in H. influenzae is TEM-1, which accounts for more than
80% of P-lactamase-positive isolates (Scriver et al., 1994). This accounts for the present
susceptibility of these organisms to P-lactam/p-lactamase inhibitor combinations and
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cephalosporins. A second p-lactamase, ROB-1, has also been detected in H. influenzae
(Rubin et al., 1981). Although less numerous than TEM-1, ROB-1 has been found in up
to 8% of isolates in some studies (Daum et al., 1988; Scriver et al., 1994). A third P-
lactamase, VAT-1, has also been identified recently in H. influenzae (Vali et al., 1994).
The significant of this enzyme is not clear at present, but it has been detected in isolates
from different geographical centres in Scotland (Shanahan et al., 1996).
P-Lactamases in H. influenzae confer resistance to P-lactam antibiotics. It is, therefore,
essential that one can identify the production of P-lactamases by clinical isolates and have
effective ways of distinguishing the different enzymes. This is necessary for
epidemiological surveys, predicting future resistance trends and to ensure that patients
receive the appropriate P-lactam or alternative therapy. The first indication of the
presence of P-lactamases is usually the observation of increased levels of resistance in
clinical isolates as detected by routine susceptibility testing. Analytical isoelectric focusing
(IEF) can then be used to characterise the P-lactamase produced. Molecular techniques
have become very effective for identifying different p-lactamases (Payne & Thomson,
1998). PCR has been used to detect ampicillin resistance genes in CSF samples
containing H. influenzae (Tenover et al., 1994). Correlation was obtained between the
result of MIC testing, P-lactamase production as determined by nitrocephin and PCR
testing (Tenover et al., 1994). Molecular typing by pulsed-field gel electrophoresis has
also been used to assess the clonal relationship of isolates (Gazagne et al., 1998).
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7.2. Materials & Methods
7.2.1. Bacterial Strains
Between 1995 and 1996, 231 isolates of H. influenzae were obtained from centres
throughout the UK (see section 2.1). Twenty percent (46) of isolates were amoxycillin-
resistant and, of these, 19% (9) were also resistant to co-amoxiclav. In this study, these
isolates were further examined for possible mechanisms of resistance to amoxycillin and
co-amoxiclav and genotyped by pulsed-field gel electrophoresis.
7.2.2. p-Lactamase Preparation
Test strains were inoculated onto the surface of Chocolate Blood Agar slopes and
incubated at 37°C in a 5% C02 incubator overnight. Bacteria were washed off the surface
of the agar with 1 ml of 50mM Sodium Phosphate buffer (pH 7.0) and transferred to an
ice cold container. The cells were cooled on ice and disrupted by sonication (MSE
Soniprep 150, MSE Instruments, Crawley, Sussex) at 4 x 15 sec pulses of 8pm amplitude
separated by a 15 sec cooling period. The cell lysate was cleared by centrifugation at 4°C
in an MSE Microcentaur centrifuge at ll,600g (13,000 rpm) for 20 min. The cell free
supernatant was stored at -20°C until required.
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7.2.3. Detection of p-Lactamase Production (Nitrocephin Spot
Test)
The reaction time for a 30 pi volume of the p-lactamase preparation to change the colour
of lOOpl of chromogenic cephalosporins, nitrocephin, solution (50 mg/L) from yellow to
red was taken as an indication of the p-lactamase activity of the enzyme preparation
(O'Callaghan et al., 1972).
7.2.4. Analytical Isoelectric Focusing
P-lactamases were identified by analytical isoelectric focusing (IEF) as described by
Matthew et al., (1975). p-lactamase extracts were focused on a thin layer polyacrylamide
gel containing broad range ampholines (pH 3.5-10). The composition of the gel mixture
is shown in Table 7.1.





5% v/v Tetramethylethylenediamine Sigma 0.2 0.25 mg/L
(TEMED) in distilled water
40% w/v Ampholines pH 3.5-10 Sigma 2 2% w/v
Acrylamide (100g) & BDH 9 Acrylamide 76 g/L,
Methyl 6/sacrylamide (2.7 g) /u.sacrylamide 2 g/L
in 300 ml distilled water
Distilled water 25
Riboflavin (20 mg/L) Sigma 4 2 mg/L
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The polyacrylamide gel solution was poured between two glass plates of different sizes,
the smaller of which was coated to promote the adhesion of the gel. The plate coating
solution consisted of 0.5% w/v gelatin and 0.5% w/v chromium potassium sulphate (both
Aldrich Chemical Co. Ltd, Dorset) in sterile distilled water, and was allowed to dry on
the plate. The other glass was siliconised with Sigmacote siliconising solution to reduce
adhesion. When poured, the acrylamide was polymerised by the riboflavin in the presence
ofultraviolet light for 6 h.
When the glass plates were separated apart, the gel (which had adhered to the smaller
plate) was allowed to dry in air for up to 1 h before loading with samples of p-lactamase
preparation on to the gel surface close to the anode. The nitrocephin spot test time
determined the volume of the p-lactamase preparation loaded onto the gel, the volume
being calculated as the nitrocephin spot test time (see section 7.2.3). Up to a maximum of
50 pi of the p-lactamase preparation was loaded to any one lane.
Isoelectric focusing was carried out at a constant power of 1W, with the maximum
settings of 500V and 20 mA overnight. The gel was calibrated by focusing P-lactamase
of known pi. The focused P-lactamase bands were visualised by overlaying the surface of
the gel with sheets of filter paper (Whatman No. 54, BDH), previously soaked in
nitrocephin solution (500 mg/L). The bands of P-lactamase activity appeared red on a
yellow background. Photographs of focused p-lactamases were taken with a Polaroid
camera (setting B4, F8) with a Wratten 58 green filter.
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7.2.5. Isolation of Chromosomal DNA
H. influenzae strains were cultivated on Chocolate Blood agar and incubated in 5-10%
CO2 at 37°C overnight. Colonies were emulsified in 50 gtl sterile MiliQ water in a
microcentrifuge tube and boiled for 3 min; supernatant containing DNA was used for
PCRs.
7.2.6. DNA Amplification by Polymerase Chain Reaction
The PCR protocol used to amplify the bla-\\M-\ gene in H. influenzae was a modification
of that used by Tenover et al. (1994). The Wotem-i universal primers used (Table 7.2)
were supplied after high-pressure liquid chromatography (HPLC) purification by Oswel
DNA Services (Southhampton, UK).
Table 7.2. Primers sequence used in PCR to
amplify the Z»/«tem-i in H. influenzae
Name Sequence (5' 3Q
blajEM-i TGGGTGCACGAGTGGGTTAC
blajem-1 TTATCCGCCTCCATCCAGTC
All the PCR reagents were supplied by Advanced Biotechnologies Ltd., UK. The optimal
reaction mix included 0.5 pi of Taq DNA Polymerase (5 U/pl), 10 pi of lOx Reaction
buffer [200 mM (NH^SCb, 750 Mm Tris-HCl (pH 8.8), 0.1% Tween®20], 5 pi dNTP
Mix (20 mM), 3 pi MgCfi (25 mM), 1 pi primers Mix (10 pmole/pl), 5 pi of DNA
template, and sterilised MiliQ water to a final volume of 100 pi. This was overlaid with
sterile mineral oil and processed on Techne Thermal Cycler (Techne Cambridge Ltd.,
UK). The optimal PCR cycling conditions were as follows: 1 cycle of 94°C for 5 min
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followed by 30 cycles of 94°C for 2 min, 57°C for 1 min and 72°C for 2 min followed by
a final cycle of 72°C for 10 min. A negative control was included in each PCR run where
DNA was replaced by an equal amount of sterilised MiliQ water. Also a p-lactamase-
negative and a TEM-1 producing H. influenzae isolates were included as controls. PCR
products were analysed by electrophoresis through a 1.8 % agarose-ethidium bromide-
containing gel with 100 bp DNA ladder (GibcoBRL Life technologies) as marker and
bands visualised with UV transillumination.
7.2.7. Pulsed-Field Gel Electrophoresis (PFGE)
Preparation of Intact Chromosomal DNA in Agarose Plugs
The preparation of intact chromosomal DNA in agarose plugs was compiled with some
modifications from the method of Curran et al. (1994). H. influenzae strains were
inoculated in Brain Heart Infusion broth (Oxoid, UK) supplemented with 10 pg/ml
Hemin and 2 pg/ml Nicotinamide adenine dinucleotide (Sigma, UK) and were grown to a
density of 2 x 109 cells/ml (optical density of 0.15 at 650 nm) in 37°C incubator with 5-
10% C02 overnight. The cells were centrifiiged at 4°C at 3,000 rpm in a centrifuge for 10
min. The cell pellets were resuspeneded in 0.5 ml of SB buffer [10 mM Tris-HCl (pH
7.5), 1 M NaCl], recentrifiiged, resuspeneded finally in fresh SB buffer and held at 37°C.
Each 0.5 ml cell suspension was then mixed with 0.5 ml of molten 2% w/v low-melt
preparative grade agarose (Bio-Rad, UK) in distilled water. The mixture was
micropipetted immediately into the wells of a perspex plug mould (Bio-Rad, UK) and
cooled to 4°C to allow the agarose to set. Each set of plugs was then ejected from the
mould into bijou bottles containing 2 ml of LB buffer [10 mM Tris-HCl (pH 7.5), 1 M
NaCl, 100 mM EDTA, 0.5% polyxythylene 20 cetyl ether, 0.2% sodium deoxycholate,
0.5% n-lauroylsarcosine, 1 mg/ml lysozyme, and 20 pg/ml ribonuclease A] and the
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bottles were incubated overnight at 37°C. The LB buffer was then replaced with 2 ml of
PB buffer [0.5 M EDTA (pH 9.0), 1% n-lauroylsarcosine, 1 mg/ml proteinase K] and
incubated at 55°C for 48 h. At the end of this period, the PB buffer was replaced with 2
ml ofPMSF buffer [1 mM phenylmethylsulphonyl fluoride (PMSF), 10 mM Tris-HCl (pH
7.5), 0.1 mM EDTA] and incubated at room temperature for 2 h. This wash step was
repeated once with fresh PMSF buffer, followed by three washes for a minimum of 2 h
each in TE buffer [10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA]. The plugs were then
stored at 4°C in TE buffer until required.
Digestion of Chromosomal DNA in Agarose Plugs
Generally, digests were performed with DNA contained in about one-third of a complete
plug. Each plug portion was transferred to a sterile microcentrifuge tube and equilibrated
at 4°C in 100 pi of the Smal digestion buffer (Promega, UK). After 1 h, the buffer was
replaced with 100 pi of fresh digestion buffer and 12 U of Smal (Promega, UK) was
added. After 4-6 h digestion at 37°C, the buffer-enzyme mixture was replaced with 100
pi of inactivation buffer [0.5 M EDTA (pH 9.0), 1% w-lauroylsarcosine] and kept at 4°C
until ready for electrophoresis.
Electrophoresis
DNA macrorestriction fragments were separated on 1% agarose gel by PFGE employing
a CHEF-DR II system (Bio-Rad, UK) at 6 V/cm for 30 h with a switching time of 1-26
sec at 12°C. The gels were stained with 1 pg/ml of ethidium bromide (Sigma, UK) and
were destained in water for lh before photography.
142
Gelcompar Software
The PFGE patterns were analysed employing Gelcompar software (Applied Math,
Kortrijk, Belgium). The PFGE patterns were compared by the UPGMA (unweighted pair
group method with arithmetic averages) clustering method by employing the Dice
coefficient (Shi et al., 1996). A tolerance in the band position of 1.2% was applied during
the comparison ofPFGE fingerprinting patterns.
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7.3. Results
7.3.1. The Prevalence of p-Lactamase Production in
H. influenzae
The cell-free extracts of the 231 isolates were prepared (section 7.2.2) and the P-
lactamase activity of each preparation was assayed by the nitrocephin spot test. The
change in colour of nitrocephin solution from yellow to red after 30 min was taken as an
indication of p-lactamase activity. Based on this method 16% (37) of the H. influenzae
isolates harboured a detectable P-lactamase enzyme (Table 7.3).
7.3.2. Characterisation of p-Lactamases in H. influenzae
To identify the P-lactamases in H. influenzae, sonicated extracts of the 37 P-lactamase
producing isolates were examined by analytical isoelectric focusing. It was demonstrated
that all the P-lactamase producing strains produced a single P-lactamase that was focused
as a single band at pi 5.4 in IEF gel and co-focused with TEM-1 p-lactamase control
(Figure 7.1).
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Figure 7.1. IEF pattern of the (^-lactamases isolated from 37
({-lactamase producing H. influenzae isolates on 10% polyacrylamide
gel containing broad-range ampholines (pH 3.5-10)
<4- ROB-l (pi 8.1)
TEM-1 (pi 5.4)
1 2 3
Lane 1 TEM-1 (pi 5.4) isolated from the P-lactamase producing
Haemophilus influenzae isolates
Lane 2 TEM-1 control (pi 5.4)
Lane 3 ROB-l control (pi 8.1)
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7.3.3. Identification of TEM-1-Derived (3-lactamases by PCR
A total of 46 amoxycillin-resistant H. influenzae isolates were tested for the presence of
bla-\Eu-\ type enzyme gene by PCR. According to the IEF results, 37 of these isolates
were P-lactamase producers and the remaining 9 isolates were P-lactamase-negative.
Oligonucleotide primer pairs allowed amplification and isolation of 526 bp blayem-i PCR
products (Figure 7.2). All 37 amoxycillin-resistant P-lactamase-positive isolates,
identified by nitrocephin spot test, produced the blayem-i PCR product (Table 7.3).
Interestingly, 6 of the 9 amoxycillin-resistant p-lactamase-negative isolates, missed by
nitrocephin spot test, also produced the 6/aTEm-i PCR product (Table 7.3). This could be
explained that these isolates carry the 6/otem-i gene responsible for P-lactamase
production, but the gene is switched off, or the P-lactamase produced is so weak that can
not be detected by nitrocephin spot test.
From the PCR results we can conclude that, in the 46 amoxycillin-resistant strains, 94%
(43) possessed the TEM-1 P-lactamase gene and of these, 80% have active P-lactamase
activity capable of conferring resistance.
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Figure 7.2. Agarose gel showing amplified em-i PCR products
(526 bp) from TEM-1 P-lactamase-positive amoxycillin-resistant
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Lane M 100 bp lambda DNA ladder molecular marker
Lane 1 p-lactamase-negative H. influenzae control strain
Lane 2-8 6/otem-i PCR products from amoxycillin-resistant P-lactamase-
positive H. influenzae clinical isolates
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7.3.4. Pulsed-Field Gel Electrophoresis (PFGE) Profiles
A total of 46 amoxycillin-resistant (and of these, 9 were also coamoxiclav-resistant) H.
influenzae isolates were genotyped by PFGE (Figure 7.3 & 7.5). Cluster analysis of
patterns produced by PFGE of chromosomal DNA digested with Smal revealed that
amoxycillin-resistant isolates susceptible to clavulanic acid showed little genetic
relatedness. In contrast, among coamoxiclav-resistant strains two major groups were
identified. PFGE patterns were classified into groups alphabetically.
Amoxycillin-Resistant Co-amoxiclav-susceptible Isolates
The PFGE patterns of 37 isolates from the UK are shown in Figure 7.3. PFGE
fingerprinting of the 37 isolates analysed by Gelcompar revealed that only 10 of the
isolates were identical. Taking a cut off value of 80% similarity produced 4 clusters of
isolates (A to D) within 13 strains from a total of 37 strains examined (Table 7.3). The
remaining 24 isolates were unrelated and demonstrated 24 distinct types.
A dendrogram was constructed to show the degree of relatedness among the strains of
clusters from the UK (Figure 7.4). Cluster A included two identical isolates from the
same hospital both of which had the same amoxycillin MICs of 64 mg/L (RIE-238 &
RIE-239). Cluster B included 5 isolates and were subtyped BI (RIE-195 & RIE-237), B2
(R1E-544 & RIE-547) and B3 (WH-621). Interestingly, all isolates in cluster B were from
the same hospital, except WH-621, and have the same amoxycillin MICs of 64 mg/L.
Cluster C included 3 isolates. Two isolates, LRI-319 & BSH-336, have the same PFGE
patters but were from different geographic locations and have different amoxycillin MICs.
They were subtyped as CI. The remaining isolate, B-410, was subtyped C2. Cluster D,
with similar profile to cluster C, included 3 isolates. Two isolates, L-449 & RIE-506,
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have the same PFGE patterns but were from different geographic locations and have
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Amoxycillin-Resistant Co-amoxiclav-Resistant Isolates
Cluster analysis ofpatterns produced by PFGE of chromosomal DNA digested with Smal
revealed that among co-amoxiclav-resistant isolates only two major groups of strains
were identified (Figure 7.5 & 7.6). One group were TEM-1 producers and exhibited high
MICs to amoxycillin (>8 mg/L) which were reduced by the addition of clavulanic acid.
Taking a cut off value of 80% similarity produced one cluster of isolates (I) within 2
strains (RIE-191 & AH-763) from total of 5 strains within this group. The second group
had the same MIC to amoxycillin as to co-amoxiclav and showed no evidence of (3-
lactamase production (Figure 7.6). Cluster analysis produced one cluster of isolates (II)
within 2 strains (RIE-233 & FL-258) from total of 4 strains within this group. Neither
group was restricted to isolates from the same geographic area.
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Figure7.5.Pulsed-fieldeelectrophoresisofSmaldi stchromosomalDNAfr9co-amoxiclav- resistantH.influenz esolatesfr mthUK ClusterI I11 Lane123456789M Ifmmwm§mm mJ 9k.|wBlJm®S:Hrft̂H m«mm®§Sfl Hk.JH[^bL91:Ejj fth|H9999 Lanes1-99co-amoxiclav-resistant7/.influenzaeisol te :RIE-191,LRI 21363 FL-258,RIE-502WH 624AH 742and-763respectively. LaneMLambdaDNAladderarker
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Table 7.3. Amoxycillin and co-amoxiclav MICs of amoxycillin-resistant
and co-amoxiclav-susceptible and -resistant H. influenzae isolates,








Amoxycillin Co-amoxiclav IEF PCR
Amoxycillin-resistant, co-amoxiclav-susceptible H. influenzae isolates
1 RJE-188 64 + +
2 RIE-189 64 + +
3 LRI-205 16 + +
4 LRI-211 4 + +
5 LRI-218 4 + +
6 RIE-231 32 + +
7 RIE-234 4 + +
8 RIE-238 A 64 + +
9 RIE-239 A 64 + +
10 BRJ-244 4 + +
11 BRI-246 4 + +
12 LRI-319 CI 32 + +
13 BSH-336 CI 8 + +
14 BSH-341 2 + +
15 BSH-348 8 + +
16 LRI-362 4 + +
17 LRI-363 2 + +
18 WH-411 16 + T
19 WH-414 4 + +
20 L-449 D1 4 + +
21 L-463 8 + +
22 RIE-499 64 + +
23 RIE-500 2 + +
24 RIE-506 D1 32 + +











Amoxycillin Co-amoxiclav IEF PCR
26 RIE-544 B2 64 + +
27 RIE-546 64 + +
28 RIE-547 B2 64 + +
29 WH-621 B3 32 + +
30 RIE-637 64 + +
31 AH-748 32 + +
32 AH-749 4 + +
33 D-772 16 + +
34 RIE-195 B1 64 - +
35 RIE-237 B1 64 - +
36 B-410 C2 8 - +
37 RIE-587 2 - +
Amoxycil in-resistant, co-amoxiclav-resistant H. influenzae isolates
38 RIE-191 I 64 4 + +
39 AH-763 1 64 4 + +
40 WH-624 16 4 + +
41 LRI-216 64 2 + +
42 RIE-502 16 4 - +
43 AH-742 2 2 - +
44 RIE-233 11 2 2 - -
45 FL-258 II 2 2 - -
46 LRI-213 4 4 - -
IEF Isoelectric foucsing, PCR Polymerase chain reaction, MIC Minimum inhibitory concentration,
PFGE Pulsed-field gel electrophoresis
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7.4. Discussion
p-lactams compounds are among the drugs of choice for treating respiratory infections
caused by H. influenzae. However, the emergence of ft-lactam resistant strains has
influenced the therapeutic efficacy of these compounds. The most common mechanism of
P-lactam resistance in H. influenzae is the production of an enzyme with P-lactamase
activity. It is, therefore, essential that one can identity the production of P-lactamases by
clinical isolates and have effective ways of distinguishing the different enzymes. This is
necessary for epidemiologic surveys, predicting future resistance trends, and to ensure
that patients receive the appropriate p-lactam or alternative therapy.
From 231 H. influenzae strains examined in this study, 16% produced detectable P-
lactamase enzymes. This rate was similar to the Canadian (25%) (Matsumura et al.,
1995) and American (16.5%) (Jorgensen et al., 1990) studies. Also the results showed
that the prevalence of P-lactamase mediated amoxycillin resistance (18.6%) was
comparatively higher than the 8.6% and 8.4% recorded in the studies conducted in the
UK (Powell et al., 1992) and Wales (Howard & Williams, 1988). To extend the
antimicrobial spectrum, clavulanic acid was combined with amoxycillin (2:1), however; a
high proportion (21%) of the p-lactamase-producing amoxycillin-resistant strains
remained insensitive to amoxycillin. This may be explained by the hyper-production of P-
lactamase enzymes in clinical strains which, in turn, is a threat to the effectiveness of the
P-lactamase inhibitors currently administered for the treatment of P-lactamase-positive H.
influenzae infections. TEM-1 production accounted for all the P-lactamase-positive
strains isolated in this study. None of the strains contained enzymes identified as ROB-1
or VAT-1. In previous studies, TEM-1 and ROB-1 production accounted for
approximately 96% and 7% of the p-lactamase-positive strains, respectively (Scriver et
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al., 1994; Powell et al., 1992). The isolation of a VAT-1 type enzyme has been reported
only on rare occasions (Vali et al., 1994; Shanahan et al., 1996).
Cluster analysis of patterns produced by PFGE ofchromosomal DNA digested with Smal
revealed that amoxycillin-resistant isolates showed little genetic relatedness. However,
few clusters of isolates have been identified. According to these results, it seems that the
clonal propagation of these resistant strains does not occur as previously described in S.
pneumoniae clinical isolates (Munoz et al., 1991).
In summary, amoxycillin resistance in H. influenzae throughout the UK is mediated by
the TEM-1 enzyme which appears to have spread into a wide variety of dilferent strains.
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(3-Lactamase enzymes play a major role in H. influenzae resistance to p-lactam
antibiotics. However, there are increasing numbers of reports ofH. influenzae strains that
owe their P-lactam resistance to a mechanism other than the production of a p-lactamase.
Changes in the penicillin-binding proteins (PBPs) and outer-membrane proteins (OMPs)
can both result in P-lactam resistance (Malouin & Bryan, 1986; Reid et al., 1987;
Nikaido, 1989).
Ampicillin-resistant non-p-lactamase-producing H. influenzae strains (AMPr P") are more
difficult to detect because of their low incidence rate. Also they have lower-level
resistance than do P-lactamase-producing strains (Mendelman et al., 1986). The AMPr P"
H. influenzae strains are genetically diverse and have been reported in the United States,
Canada, the United Kingdom and New Zealand (Mendelman et al., 1987). Their overall
incidence in the United Kingdom increased from 2 % in 1981 to 4% in 1986 and to 5.8%
in 1991 (Powell et al., 1987; 1992). However, conventional methods for testing the
susceptibility of H. influenzae to antibiotics are inoculum dependent and have been
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shown to be unreliable (Mendelman et al., 1986; Powell & Williams, 1988; Heelan et al.,
1992). It has also been suggested that the frequency of AMPr (3 //. influenzae strains are
underestimated (Powell & Williams, 1988; Brown et al., 1992). The usual disk diffusion
method with a 10- or 25-pg amoxycillin disk does not permit the detection of this mode
of resistance. Detection of this kind of resistance (diameter of inhibition, <19 mm,
corresponding to an MIC of >2 mg/L) is only obtained with a 2-pg ampicillin disk
(BSAC, 1998).
PBPs are targets for (3-lactams. Binding ofP-lactam antibiotics to PBPs leads to cell lysis,
death or growth arrest (Tomasz, 1979; Tipper, 1985). Alterations in PBPs profile is one
of the mechanisms that develops resistance to p-lactam compounds. The number, amount
and size of PBPs as well as their affinity for P-lactam antibiotics vary from species to
species (Makover et al., 1981). Among the 10 Haemophilus species isolated from
humans, only H. influenzae and H. aegyptius appear to have similar PBPs (Mendelman &
Serfass, 1988). Ampicillin-susceptible strains of H. influenzae have a relatively
homogeneous pattern of 8 PBPs (Mendelman et al., 1990). In contrast, AMPr P" H.
influenzae strains have heterogeneous PBP profiles (Mendelman et al., 1990).
Although it is likely that the alteration of PBPs is the most frequent cause of AMPr P" in
H. influenzae strains, decreased outer-membrane permeability has also been reported.
Burns and Smith (1987) found that some H. influenzae strains resistant to P-lactams
lacked a 40 kDa major porin. However, the PBPs of that particular isolate were not
investigated. Outer-membrane protein profiles of both capsulated and non-capsulated H.
influenzae strains, have proved to be diverse and variant (Loeb & Smith, 1980). Many
workers have suggested that AMPr P~ in H. influenzae strains may only be caused by
altered PBPs (Clairoux et al., 1992), however, Reid et al. (1987) implied that OMP
profile differences exist between ampicillin-susceptible and AMPr P" H. influenzae strains
of the same biotype. However, no specific protein change accounted for this finding.
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During the study of amoxycillin-resistant H. influenzae strains, a group of 9 strains were
identified as also co-amoxiclav-resistant (see Chapter 3). In the current study these 9
strains were further examined for their PBP and OMP profiles.
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8.2. Materials & Methods
8.2.1. Bacterial Strains
Nine co-amoxiclav-resistant H. influenzae isolates were examined for their OMPs and
PBPs profiles. An amoxycillin-susceptible H. influenzae isolate was also included as
control.
8.2.2. Alterations in Outer-Membrane Proteins (OMPs)
OMPs Preparation
Membrane fractions were prepared by a modification of the methods of Reid et al.,
(1987). Volumes of 10 ml of overnight cultures were inoculated into 90 ml of Heart
Infusion Broth supplemented with 10 pg/ml Haemin and 10 pg/ml NAD and incubated at
37°C, with shaking at 200 rpm for 4 h, to yield mid-log phase cells. Cells were then
harvested by centrifiigation at 6,000 g and 4°C for 10 min and the pellet resuspeneded in
10 ml of cold sodium phosphate buffer (50 mM, pH 7.0). The suspensions were sonicated
(MSE Soniprep 150, MSE Instruments, Crawley, Sussex) at 8 pm for 6 cycles of 30 sec
each in an ice bath, separated by 30 sec cooling periods. They were then centrifiiged at
2,500 g and 4°C for 10 min to remove debris and unbroken cells. The supernatants were
retained and the cell-envelopes harvested by centrifugation at 15,600 g and 4°C for 30
min to sediment the cell membrane. The inner membranes were solubilised by the addition
of 2 ml of 2% rc-lauroylsarcosine. Then the OMPs were sedimented by ultracentrifugation
at 40,000 g for 1 h at 4°C, resuspended in 1 ml MilliQ water, dispensed into aliquots and
stored at -20°C until required.
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Protein Concentrations in the OMP Preparations
OMPs were diluted in MilliQ water to a concentration of 1 mg/ml. The Protein
concentrations in the OMP preparations were determined by the method of Waddell and
Hill (1956). The samples were diluted in sterile distilled water and their absorbance was
measured at wavelengths of 215 and 225 nm on a Perkin-Elmer LJV/Vis Lambda II
Spectrophotometer. The protein concentration was determined by reference to a
previously prepared standard curve.
Gel Electrophoresis
After adjusting their protein concentration to 1 mg/ml, 50 pi volumes of the membrane
extracts were mixed with 50 pi of loading buffer comprising 20% glycerol, 0.005%
bromophenol blue, 4% sodium dodecyl sulphate (SDS) and 5% P-mercaptoethano 1 in
0.25 M Tris-HCl (pH 6.8), and boiled for 5 min. After cooling, samples were loaded onto
12% Tris-HCl SDS polyacrylamide Mini-Protean Ready gel (BioRad, UK) and sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out in the
Mini-Protean II System (Bio-Rad, UK) at 200 V constant voltage for 30 min. The
running buffer consisted of 0.025 M Tris-HCl, 0.19 M glycine and 0.1% SDS. A low
range molecular weight standard (Bio-Rad, UK) was also loaded in the gel. After
electrophoresis, the gel was removed from the apparatus and stained overnight with
Coomassie blue R-250 staining solution (Sigma, UK), then destained in several changes
ofdistilled water before being photographed.
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8.2.3. Alterations in Penicillin Binding Proteins (PBPs)
PBPs Preparation
Membrane fractions were prepared by a modification of the methods of Reid et a/.,
(1987). Volumes of 100 pi of overnight cultures were inoculated into 400 ml amounts of
Heart Infusion Broth (Oxoid, UK) supplemented with 10 pg/ml Haemin and 10 pg/ml
NAD and incubated at 37°C, with shaking at 200 rpm for 4 h, to yield mid-log phase
cells. The cells were then harvested at 5,000 g for 20 min at 4°C, washed with 10 ml ice-
cold 20 mM sodium phosphate buffer (pH 7.0), and resuspended in 10 ml of the same
buffer containing 140 mM P-mercaptoethanol. The resulting suspensions were subjected
to sonication (MSE Soniprep 150, MSE Instruments, Crawley, Sussex) at 18 pm
amplitude for 6 cycles of 30 sec each in an ice bath, then centrifuged at 1,500 g for 15
min at 4°C to remove debris. The supernatants were retained and the membrane particles
were deposited by centrifugation at 150,000 g for 30 min at 4°C and resuspended in 0.5
ml of 20 mM sodium phosphate buffer (pH 7.0). These suspensions were then dispensed
in aliquots and stored at -70°C until required. The PBPs were diluted in MilliQ water to a
concentration of 5 mg/ml as described above.
Direct PBP Labelling
Membrane fractions, in 90 pi volumes, were thawed slowly and mixed with 10 pi
amounts of 330 mg/L 14[C] benzyl penicillin (Amersham Life Science) in phosphate buffer
(pH 7.0) and incubated at 30°C for 10 min. Ten-microlitre amounts of non-radioactive
benzylpenicillin solutions, 60 mg/ml, in phosphate buffer (pH 7.0) were then added
followed by 10 pi of 10% //-lauroylsarcosine. The mixtures were vortexed briefly, held at
room temperature for 20 min and the preparations were then ready for electrophoresis.
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Gel Electrophoresis
The above preparations were mixed with 50 pi of loading buffer comprising 20%
glycerol, 0.005% bromophenol blue, 4% sodium dodecyl sulphate (SDS) and 5% (3-
mercaptoethanol in 0.25 M Tris-HCl (pH 6.8), and boiled for 3 min. After cooling,
samples were loaded onto the gel and run exactly as described in the section on OMP gel
electrophoresis (see section 8.2.2). After running, the gel was stained and destained
before being photographed.
Fluorography
The destained gel was impregnated with aqueous scintillant, Amplify (Amersham Life
Science), for 1 h, then transferred on to Whatman no. 17 card and dried under vacuum
using a gel dryer (BioRad, UK). The dried gel was exposed to X-ray film (Kodak
XOMAT AR) at -70°C for 3 months before developing.
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8.3. Results
8.3.1. Outer-Membrane Proteins (OMPs) Profiles
The OMP profiles of the 9 amoxycillin-resistant co-amoxiclav-resistant strains were
compared to that of an amoxycillin- and co-amoxiclav-susceptible strain. All strains
produced a limited number ofmajor OMPs with molecular sizes between 31 and 45 kDa,
together with various other minor protein components (Figure 8.1).
Comparison of the OMPs profiles revealed that similar patterns were observed in most of
the co-amoxiclav-resistant strains compared with the susceptible strain (Figure 8.1).
However, two strains, RIE-233 and FL-258, lacked the 39.8 kDa band which was present
in all the other strains (Figure 8.1 & 8.2). Interestingly, these two isolates have the same
MIC results for amoxycillin and co-amoxiclav (2 mg/L), are non-[3-lactamase producers,
and gave similar PFGE patterns as shown in Table 8.1. Both isolates were from different
geographical locations. The lacking of 39.8 kDa band in these two isolates suggest a
correlation of this band with amoxycillin and co-amoxiclav reduced susceptibility.
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Figure 8.2. SDS-PAGE of outer-membrane proteins (OMPs) of
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Lanes 1-3 H. influenzae strains LRI-213, RIE-233 and FL-258, respectively.
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8.3.2. Penicillin Binding Proteins (PBPs) Profiles
The PBPs of the 9 amoxycillin-resistant co-amoxiclav-resistant isolates and the
susceptible strain were compared. Eight distinct PBPs were detected in the amoxycillin-
susceptible strain examined, with molecular weights between 37 and 87 kDa (Figure 8.3).
In contrast, the 9 co-amoxiclav-resistant strains tested exhibited marked heterogenicity in
patterns (Figure 8.3). PBPs 1 (87 kDa), 2 (77 kDa), 3 (69 kDa), 7 (39 kDa) and 8 (37
kDa) were present in all 9 isolates and variation in electrophoretic mobility as well as in
the amount of penicillin bound by certain PBPs was noted. However, among co-
amoxiclav-resistant strains, penicillin binding to the PBPs of certain isolates was either
markedly reduced or absent, as in PBP4 (58 kDa) and PBP5 (48 kDa) in lanes 2 and 8;
and PBP6 (43 kDa) in lanes 4 and 8 (Figure 8.3).
Table 8.1 shows a summary of the possible mechanisms of resistance to amoxycillin and
co-amoxiclav in H. influenzae isolates.
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8.4. Discussion
H. influenzae have acquired a wide range of defence mechanisms which may protect
them from the actions of antibiotics. However, one way of overcoming the resistance
caused by these defence systems is to understand the biochemical mechanisms. When
these mechanisms are fully understood and combined with information on the prevalence,
strategies may be designed for maximising the usefulness of antimicrobial agents whilst
minimising the frequency of antibiotic resistance.
Amoxycillin resistance in H. influenzae is mainly caused by P-lactamase production.
However, intrinsic mechanisms entailing target modification (PBP alterations) and/or
impermeability (OMP alterations) have also been described (Reid et al., 1987).
Ampicillin-resistant non-p-lactamase-producing H. influenzae strains (AMPr P") are not
frequently encountered. Depending on which breakpoints are considered, the incidence of
these strains varies. The frequencies of occurrence of resistant strains are <1 to 2.5%
(MICs >2 mg/L) in Canada and the United States (Barry et al., 1993; Clairoux et al.,
1992; Doern et al., 1988), 5 to 7% (MICs >1 mg/L) in the United Kingdom (Reid et al.,
1987; Powell et al., 1990; Powell & Livermore, 1990), <1 to 7% (MICs >1 or >2 mg/L)
in Australia (Bell & Plowman; 1980; Collignon et al., 1992), 1% (MICs >2 mg/L) and
0.3% (MICs >4 mg/L) in an international study (Kayser et al., 1990). This variability in
the incidence ofAMPr P" illustrates the difficulties encountered in highlighting this kind of
resistance.
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In the current study, in common with other investigators (Serfass et al., 1986; Reid et al.,
1987; Mendelman et al., 1990), eight PBPs were detected in a fully-susceptible H.
influenzae strain. However, different PBP numbering schemes have been used by
different workers (Mendelman et al., 1990). In the present study, 3 of the nine co-
amoxiclav-resistant H. influenzae strains showed differences in the PBPs profile relative
to the amoxycillin-susceptible control strain.
Also the absence of OMP band at 39.8 kDa in two P-lactamase-negative co-amoxiclav-
resistant strains (RIE-233 and FL-258) but not in the amoxycillin-susceptible control
strains, suggested an association between the absence of this protein and co-amoxiclav
resistance.
The OMP and PBP results show that several mechanisms, either acting individually or in
combination, are implicated in amoxycillin and co-amoxiclav resistance in H. influenzae.
It is thus apparent that P-lactamase enzymes are not the sole mechanisms of amoxycillin






The development of antibiotics has undoubtedly been one of the greatest achievements of
modern medicine. However, increasing bacterial resistance to these agents is
compromising their usefulness and there is genuine concern that we may be approaching
the end of the antibiotic era. There are two approaches to overcome this, one is a need to
develop new agents and the other is a better understanding of how resistance to current
antibiotics is developing and spreading. This thesis attempts to reveal the latter in
common lower respiratory pathogens.
(3-Lactams account for approximately 50% of global antibiotic consumption (Livermore,
1998) and this heavy usage exerts considerable selection for resistance arising via (i)
modification and addition of the normal penicillin-binding proteins (PBPs) the latter
allowing bypassing of the normal PBPs, (ii) impermeability of the gram-negative
organism outer membrane and (iii) production of P-lactamases (Livermore, 1998). PBP
modification and bypassing are the most important mechanisms of resistance in gram-
positive cocci (except p-lactamase-producer Staphylococcus aureus strains), whereas P-
lactamases are pre-eminent in gram-negative species.
One of the major uses of P-lactams is to treat S. pneumoniae and H. influenzae lower
respiratory infections. However, resistance to P-lactams is increasing in the UK
(Goldsmith et al., 1997; Powell et al., 1992). To establish if this increase results from
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spread of a small number of resistant strains or from a wider emergence of resistance, the
molecular type and mechanisms of resistance in penicillin-resistant S. pneumoniae and
amoxycillin-resistant H. influenzae clinical isolates were examined. In an attempt to
establish if alternative therapies might be viable, the sensitivity and resistance of penicillin-
resistant S. pneumoniae to fluoroquinolones was also investigated.
To be a useful epidemiologic tool, a typing system must give an unambiguous result for
each isolate (typeability), give the same result each time the same isolate is tested
(reproducibility), and differentiate among epidemiologically unrelated strains
(discriminatory power) (Weber et al., 1997). The earliest typing methods used for
epidemiologic purposes were phenotypic methods. Phenotypic methods can detect
characteristics expressed by microorganisms, in response to antibiotics or other inhibitors,
often as a product of one of their enzymes, or even as a protein antigen on their cell
surface (Grandsen et al., 1985; Mulligan et al., 1988; Boyce et al., 1992). Phenotypic
methods rely on gene expression and are not as stable as DNA-based methods. In
addition, phenotypic methods tend to categorize isolates together in large groups and
thus do not discriminate between strains as efficiently as DNA-based methods (Weber et
al., 1997). Genotypic typing methods evaluate differences at the DNA level and probably
should be more commonly used because of their greater discrimination than phenotypic
methods (Hall, 1998). In addition, in theory at least all isolates should be typeable by tests
evaluating the chromosomal DNA and the results should be reproducible, which has not
been the case for phenotypic methods (Weber et al., 1997).
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9.2. The Level of Antibiotic Resistance in Lower Respiratory Pathogens
S. pneumoniae
In the current study, the rate of penicillin resistance in pneumococcal isolates from
selected laboratories in the UK was 11.4%. Significant and rising levels of pneumococcal
penicillin resistance have now been reported from several parts of the UK. Nair (1988)
reported low-level penicillin resistance amongst 4% of 100 pneumococcal strains tested
in Hammersmith, London. Ridgway et al. (1991) examined 915 strains isolated between
1987 and 1989 in the Merseyside area and showed that the prevalence of resistance rose
from 1.4% to 2.5% during this time. A subsequent study in 1993 found 48% of 521
pneumococci to be resistant to at least one antibiotic (Ridgway et al., 1995) and in 1995
the level of penicillin resistance had risen to 7.5% (Allen & Anson, 1996). In Newham,
London, Wilson et al., (1996) found 12% of isolates in 1994-1995 to be similarly
resistant. Data from the Ptolemy Project multi-centre survey (Felmingham et al., 1996)
between 1994-1995 showed an overall UK prevalence of amoxycillin resistance 6.8%.
However, these figures varied from 3.6% in Bristol and 5% in Bangor, up to 10% in
Newcastle, 10.7% in Notingham, 11.9% in Belfast and 20% in Liverpool. In contrast no
penicillin-resistant pneumococci were reported from centres in Glasgow and London. The
number of laboratories in England and Wales reporting the isolation of penicillin-resistant
pneumococci to the Central Public Health Laboratory (CPHL) increased four-fold
between 1987 and 1991 (George et al., 1992) and a recent study from this reference
laboratory showed 2.5-fold increase between 1990 and 1995 (Johnson et al., 1996).
Clearly penicillin-resistant pneumococci are increasing in prevalence in the UK, and this
increase appears likely to continue.
High proportion of penicillin-resistant pneumococci are also resistant to erythromycin
(Schutze et al., 1994; Boswell et al., 1996). Erythromycin resistance was detected in
12.9% of the pneumococcal isolates in this thesis. The CPHL has reported a three-fold
increase in erythromycin resistance in pneumococci from point prevalence studies
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performed in 1990 and 1995 (Johnson et al., 1996). The frequency of erythromycin
resistance in pneumococci in 1995 was estimated to be 8.6%, thus the increase in
pneumococcal erythromycin resistance seems to have paralleled that of penicillin and
indeed many pneumococci are resistant to both antibiotics. In this thesis, the associated
resistance to erythromycin, tetracycline and trimethoprim amongst penicillin-resistant
pneumococci were 56%, 46% and 71%, respectively. In contrast, the associated
resistance to erythromycin, tetracycline and trimethoprim amongst penicillin-sensitive
pneumococci were 8%, 8% and 32%, respectively. This high level of associated
resistance amongst penicillin-resistant pneumococci is cause of concern.
//. influenzae
In the current study, the prevalence of P-lactamase-mediated amoxycillin resistance
(18.6%) was comparatively higher than the 6.2%, 8.6% and 8.4% recorded in the studies
conducted in UK in the 1986 and 1991 (Powell et al 1987; 1992) and in Wales (Howard
& Williams, 1988), respectively. However, this rate of resistance was similar to the
overall prevalence of P-lactamase-positive H. influenzae (19.2%) reported from the
Alexander Project Group in 1995 (Schito et al., 1997). Variations in testing
methodologies carried out in this study compare with other studies may have affected the
results of the sensitivity testing, therefore, it is likely that resistance patterns may have
been under-estimated. To extend the range of susceptible bacteria clavulanic acid was
combined with amoxycillin (2:1); however, a high proportion (14%) of the p-lactamase-
producing amoxycillin-resistant strains remained insensitive to amoxycillin in the presence
of clavulanic acid. This may be explained by the hyper-production of P-lactamase
enzymes in clinical strains which, in turn, is a threat to the effectiveness of the P-
lactamase inhibitors currently administered for the treatment of P-lactamase-positive H.
influenzae infections. It may also be due to multiple-resistance mechanisms where there
are permeability mutations or altered PBPs in addition to p-lactamase production.
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The incidence of amoxycillin-resistant (3-lactamase-negative strains was 6.5%, slightly
higher than those reported in the UK in the 1986 and 1991 (4% and 5.8%, respectively)
(Powell etal., 1987; 1992), but this difference is probably not statistically significant. The
overall rate of non-(3-lactamase amoxycillin-resistance appears stable at around 5%.
Overall, 10% of the isolates were resistant to cefaclor and 5.2% to cefuroxime.
Resistance to cefaclor has increased markedly over the past years compared to the 1.6%
recorded in Wales in 1988 (Howard & Williams, 1988). The differences in the incidence
of cefaclor resistance is either due to the increased usage of the drug or may be related to
the introduction of amoxycillin plus clavulanic acid as the current results suggested some
degree of cross-resistance.
The incidence of tetracycline resistance was 3.9%, slightly higher than that reported in the
UK in 1986 and 1991 (2.7% and 1.4%, respectively) (Powell et al., 1987; 1992).
Resistance to trimethoprim has increased further to 9.6%, continuing the trend
demonstrated previously between 1986 (4.2%) and 1991 (6.4%) (Powell et al 1987;
1992). There were no strains in the current study that had reduced sensitivity to
ciprofloxacin.
9.3. The Relationship between Classical Serotyping and Molecular
Typing of Penicillin-Resistant S. pneumoniae Strains
Conclusions on Typing Techniques
The spread of antibiotic resistance and the development of new vaccines have focused
attention on the epidemiology of S. pneumoniae over recent years. While serotyping and
the determination of antibiotic resistance remain primary methods for characterising
pneumococci, molecular typing, such as PFGE, can add greater discrimination and
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complementary information. In this study, the usefulness of capsular serotyping and
PFGE macrorestriction with Smal enzyme of pneumococcal chromosomal DNA was
investigated to establish if penicillin resistance was the result of clonal spread and to
determine whether isolates of a given serotype were more closely related to each other
than to isolates of other serotypes. The results obtained by PFGE separations of
restriction fragments of S. pneumoniae DNA indicate that there is no correlation
demonstrated between PFGE profiles and serotyping. In a previous study, DNA
fingerprint differences were found among serotypes, with significantly greater similarity
among strains of a given serotype (Viering & Fine, 1989). The data in this thesis clearly
show that different capsular types can be genetically closely related whereas strains with
the same serotype may show quite different PFGE fingerprints and presumably, greater
diversity of genetic backgrounds. The results presented here confirm that capsular type
may not a good criterion for genetic relatedness as reported in several previous studies
(Sibold et al., 1992; Lefevre et al., 1993; Hall et al., 1996). The distinguishable PFGE
patterns in strains with the same serotype, suggests either that serotype is not closely
linked to the genetic relatedness of the isolate or that population is not truly clonal in
structure, or both (Hall et al., 1996).
The deception that S. pneumoniae employs to make itself unrecognisable to the immune
system is to change its antigenic structure; this is achieved by some considerable genetic
changes largely achieved by importing foreign DNA. As a result, there are 90 known
different capsular serotypes together with their antigenic formulae (Henrichsen, 1995).
Several groups have provided evidence that members of a single-resistant clone may
express distinct and different capsular polysaccharides. Variants of a particular clone that
are identical in overall genotype and in their antimicrobial resistance profile, but which are
of different serotype, have been reported (Coffey et al., 1991; Barnes et al., 1995). The
serotypes variants have been shown to have arisen, on multiple occasions, by large
recombinational exchanges at the capsular biosynthetic locus (Coffey et al., 1998). These
results do question the validity of phenotypic typing systems and infer that they should
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probably never be used in isolation but in combination with a genotypic typing system. If
measurement of clonal spread is needed, then an consistent and stable parameter must be
measured. Serotyping does not fall into this category.
9.4. Molecular Analysis of Penicillin Resistance and the Role of Clonal
Spread
S. pneumoniae is one of the few bacterial species in which P-lactamases remain unknown
and resistance to P-lactam antibiotics is entirely due to the development of altered PBPs
that have greatly decreased affinity for penicillins and cephalosporins (Coffey et al.,
1995). Pneumococci possess five high molecular weight PBPs, but genetic studies have
shown that high-level resistance to penicillin in clinical isolates results entirely from
alterations of PBPla, 2b and 2x (Barcus et al., 1995), whereas high-level resistance to
extended-spectrum cephalosporins derives from alterations of only PBPla and 2x (Coffey
et al., 1995).
Several different approaches have been adopted for the molecular diagnosis of penicillin
resistance. Ubukata et al. (1996) used a combination of PCRs that were targeted on lytA,
a 240-bp fragment from the pbp susceptible strains, and two different penicillin mutant
pbp2b gene sequences. Another group used primers based on susceptible pbp2x and 2b
genes and a resistant pbpla gene (Jalal et al., 1997). Their results show that all of these
approaches are excellent at verifying fully susceptible strains. This is to be expected
because of the genetic conservation of penicillin-susceptible genes (Dowson et al., 1994).
On the other hand, both fully PCR-based systems had difficulty detecting resistant isolates
(Ubukata et al. 1996; Jalal et al., 1997). All of the resistant isolates identified were truly
resistant, but those strains with a sequence not encompassed by the primers were not
amplified and thus gave false-negative results (Ubukata et al. 1996; Jalal et al., 1997;
O'Neill et al., 1999). This problem is overcome by another PCR approach in which the
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primer designed is based on a sequence which is conserved in susceptible and resistant
strains (Gillespie et al., 1997; Moissenet et al., 1997; O'Neill et al., 1999; Yoshida et al.,
1999). Thus, genes from susceptible and resistant isolates are amplified. It is then possible
to determine resistance because the pattern of endonuclease digestion differs enough
between different resistant alleles (O'Neill et al., 1999).
In this thesis, two PCR protocols were employed to analyse the alteration in PBP2x, 2b
and la in penicillin-resistant strains. Using the first PCR protocol, all the penicillin-
resistant isolates were screened with primers to amplify susceptible genotypes ofpbp2x
and 2b genes, and resistant genotype ofpbpla gene (Jalal et al., 1997). The second PCR
protocol involved the amplification of PBP2x, 2b and la whole genes followed by
restriction of the PCR products using Hinfl restriction endonuclease (Gillespie et al.,
1997).
Screening for changes in PBPs showed that there was a correlation between resistance
and alteration in PBP. All 10 strains with an MIC of penicillin of 2 mg/L or above had
changes in pbpla and all but one also had a change in pbp2b. In contrast only 6 had
alterations in pbp 2x. However, isolates with MICs of penicillin less than 1 mg/L showed
a more heterogeneous pattern ofPBP changes and 2 isolates had no change in pbp la, 2x
or 2b. This approach also had difficulty in detecting resistant isolates, simply because the
sequences of these strains are not recognised by the primers used in PCR and gave false
negative results. To overcome this problem, a restriction digestion of the amplified
PBP2x, 2b and la whole genes with Hinfl restriction endonuclease was performed. S.
pneumoniae strains with an MIC of penicillin of 1 mg/L or above exhibited considerable
homogeneity in pbp2b and 2x RFLP. However, strains with an MIC less than 1 mg/L
gave more heterogeneous patterns. It proved impossible to amplify pbpla gene. This
results is in agreement with recent published papers which concluded that RFLP of PBPs
genes are likely to be one of the most useful tools for genetic analysis and for determining
penicillin susceptibility in S. pneumoniae (O'Neill et al., 1999; Yoshida et al., 1999).
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9.5. The Role of Fluoroquinolone Resistance in Limiting the Efficacy of
These Drugs
Over the past two decades, the emergence and, in some areas, the prevalence of
pneumococci with decreased susceptibility to penicillin have emphasised the need for new
therapeutic agents and have focused attention on the fluoroquinolones. However,
ciprofloxacin, the main quinolone in current clinical use, has modest activity against
gram-positive bacteria such as S. pneumoniae. Although the rates of resistance of S.
pneumoniae to ciprofloxacin are currently low, selection of resistance on exposure in
vitro has been reported (Pan & Fisher, 1996; Pan et al., 1996). Resistance to quinolone
results from mutational alterations in the target sites: topoisomerase IV and DNA gyrase,
coded for by the parC and gyrA genes respectively. Moreover, it has recently been
observed that a third mechanism of ciprofloxacin resistance, in form of active efflux
mechanism, exists in S. pneumoniae (Brenwald et al., 1998).
In this study, the mechanisms of high-level ciprofloxacin resistance (MIC > 2 mg/L) in in
v/Yro-selected mutants and clinical isolates of penicillin-resistant S. pneumoniae have been
examined. Characterisation of the quinolone resistance-determining regions (QRDRs) of
the gyrA and parC genes by PCR, Hinfl restriction fragment length polymorphism
(RFLP), and DNA sequence analysis revealed no apparent changes in gyrA and parC
genes in clinical strains. Also no evidence of an efflux pump mechanism have been found.
There may be nucleotide changes occurred outside the QRDRs of the gyrA orparC genes
which not been amplified by the primers used in the current study. In contrast, in vitro-
selected mutants from clinical strain, D-680, showed an 8-fold increase in ciprofloxacin
MIC and corresponding to an increase for the new quinolones MICs from 2- to 16-fold.
These mutants had acquired mutations in gyrA and parC QRDRs at Glu-87 to-Lys and at
Ser-79 to-Tyr, respectively. These genetic changes are associated with increase in
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ciprofloxacin and new quinolones MICs. The results show that mutants selected in the
laboratory and those examined from clinical isolates may be quite distinct and it may be
impossible to extrapolate information from in vitro studies to the clinical situation.
A recent study by Pan & Fisher (1998) suggested that there was dual targeting, ofDNA
gyrase and topoisomerase IV, by clinafloxacin against S. pneumoniae. They conclude this
from examination of first and second step laboratory mutants in the emergence of
bacterial resistance. The mutations selected by clinafloxacin challenge in their study were
the gyrA mutations altered GyrA Glu-87 (to Gin or Lys), and the parC mutations resulted
in ParC Ser-79 (to Phe or Tyr) and Asp-83 (to Ala) changes. They used this anecdotal
information to conclude that the two targets were of equal importance. If mutations in
clinical strains are quite unlike these laboratory-generated mutants, then the action of the
fluoroquinolones may not be so easy to predict from mutation studies.
Correlations between the in vitro activity of ciprofloxacin against S. pneumoniae and its
clinical efficacy are instructive. In a large study of both penicillin-susceptible and
penicillin-resistant isolates, a mean MIC50 of 1.1 mg/L (range 0.5-2 mg/L) and a mean
MIC90 of 2 mg/L (range 1-4 mg/L) were found in the two groups respectively (Kayser &
Novak, 1987). These MICs are close to the current BSAC breakpoints for ciprofloxacin-
susceptible S. pneumoniae (<2 mg/L). Although the rates of resistance of S. pneumoniae
to ciprofloxacin are currently low, selection of resistance on exposure in vitro has been
reported. Resistance results from single step mutations which lead to a stepwise increase
in MICs and as ciprofloxacin MICs of S. pneumoniae already close to resistance
breakpoint those organisms are much likely to become resistant.
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9.6. The Influence of P-Lactam Resistance in the Spread of
//. influenzae
B-Lactamases
The major mechanism of resistance to P-lactams drugs in H. influenzae is the production
of P-lactamases, and the prevalence of lactamase-producing isolates has increased over
the last 20 years (Powell et al., 1987 & 1992; Barry et al., 1994). Impermeability and
alteration in PBPs are further mechanisms that mediate resistance to P-lactams (Reid et
al, 1987).
The most important P-lactamase in H. influenzae is TEM-1, which is found in more than
80% of P-lactamase-positive isolates (Scriver et al., 1994). A second P-lactamase, ROB-
1, has also been detected in H. influenzae (Robin et al., 1981). Although less numerous
than TEM-1, ROB-1 has been found in up to 8% of isolates in some studies (Daum et al.,
1988). Until recently, these were the only P-lactamases that had been described in H.
influenzae; however, recent evidence suggests that the situation may be more complex.
First, DNA sequence analysis of TEM-1 genes in H. influenzae suggested that the blajEu-
i gene in this species may differ from its E. coli counterpart, and that silent amino-acid
substitutions in TEM-1 have occurred (Vali et al., 1995). Second, a completely novel P-
lactamase, VAT-1, has also been identified recently in H. influenzae (Vali et al., 1994).
The significant of this enzyme is not clear at present, but it has been detected in isolates
from different geographical centres in Scotland (Shanahan et al., 1996; Vali et al., 1995).
P-lactamases in H. influenzae confer significant resistance to p-lactam antibiotics. It is,
therefore, essential that the production of P-lactamases can be identified in clinical
isolates and that there effective ways of distinguishing the different enzymes. This is
necessary for epidemiologic surveys, predicting future resistance trends, and to ensure
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that patients receive the appropriate P-lactam or alternative therapy. The first indication
of the presence of P-lactamases is usually the observation of increased levels of resistance
in clinical isolates as detected by routine susceptibility testing. Analytical isoelectric
focusing (IEF) can then be used to characterised the P-lactamase produced. Molecular
techniques have become very effective for identifying different P-lactamases (Payne &
Thomson, 1998). PCR has been used to detect ampicillin resistance genes in CSF samples
containing H. influenzae (Tenover et al., 1994). Correlation was obtained between the
results of MIC testing, P-lactamase production as determined by nitrocephin and PCR
testing (Tenover et al., 1994). Molecular typing by pulsed-field gel electrophoresis has
also been used to assess clonal relationship of isolates (Gazagne et al., 1998; Moor et al.,
1999).
Molecular Typing
In this study, the epidemiology and mechanisms of resistance to amoxycillin in H.
influenzae isolates was examined. Isolates were genotyped by pulsed-field gel
electrophoresis (PFGE), and screened for P-lactamase production by isoelectric focusing
(IEF) followed by PCR employing primers for the TEM-1 P-lactamase. IEF demonstrate
that all the P-lactamase-positive strains produced an enzyme that co-focused with TEM-
1. PCR employing a universal TEM-1 primer confirmed identity of the P-lactamase.
Cluster analysis ofpatterns produced by PFGE of chromosomal DNA digested with Smal
revealed that amoxycillin-resistant isolates showed little genetic relatedness. However,
few clusters of isolates have been identified. According to these results, it seems that the
clonal propagation of these resistant strains does not occur as previously described in S.
pneumoniae clinical isolates (Munoz et al., 1991). It suggests that the M?TEm-i gene is
located on a mobile genetic element, such as a plasmid, as it is in large gram-negative
rods. In this study, amoxycillin resistance in H. influenzae throughout the UK is
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predominantly mediated by the TEM-1 enzyme which appears to have disseminated into a
wide variety of different strains.
Non-Enzvmic Mechanisms of Resistance
P-Lactam resistance in H. influenzae is mainly mediated by the production of (3-
lactamases. The extent of non-P-lactamase-mediated resistance has always been difficult
to assess and it is possible that P-lactamase production may be missed by routine testing
(Scriver et al., 1994). P-lactam resistance in strains apparently negative for P-lactamase
production has been attributed to target modification (PBP alterations) and/or
impermeability (OMP alterations) (Reid et al., 1987). However, some of this evidence
was circumstantial.
In the current study, impermeability and modification of PBPs were demonstrated in few
co-amoxiclav-resistant isolates. Comparison of the OMPs profiles revealed that similar
patterns were observed in most of the co-amoxiclav-resistant strains compared with the
susceptible strain. However, two strains, RIE-233 and FL-258, lacked the 39.8 KDa band
which was present in all the other strains. Interestingly, these two isolates have the same
MIC results for amoxycillin and co-amoxiclav (2 mg/L, respectively), non-P-lactamase
producer, and gave similar PFGE patterns. Both isolates were from different geographical
location. In contrast, the 9 co-amoxiclav-resistant strains tested exhibited marked
heterogenicity in PBPs patterns. As there was variations in electrophoretic mobility as
well as in the amount of penicillin bound by certain PBPs compared with susceptible
control strain. Also the PBPs of certain isolates was either markedly reduced or absent.
Doern et al., (1997) also demonstrated that non-(3-lactamase resistance to amoxycillin
also confered resistance to co-amoxiclav. They concluded that this could cause problems
for treatment but would also require close interpretation of diagnostic sensitivity tests.
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The increase in this type of resistance would certain cause significant treatment
difficulties. This study has established that (3-lactamase enzymes are not the sole
mechanism of amoxycillin resistance in the H. influenzae strains and resistance may also
result from PBP and OMP alterations. However, the introduction of the non-enzymic
resistance mechanisms does broaden the spectrum of resistance to embrace (3-lactamase
inhibitor combinations and some cephalosporins such as cefaclor.
Concluding Remarks
Treatment of community-acquired respiratory infections often starts empirically. Thus, it
is important to know which organism are most likely to occur, the usual resistance
patterns, and which is the best group of antibiotics to use. The choice of appropriate
antibiotics should take into account not only the interests of the individual patient, but
also the ecological impact of different drugs and their delivery schedules. Avoidance of
selection of antibiotic-resistant organisms is a key aspect to remember.
It is indisputable that aminopenicillins promote the carriage of penicillin-resistant
pneumococci (Baquero, 1996). In common with other P-lactams, they may select
penicillin-resistant strains already present in the oropharynx or other penicillin-resistant
oral streptococci which might serve as reservoirs for resistance genes that encode
mutations leading to alterations to the PBPs of pneumococci. However, because of cross-
resistance and reduced activities against penicillin-resistant pneumococci, the selective
pressures exerted by oral cephalosporins are even greater. The selection of penicillin-
resistant pneumococci by oral cephalosporins, both in vitro and in vivo, can be explained
by their reduced activity against penicillin-resistant strains, as well as by the fact that the
modification of a single PBP, PBP 2x, may result in marked increase in MICs (Coffey et
al., 1995; Hakenbeck, 1999). Concurrent resistance to other antibiotics, including
macrolides and co-trimoxazole, in multidrug-resistant strains will not only select still
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greater numbers of resistant clones in the nasopharynx, but may also lead to clinical
failures, thereby increasing the risk of disseminating penicillin-resistant pneumococci
(Arason et al., 1996).
Over 20 years children have received oral ampicillin or amoxycillin for the treatment of
H. influenzae meningitis of which a significant percentage must have been caused by |3-
lactamase-producing strains. The clinical relevance of P-lactamase production by H.
influenzae for treatment failure in meningitis is clearly established (Needham, 1988).
While it is intuitive to believe that P-lactamase production by H. influenzae may lead to
treatment failure in the management of pneumonia, there is little confirmation of this in
the literature. The in vitro identification of ampicillin resistance due to P-lactamase
production depends upon a sufficient inoculum of organisms, usually >105/ml (Needham,
1988). While this concentration of organisms is regularly achieved in the CSF of children
with H. influenzae meningitis (Feldman, 1976), it is possible that lower numbers of
organisms may be susceptible in vivo to ampicillin even though they produce P-lactamase.
The breakpoint for H. influenzae resistance to P-lactams of 1 mg/L was defined on the
basis of laboratory criteria (Philips et al., 1991) and is much lower than the achievable
blood concentrations. As the concentration of organisms in blood is very low, it is
probable that amoxycillin therapy would be successful.
Erythromycin has little activity against H. influenzae. However, data demonstrating
azithromycin activity is currently being accumulated (Retsema et al., 1987; Doern et al.,
1997). Resistance to tetracycline and trimethoprim has been detected, but is currently low
(Brown et al., 1996). Although there are a number of isolated reports of the emergence
of quinolone resistance in H. influenzae (Gould et al., 1994), this does not appear to be a




The results of this thesis show that aminopenicillins select both resistant S. pneumoniae
and H. influenzae. Also it shows that the use of amoxycillin plus clavulanic acid has little
impact on the development of resistance in H. influenzae but may have a great impact on
the selection of penicillin resistant pneumococci. As new therapies are considered, the
new fluoroquinolones must be prime candidates. This thesis suggests that resistance in H.
influenzae is effectively non-existent despite the fact that ciprofloxacin has been used for
12 years and also suggests that the impact on the control of S. pneumoniae will be
substantial. Even though these bacteria have been exposed to ciprofloxacin for more than
a decade, there is no evidence for cross-resistance to newer fluoroquinolones.
My results demonstrate that the increased resistance in S. pneumoniae and H. influenzae
may affect treatment options with traditional penicillin-containing therapy. They suggest
that amoxycillin plus clavulanic acid probably remains the best therapy in susceptible
populations but if they become resistant, the newer fluoroquinolones stand a very good
chance in empirical therapy. It looks as though the newer macrolides are not a good
general therapy. If these fail particularly against Gram-positive bacteria, we should
probably have to consider combination therapy with one antibiotic, such as a
fluoroquinolone, to control the Gram-negative pathogens and a glycopeptide to control S.
pneumoniae. We hope that judicious use of the fluoroquinolones as a supplement to p-
lactam therapy may make this scenario unnecessary.
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